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The EditorsRisk Factors for Sudden Cardiac Death in
Post-Menopausal Women
Objectives The aim of this study was to estimate the
annual incidence rate of sudden cardiac death (SCD)
and to identify risk factors for SCD in post-menopausal
women.
Background With the aging U.S. population, post-
menopausal women now have the greatest population
burden of cardiovascular disease including SCD.
Methods We examined 161,808 women who participated
in the Women’s Health Initiative clinical trials and obser-
vational study. The women were recruited at 40 clinical
sites across the United States, enrolled between 1993 and
1998, and followed until August 2009. Our primary
endpoint is incident SCD, deﬁned as death occurring
within 1 h of symptom onset or within 1 h after the
participant was last seen without symptoms and death that
occurred in the absence of a potentially lethal non-coronary
disease process.
Results Four hundred eighteen women experienced adju-
dicated SCD. The incidence rate of SCD was 2.4/10,000
women/year (95% conﬁdence interval: 2.2 to 2.7). We
identiﬁed the following independent risk factors for SCD:
older age, African-American race, tobacco use, higher
pulse, higher waist-to-hip ratio, elevated white blood cell
count, history of heart failure, diabetes, history of
myocardial infarction, previous carotid artery disease, and
hypertension. Population-attributable fractions were great-
est for hypertension, waist-to-hip ratio, and myocardial
infarction.
Conclusions Besides traditional risk factors for coronary
heart disease, risk factors for sudden cardiac death in post-
menopausal women include African-American race, higher
pulse, higher waist-to-hip ratio, elevated white blood cell
count, and heart failure. Nearly one-half of women who
experienced sudden cardiac death had no previous diagnosis
of coronary heart disease (1).As a service to our readers, we have compiled all the relevant manuscripts in individual
subject areas of cardiology. These collections should provide a single repository of
JACC publications in the speciﬁc areas. In addition, these compilations should put in
perspective the recent advancements and future directions in the important disciplines
of cardiovascular medicine.Ventricular Arrhythmia After Cardiac Surgery:
Incidence, Predictors, and Outcomes
Objectives This study sought to investigate the prevalence,
predictors, and outcomes of patients with post-operative
ventricular arrhythmia (POVA) in a large cohort of patients.
Background New-onset POVA after cardiac surgery (CS)
is uncommon and has controversial prognostic value.
Methods A total of 14,720 consecutive patients undergoing
CS at Emory University between January 2004 and July
2010 were included in the study. Data on all-cause mortality
were obtained from Social Security Administration death
records. Multivariable regression models were constructed to
determine the risk factors for POVA and to estimate the
independent impact of POVA on long-term survival after
adjusting for 40 different covariates.
Results POVA occurred in 248 patients (1.7%). Patients
with POVA were older (63.5 vs. 61.6 years), had lower left
ventricular ejection fraction (EF) (43.7 vs. 51.3), and had
greater comorbidities (Society of Thoracic Surgeons
mortality risk score of 7.2% vs. 3.1%, p < 0.001). Multi-
variable analysis showed that older age (odds ratio [OR]:
1.018 per 1-year increase, p < 0.001), emergent surgery
(OR: 1.77, p ¼ 0.019), and the presence of PVD (OR: 1.41,
p ¼ 0.049) were associated with a higher incidence of
POVA, whereas higher left ventricular EF (OR: 0.97 per 1%
increase, p < 0.001), mild chronic obstructive pulmonary
disease (OR: 0.37, p < 0.001), and off-pump surgery (OR:
O.41, p < 0.001) were associated with a lower incidence of
POVA. POVA was associated with substantially increased
adjusted long-term mortality (hazard rate: 2.53, p < 0.001)
over 3.5 years of follow-up.
Conclusions POVA is associated with increased long-term
mortality after CS. Older age, PVD, lower EF, and emer-
gent surgery are associated with a higher risk of POVA,
whereas off-pump surgery seems to be protective (2).Vagal Reﬂexes Following an Exercise Stress Test:
A Simple Clinical Tool for Gene-Speciﬁc Risk
Stratiﬁcation in the Long QT Syndrome
Objectives The study assessed whether heart rate (HR)
reduction following an exercise stress test (ExStrT), an easily
quantiﬁable marker of vagal reﬂexes, might identify high-
and low-risk long QT syndrome (LQTS) type 1 (LQT1)
patients.
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be symptomatic remains elusive. We have previously shown
that depressed baroreﬂex sensitivity, an established marker of
reduced vagal reﬂexes, predicts low probability of symptoms
among LQT1.
Methods We studied 169 LQTS genotype-positive
patients < 50 years of age who performed an ExStrT with
the same protocol, on and off b-blockers including 47 South
African LQT1 patients all harboring the KCNQ1-A341V
mutation and 122 Italian LQTS patients with impaired
(IKs–, 66 LQT1) or normal (IKsþ, 50 LQT2 and 6 LQT3)
IKs current.
Results Despite similar maximal HR and workload, by the
ﬁrst minute after cessation of exercise the symptomatic
patients in both IKs– groups had a greater HR reduction
compared with the asymptomatic (19  7 beats/min vs. 13
 5 beats/min and 27  10 beats/min vs. 20  8 beats/min,
both p ¼ 0.009). By contrast, there was no difference
between the IKsþ symptomatic and asymptomatic patients
(23  9 beats/min vs. 26  9 beats/min, p ¼ 0.47). LQT1
patients in the upper tertile for HR reduction had a higher
risk of being symptomatic (odds ratio: 3.28, 95% conﬁdence
interval: 1.3 to 8.3, p ¼ 0.012).
Conclusions HR reduction following exercise identiﬁes
LQT1 patients at high or low arrhythmic risk, indepen-
dently of b-blocker therapy, and contributes to risk strati-
ﬁcation. Intense exercise training, which potentiates vagal
reﬂexes, should probably be avoided by LQT1 patients (3).Diffuse Ventricular Fibrosis in Atrial Fibrillation:
Noninvasive Evaluation and Relationships With
Aging and Systolic Dysfunction
Objectives The purpose of this study was to evaluate
diffuse myocardial ﬁbrosis of the left ventricle (LV) in
patients with atrial ﬁbrillation (AF).
Background Diffuse myocardial ﬁbrosis is a hallmark of
cardiomyopathy. Unlike replacement ﬁbrosis, it is not visu-
alized on delayed-enhancement cardiac magnetic resonance
(CMR) imaging, but may be quantiﬁed with contrast-
enhanced T1 mapping methods. In atrial ﬁbrillation (AF),
it may be induced by arrhythmia or reﬂect pre-existing
cardiomyopathy.
Methods Ninety subjects underwent CMR using a
clinical 1.5-T scanner: 23 controls, 40 paroxysmal AF
patients, and 27 persistent AF patients. Cardiac
morphology and function was evaluated from CMR cine
imaging. A histologically validated T1 mapping sequence
was used to calculate post-contrast T1 relaxation time (T1
time) of the LV myocardium as an index of diffuse
myocardial ﬁbrosis.
Results Age was similar across controls, paroxysmal AF
patients, and persistent AF patients (54  12 years, 58  9
years, and 56  10 years, p ¼ NS). Persistent AF patients
had larger indexed left atrium volume (55  18 ml vs.
41  12 ml and 47  14 ml) and lower ejection fraction(54  10% vs. 65  6% and 61  8%) than controls and
paroxysmal AF patients (p < 0.05). Post-contrast
ventricular T1 time differed across all groups (controls,
535  86 ms; paroxysmal AF, 427  95 ms; persistent
AF, 360  84 ms; p < 0.001). Univariate predictors of
post-contrast ventricular T1 time included age, sex, AF
category, ejection fraction, LV mass, congestive heart
failure, and body mass index. After multivariate analysis,
age, AF category, and ejection fraction remained inde-
pendent predictors.
Conclusions Post-contrast ventricular T1 mapping iden-
tiﬁes diffuse LV ﬁbrosis in patients with AF and provides
new insights into the association between AF and adverse
ventricular remodeling (4).A Novel Low-Energy Electrotherapy That
Terminates Ventricular Tachycardia With Lower
Energy Than a Biphasic Shock When
Antitachycardia Pacing Fails
Objectives The authors sought to develop a low-energy
electrotherapy that terminates ventricular tachycardia (VT)
when antitachycardia pacing (ATP) fails.
Background High-energy implantable cardioverter-
deﬁbrillator (ICD) shocks are associated with device failure,
signiﬁcant morbidity, and increased mortality. A low-energy
alternative to ICD shocks is desirable.
Methods Myocardial infarction was created in 25 dogs.
Sustained, monomorphic VT was induced by programmed
stimulation. Deﬁbrillation electrodes were placed in the
right ventricular apex, and coronary sinus and left ventricular
epicardium. If ATP failed to terminate sustained VT, the
deﬁbrillation thresholds (DFTs) of standard versus experi-
mental electrotherapies were measured.
Results Sustained VT ranged from 276 to 438 beats/min
(mean 339 beats/min). The right ventricular–coronary
sinus shock vector had lower impedance than the right
ventricular–left ventricular patch (54.4  18.1 U versus
109.8  16.9 U; p < 0.001). A single shock required
between 0.3  0.2 J to 5.9  2.5 J (mean 2.64  3.22 J;
p ¼ 0.008) to terminate VT, and varied depending upon
the phase of the VT cycle in which it was delivered. By
contrast, multiple shocks delivered within 1 VT cycle
length were not phase dependent and achieved lower DFT
compared with a single shock (0.13  0.09 J for 3 shocks,
0.08  0.04 J for 5 shocks, and 0.09  0.07 J for 7 shocks;
p < 0.001). Finally, a multistage electrotherapy (MSE)
achieved signiﬁcantly lower DFT compared with a single
biphasic shock (0.03  0.05 J versus 2.37  1.20 J;
respectively, p < 0.001). At a peak shock amplitude of
20 V, MSE achieved 91.3% of terminations versus 10.5%
for a biphasic shock (p < 0.001).
Conclusions MSE achieved a major reduction in DFT
compared with a single biphasic shock for ATP-refractory
monomorphic VT, and represents a novel electrotherapy to
reduce high-energy ICD shocks (5).
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Atrial ﬁbrillation (AF) is associated with increased risk for
stroke and systemic embolism. There is plausible evidence
linking inﬂammation to the initiation and perpetuation of
AF and AF-related thrombosis. Various inﬂammatory
markers (C-reactive protein, tumor necrosis factor-a,
interleukin-2, interleukin-6, and interleukin-8) have been
associated with AF. Proposed mechanisms linking inﬂam-
mation and the prothrombotic AF state include endothelial
activation/damage, production of tissue factor from mono-
cytes, increased platelet activation, and increased expression
of ﬁbrinogen. The present review aims to provide an update
on the association of inﬂammation and AF, including the
impact of inﬂammatory markers on clinical presentation and
outcome of AF patients (6).Anatomic Localization of Rapid Repetitive Sources
in Persistent Atrial Fibrillation: Fusion of Biatrial
CT Images With Wave Similarity/Cycle Length
Maps
Objectives The aim of this study was to investigate the
anatomic distribution of critical sources in patients with
atrial ﬁbrillation (AF) by fusion of biatrial computed
tomography (CT) images with cycle length (CL) and wave
similarity (WS) maps.
Background Experimental and clinical studies show that
atrial ﬁbrillation (AF) may originate from rapid and repet-
itive (RR) sources of activation. Localization of RR sources
may be crucial for an effective ablation treatment. Atrial
electrograms showing rapid and repetitive activations can be
identiﬁed by combining WS and CL analysis.
Methods Patients with persistent AF underwent biatrial
electroanatomic mapping and pre-procedural CT cardiac
imaging. WS and CL maps were constructed in 17 patients
by calculating the degree of repetitiveness of activation
waveforms (similarity index [S]) and the cycle length at
each atrial site. WS/CL maps were then integrated with
biatrial 3-dimensional CT reconstructions by a stochastic
approach.
Results Repetitive sources of activation (S 0.5) were
present in most patients with persistent AF (94%) and were
mainly located at the pulmonary veins (82% of patients), at
the superior caval vein (41%), on the anterior wall of the
right atrium (23%), and at the left atrial appendage (23%).
Potential driver sources showing both rapid and repetitive
activations (CL ¼ 140.7  25.1 ms, S ¼ 0.65  0.15) were
present only in a subset of patients (65%) and were conﬁned
to the pulmonary vein region (47% of patients) and left atrial
appendage (12%). Differently, the repetitive activity of the
superior caval vein was characterized by a slow activation rate
(CL ¼ 184.7  14.6 ms).
Conclusions The identiﬁcation and localization of RR
sources is feasible by fusion of biatrial anatomic images with
WS/CL maps. Potential driver sources are present only ina subset of patients with persistent AF and are mainly
located in the pulmonary vein region (7).
Impact of a New Conduction Defect After
Transcatheter Aortic Valve Implantation on Left
Ventricular Function
Objectives This study sought to evaluate the impact of new
conduction defects after transcatheter aortic valve implan-
tation (TAVI) on the evolution of left ventricular (LV)
function during 1-year follow-up.
Background New left bundle branch block (LBBB) or
need for permanent pacing due to atrioventricular (AV)
block are frequent after TAVI.
Methods A total of 90 consecutive patients treated with
TAVI and who had 12-month echocardiographic follow-up
were included in the study. In 39 patients, a new conduction
defect (new LBBB or need for permanent pacemaker
activity.) persisted 1 month after TAVI. In 51 patients, no
persistent new conduction defect was observed. Two-
dimensional echocardiography using parasternal short-axis,
apical 4-chamber, and apical 2-chamber views was per-
formed before TAVI and at 1-year follow-up to determine
LV volumes and ejection fraction based on Simpson’s rule.
Speckle-tracking echocardiography was applied using stan-
dard LV short-axis images to assess the effect of new
conduction defects on time-to-peak radial strain of different
LV segments as a parameter of LV dyssynchrony.
Results New conduction defects resulted in marked
heterogeneity in time-to-peak strain between the 6 analyzed
short-axis segments. During 1-year follow-up after TAVI,
there was a signiﬁcant increase in left ventricular ejection
fraction (LVEF) in patients without new LBBB (53  11%
pre TAVI to 59  10% at follow-up; p < 0.001), whereas
there was no change in LVEF in patients with a new
conduction defect (52  11% pre TAVI to 51  12% at
follow-up, p ¼ 0.740). Change in LV end-systolic volume
was also signiﬁcantly different between patient groups (1.0
 14.2 vs. 11.2  15.7 ml, p ¼ 0.042). New conduction
defect and LVEF at baseline were independent predictors of
reduced LVEF at 12-month follow-up after TAVI.
Conclusions LVEF improves after TAVI for treatment of
severe aortic stenosis in patients without new conduction
defects. In patients with a new conduction defect after
TAVI, there is no improvement in LVEF at follow-up (8).
In Silico Cardiac Risk Assessment in Patients With
Long QT Syndrome: Type 1: Clinical Predictability
of Cardiac Models
Objectives The study was designed to assess the ability of
computer-simulated electrocardiography parameters to
predict clinical outcomes and to risk-stratify patients with
long QT syndrome type 1 (LQT1).
Background Although attempts have been made to corre-
late mutation-speciﬁc ion channel dysfunction with patient
phenotype in long QT syndrome, these have been largely
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used to predict consequences of complex changes in channel
function to the overall heart rhythm.
Methods A total of 633 LQT1-genotyped subjects with 34
mutations from multinational long QT syndrome registries
were studied. Cellular electrophysiology function was deter-
mined for the mutations and introduced in a 1-dimensional
transmural electrocardiography computer model. The muta-
tion effect on transmural repolarization was determined for
each mutation and related to the risk for cardiac events
(syncope, aborted cardiac arrest, and sudden cardiac death)
among patients.
Results Multivariate analysis showed that mutation-speciﬁc
transmural repolarization prolongation (TRP) was associ-
ated with an increased risk for cardiac events (35% per
10-ms increment [p < 0.0001]; upper quartile hazard
ratio: 2.80 [p < 0.0001]) and life-threatening events
(aborted cardiac arrest/sudden cardiac death: 27% per 10-ms
increment [p ¼ 0.03]; upper quartile hazard ratio: 2.24
[p ¼ 0.002]) independently of patients’ individual QT
interval corrected for heart rate (QTc). Subgroup analysis
showed that among patients with mild to moderate QTc
duration (<500 ms), the risk associated with TRP was
maintained (36% per 10 ms [p < 0.0001]), whereas the
patient’s individual QTc was not associated with a signiﬁ-
cant risk increase after adjustment for TRP.
Conclusions These ﬁndings suggest that simulated repo-
larization can be used to predict clinical outcomes and to
improve risk stratiﬁcation in patients with LQT1, with
a more pronounced effect among patients with a lower-range
QTc, in whom a patient’s individual QTc may provide less
incremental prognostic information (9).New Unipolar Electrogram Criteria to Identify
Irreversibility of Nonischemic Left Ventricular
Cardiomyopathy
Objectives This study sought to assess the value of left
ventricular (LV) endocardial unipolar electroanatomical
mapping (EAM) in identifying irreversibility of LV systolic
dysfunction in patients with left ventricular nonischemic
cardiomyopathy (LVCM).
Background Identifying irreversibility of LVCM would be
helpful but cannot be reliably accomplished by bipolar EAM
or cardiac magnetic resonance identiﬁcation of macroscopic
scar.
Methods Detailed endocardial LV EAM was performed in
3 groups: 1) 24 patients with irreversible LVCM (I-LVCM)
but with no or minimal macroscopic scar (<15% LV
surface) evidenced on bipolar voltage EAM and/or cardiac
magnetic resonance; 2) 14 patients with reversible ventricular
premature depolarization–mediated LVCM (R-LVCM);
and 3) 17 patients with structurally normal hearts. LV
endocardial unipolar electrogram amplitude and area of
unipolar amplitude abnormality were deﬁned after excluding
macroscopic scar.Results Unipolar amplitude differed in the 3 groups:
median of 7.6 (interquartile range [IQR]: 5.5 to 9.7) mV in
I-LVCM group, 13.2 (IQR: 10.4 to 16.2) mV in R-LVCM
group, and 16.3 (IQR: 13.6 to 19.8) mV in structurally
normal hearts group (p < 0.001). Areas of unipolar abnor-
mality represented a large proportion of total LV surface in
I-LVCM, 64.7% (IQR: 47.5% to 75.9%) compared with
R-LVCM, 5.2% (IQR: 0.0% to 19.1%) and structurally
normal hearts, 0.1% (IQR: 0.0% to 0.9%), groups (p <
0.001). A unipolar abnormality area cutoff of 32% of total
LV surface was 96% sensitive and 100% speciﬁc in identi-
fying irreversible cardiomyopathy among patients with LV
dysfunction (I-LVCM and R-LVCM), p < 0.001.
Conclusions Detailed unipolar voltage mapping can iden-
tify irreversible myocardial dysfunction consistent with
ﬁbrosis, even in the absence of bipolar EAM or cardiac
magnetic resonance abnormalities, and may serve as valuable
prognostic tool in patients presenting with LVCM to
facilitate clinical decision making (10).Not All Beta-Blockers Are Equal in the
Management of Long QT Syndrome Types 1 and 2:
Higher Recurrence of Events Under Metoprolol
Objectives The purpose of this study was to compare the
efﬁcacy of beta-blockers in congenital long QT syndrome
(LQTS).
Background Beta-blockers are the mainstay in managing
LQTS. Studies comparing the efﬁcacy of commonly used
beta-blockers are lacking, and clinicians generally assume
they are equally effective.
Methods Electrocardiographic and clinical parameters of
382 LQT1/LQT2 patients initiated on propranolol (n ¼
134), metoprolol (n ¼ 147), and nadolol (n ¼ 101) were
analyzed, excluding patients <1 year of age at beta-blocker
initiation. Symptoms before therapy and the ﬁrst break-
through cardiac events (BCEs) were documented.
Results Patients (56% female, 27% symptomatic, heart rate
76  16 beats/min, QTc 472 46 ms) were started on beta-
blocker therapy at a median age of 14 years (interquartile
range: 8 to 32 years). The QTc shortening with propranolol
was signiﬁcantly greater than with other beta-blockers in the
total cohort and in the subset with QTc >480 ms. None of
the asymptomatic patients had BCEs. Among symptomatic
patients (n ¼ 101), 15 had BCEs (all syncopes). The QTc
shortening was signiﬁcantly less pronounced among patients
with BCEs. There was a greater risk of BCEs for symp-
tomatic patients initiated on metoprolol compared to users
of the other 2 beta-blockers combined, after adjustment for
genotype (odds ratio: 3.95, 95% conﬁdence interval: 1.2 to
13.1, p ¼ 0.025). Kaplan-Meier analysis showed a signiﬁ-
cantly lower event-free survival for symptomatic patients
receiving metoprolol compared to propranolol/nadolol.
Conclusions Propranolol has a signiﬁcantly better QTc
shortening effect compared to metoprolol and nadolol,
especially in patients with prolonged QTc. Propranolol and
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started on metoprolol are at a signiﬁcantly higher risk for
BCEs. Metoprolol should not be used for symptomatic
LQT1 and LQT2 patients (11).Nonsustained Ventricular Tachycardia
Nonsustained ventricular tachycardia (NSVT) has been
recorded in a wide range of conditions, from apparently
healthy individuals to patients with signiﬁcant heart disease.
In the absence of heart disease, the prognostic signiﬁcance of
NSVT is debatable. When detected during exercise, and
especially at recovery, NSVT indicates increased cardiovas-
cular mortality within the next decades. In trained athletes,
NSVT is considered benign when suppressed by exercise. In
patients with non–ST-segment elevation acute coronary
syndrome, NSVT occurring beyond 48 h after admission
indicates an increased risk of cardiac and sudden death,
especially when associated with myocardial ischemia. In
acute myocardial infarction, in-hospital NSVT has an
adverse prognostic signiﬁcance when detected beyond the
ﬁrst 13 to 24 h. In patients with prior myocardial infarction
treated with reperfusion and beta-blockers, NSVT is not an
independent predictor of long-term mortality when other
covariates such as left ventricular ejection fraction are taken
into account. In patients with hypertrophic cardiomyopathy,
and most probably genetic channelopathies, NSVT carries
prognostic signiﬁcance, whereas its independent prognostic
ability in ischemic heart failure and dilated cardiomyopathy
has not been established. The management of patients with
NSVT is aimed at treating the underlying heart disease (12).The Entirely Subcutaneous Implantable
Cardioverter-Deﬁbrillator: Initial Clinical
Experience in a Large Dutch Cohort
Objectives The purpose of the study was to evaluate the
efﬁcacy and safety of the entirely subcutaneous implantable
cardioverter-deﬁbrillator (S-ICD).
Background A new entirely S-ICD has been introduced,
that does not require lead placement in or on the heart. The
authors report the largest multicenter experience to date with
the S-ICD with a minimum of 1-year follow-up in the ﬁrst
118 Dutch patients who were implanted with this device.
Methods Patients were selected if they had a class I or IIa
indication for primary or secondary prevention of sudden
cardiac death. All consecutive patients from 4 high-volume
centers in the Netherlands with an S-ICD implanted
between December 2008 and April 2011 were included.
Results A total of 118 patients (75% males, mean age 50
years) received the S-ICD. After 18 months of follow-up, 8
patients experienced 45 successful appropriate shocks (98%
ﬁrst shock conversion efﬁcacy). No sudden deaths occurred.
Fifteen patients (13%) received inappropriate shocks, mainly
due to T-wave oversensing, which was mostly solved by
a software upgrade and changing the sensing vector of theS-ICD. Sixteen patients (14%) experienced complications.
Adverse events were more frequent in the ﬁrst 15 implan-
tations per center compared with subsequent implantations
(inappropriate shocks 19% vs. 6.7%, p ¼ 0.03; complications
17% vs. 10%, p ¼ 0.10).
Conclusions This study demonstrates that the S-ICD is
effective in terminating ventricular arrhythmias. There is,
however, a considerable percentage of ICD related adverse
events, which decreases as the therapy evolves and experi-
ence increases (13).
Cardiac Resynchronization and Quality of Life in
Patients With Minimally Symptomatic Heart
Failure
Objectives This study compared the quality of life (QOL)
of patients with cardiac resynchronization therapy (CRT)
and an implantable cardioverter-deﬁbrillator (ICD) to
patients with an ICD only.
Background CRT with ICD is associated with a reduction
in heart failure risk among minimally symptomatic patients.
It is unknown whether this improves QOL.
Methods This study uses the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial With Cardiac
Resynchronization Therapy) data. The MADIT-CRT
enrolled 1,820 patients at 110 centers across 14 countries.
Patients had ischemic cardiomyopathy (New York Heart
Association [NYHA] functional class I or II) or non-
ischemic cardiomyopathy (NYHA functional class II only),
sinus rhythm, an ejection fraction of 30% or less, and pro-
longed intraventricular conduction with a QRS duration of
130 ms or more. QOL was evaluated on the 1,699 patients
with baseline and follow-up measures using the Kansas City
Cardiomyopathy Questionnaire (KCCQ). Six dimensions
(Physical Limitation, Symptom Stability, Symptom
Frequency, Symptom Burden, Quality of Life, and Social
Limitations) and 3 summary scores (Total Symptom,
Clinical Summary, and Overall Summary) were analyzed.
Results During an average follow-up of 2.4 years, the
CRT-ICD group had greater improvement than the ICD-
only group on all KCCQ measures (p < 0.05 on each
scale). These differences were signiﬁcant among patients
with left bundle branch block conduction disturbance (n ¼
1,204, p < 0.01 on each scale), but not among patients
without left bundle branch block (n ¼ 494).
Conclusions Compared with patients with ICD only,
CRT-ICD is associated with greater improvement in QOL
among relatively asymptomatic patients, speciﬁcally among
those with left bundle branch conduction disturbance (14).
Catheter Ablation of Long-Standing Persistent
Atrial Fibrillation: 5-Year Outcomes of the Hamburg
Sequential Ablation Strategy
Objectives This study describes the 5-year efﬁcacy of
catheter ablation for long-standing persistent atrial ﬁbrilla-
tion (LS-AF).
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tion for LS-AF are limited.
Methods Long-term follow-up of 56 months (range 49 to
67 months) was performed in 202 patients (age 61  9
years) who underwent the sequential ablation strategy for
symptomatic LS-AF. Initial ablation strategy was circum-
ferential pulmonary vein isolation (PVI). Additional ablation
was performed only in acute PVI nonresponder, if direct
current cardioversion failed after PVI.
Results After the ﬁrst ablation procedure, sinus rhythm
was documented in 41 of 202 (20.3%) patients. After
multiple procedures, sinus rhythm was maintained in 91 of
202 (45.0%) patients, including 24 patients receiving
antiarrhythmic drugs. In 105 patients, PVI was the sole
ablative therapy, 49 (46.7%) of those patients remained in
sinus rhythm during follow-up. Patients with a total AF
duration of <2 years had a signiﬁcantly higher ablation
success rate than patients whose AF duration was >2
years (76.5% vs. 42.2%, respectively; p ¼ 0.033). Persis-
tent AF duration (hazard ratio: 1.09 [95% conﬁdence
interval: 1.04 to 1.13]; p < 0.001) independently predicted
arrhythmia recurrences, and acute PVI responders had
a reduced risk of relapse (hazard ratio: 0.57 [95% conﬁ-
dence interval: 0.41 to 0.78]; p < 0.001) after the ﬁrst
ablation.
Conclusions During 5-year follow-up, single- and multiple
ablation procedure success was 20% and 45%, respectively,
for patients with LS-AF. For patients with a total AF
duration of <2 years, the outcomes were favorable (15).Elevated Pre-Operative Serum Peptides for
Collagen I and III Synthesis Result in Post-Surgical
Atrial Fibrillation
Objectives This study sought to determine if serum
markers for collagen I and III synthesis, the carboxyl
terminal peptide from pro-collagen I (PICP) and the amino
terminal peptide from pro-collagen III (PIIINP), correlate
with left atrial (LA) ﬁbrosis and post-operative atrial ﬁbril-
lation (AF).
Background AF after cardiac surgery is associated with
adverse outcomes. We recently demonstrated that LA
ﬁbrosis is associated with post-operative AF in patients with
no previous history of AF.
Methods Fifty-four patients having cardiac surgery without
a history of AF consented to left and right atrial biopsies and
a pre-operative peripheral blood draw. Picrosirius red
staining quantiﬁed the percentage of ﬁbrosis, and reverse
transcriptase polymerase chain reaction assessed atrial tissue
messenger ribonucleic acid transcripts involved in the
ﬁbrosis pathway. PICP and PIIINP levels were measured
using an enzyme immunosorbent assay.
Results Eighteen patients developed AF, whereas 36
remained in normal sinus rhythm. LA ﬁbrosis was higher
in patients who developed AF versus normal sinus rhythm
(6.13  2.9% vs. 2.03  1.9%, p ¼ 0.03). LA messengerribonucleic acid transcripts for collagen I, III, transforming
growth factor, and angiotensin were 1.5- to 2.0-fold higher
in AF patients. Serum PICP and PIIINP levels were
highest in AF versus normal sinus rhythm (PICP: 451.7 
200 ng/ml vs. 293.3  114 ng/ml, p ¼ 0.006; PIIINP:
379  286 pg/ml vs. 191.6  162 pg/ml, p ¼ 0.01).
Furthermore, there was a linear correlation between LA
ﬁbrosis and serum PICP levels (R2 ¼ 0.2; p ¼ 0.01), and
of the markers, only PICP was independently associated
with AF.
Conclusions This demonstrates that serum PICP and
PIIINP levels correlate with the presence of LA ﬁbrosis and
may act as predictors for post-operative AF even in the
absence of previous history of AF (16).Effect of Cardiac Resynchronization Therapy on
the Risk of First and Recurrent Ventricular
Tachyarrhythmic Events in MADIT-CRT
Objectives This study aimed to evaluate the effect of
cardiac resynchronization therapy with a deﬁbrillator (CRT-
D) on the risks of ﬁrst and recurrent ventricular tachyar-
rhythmic events (VTEs) in the MADIT-CRT.
Background Reverse remodeling associated with CRT-D
therapy was suggested to reduce arrhythmic risk. However,
the effect of the device on the risk of recurrent VTEs among
patients who experience a ﬁrst arrhythmic event has not been
investigated.
Methods The CRT-D versus deﬁbrillator-only risks for
ﬁrst and subsequent fast VTEs (>180 beats/min) were
assessed by Cox proportional hazards and Andersen-Gill
proportional intensity regression modeling, respectively, in
efﬁcacy analyses recognizing active device-type during
follow-up.
Results Multivariate analysis showed that CRT-D was
associated with a signiﬁcant 29% (p ¼ 0.003) reduction in
the risk of a ﬁrst VTE, with a pronounced effect among
patients with left bundle branch block (LBBB) (hazard ratio
[HR]: 0.58; p < 0.001) and no signiﬁcant effect among
non-LBBB patients (HR: 1.05; p ¼ 0.82, p for the
difference ¼ 0.02). Patients with LBBB who experienced
a ﬁrst VTE had no change in the risk of subsequent VTEs
with CRT-D (HR: 0.98; p ¼ 0.85). In contrast, the risk of
recurrent VTEs with CRT-D was signiﬁcantly increased
among non-LBBB patients (HR: 3.62; p ¼ 0.002, p for the
difference ¼ 0.009). Recurrent VTEs increased the risk of
subsequent heart failure or death.
Conclusions In MADIT-CRT, active treatment with
CRT-D was associated with a signiﬁcant reduction in the
risk of life-threatening VTEs. However, our ﬁndings
suggest that CRT-D does not reduce the risk of subsequent
VTEs in patients who experience a ﬁrst arrhythmic event
and may increase subsequent arrhythmic risk in non-LBBB
patients. (Multicenter Automatic Deﬁbrillator Implantation
With Cardiac Resynchronization Therapy [MADIT-CRT];
NCT00180271) (17).
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e457Colchicine for Prevention of Early Atrial Fibrillation
Recurrence After Pulmonary Vein Isolation: A
Randomized Controlled Study
Objectives The purpose of the present study was to test the
potential of colchicine, an agent with potent anti-
inﬂammatory action, to reduce atrial ﬁbrillation (AF)
recurrence after pulmonary vein isolation in patients with
paroxysmal AF.
Background Proinﬂammatory processes induced by AF
ablation therapy have been implicated in postablation
arrhythmia recurrence.
Methods Patients with paroxysmal AF who received
radiofrequency ablation treatment were randomized to
a 3-month course of colchicine 0.5 mg twice daily or
placebo. C-reactive protein (CRP) and interleukin (IL)-6
levels were measured on day 1 and on day 4 of treatment.
Results In the 3-month follow-up, recurrence of AF was
observed in 27 (33.5%) of 80 patients of the placebo group
versus 13 (16%) of 81 patients who received colchicine (odds
ratio: 0.38, 95% conﬁdence interval: 0.18 to 0.80). Gastro-
intestinal side-effects were the most common symptom
among patients receiving active treatment. Diarrhea was
reported in 7 patients in the colchicine group (8.6%) versus 1
in the placebo group (1.3%, p ¼ 0.03). Colchicine led to
higher reductions in CRP and IL-6 levels: the median
difference of CRP and IL-6 levels between days 4 and 1
was 0.46 mg/l (interquartile range: 0.78 to 0.08 mg/l)
and 0.10 mg/l (0.30 to 0.10 pg/ml), respectively, in the
placebo group versus 1.18 mg/l (2.35 to 0.46 mg/l)
and 0.50 pg/ml (1.15 to 0.10 pg/ml) in the colchicine
group (p < 0.01 for both comparisons).
Conclusions Colchicine is an effective and safe treatment
for prevention of early AF recurrences after pulmonary vein
isolation in the absence of antiarrhythmic drug treatment.
This effect seems to be associated strongly with a signiﬁcant
decrease in inﬂammatory mediators, including IL-6 and
CRP (18).
Predictive Factors and Long-Term Clinical
Consequences of Persistent Left Bundle Branch
Block Following Transcatheter Aortic Valve
Implantation With a Balloon-Expandable Valve
Objectives This study evaluated the predictive factors and
prognostic value of new-onset persistent left bundle branch
block (LBBB) in patients undergoing transcatheter aortic
valve implantation (TAVI) with a balloon-expandable valve.
Background The predictors of persistent (vs. transient or
absent) LBBB after TAVI with a balloon-expandable valve
and its clinical consequences are unknown.
Methods A total of 202 consecutive patients with no base-
line ventricular conduction disturbances or previous perma-
nent pacemaker implantation (PPI) who underwent TAVI
with a balloon-expandable valve were included. Patients were
on continuous electrocardiographic (ECG) monitoring
during hospitalization and 12-lead ECG was performed dailyuntil hospital discharge. No patient was lost at a median
follow-up of 12 (range: 6 to 24) months, and ECG tracing
was available in 97% of patients. The criteria for PPI were
limited to the occurrence of high-degree atrioventricular
block (AVB) or severe symptomatic bradycardia.
Results New-onset LBBB was observed in 61 patients
(30.2%) after TAVI, and had resolved in 37.7% and 57.3%
at hospital discharge and 6- to 12-month follow-up, respec-
tively. Baseline QRS duration (p ¼ 0.037) and ventricular
depth of the prosthesis (p ¼ 0.017) were independent
predictors of persistent LBBB. Persistent LBBB at hospital
discharge was associated with a decrease in left ventricular
ejection fraction (p ¼ 0.001) and poorer functional status
(p ¼ 0.034) at 1-year follow-up. Patients with persistent
LBBB and no PPI at hospital discharge had a higher inci-
dence of syncope (16.0% vs. 0.7%; p ¼ 0.001) and complete
AVB requiring PPI (20.0% vs. 0.7%; p < 0.001), but not of
global mortality or cardiac mortality during the follow-up
period (all, p > 0.20). New-onset LBBB was the only
factor associated with PPI following TAVI (p < 0.001).
Conclusions Up to 30% of patients with no prior
conduction disturbances developed new LBBB following
TAVI with a balloon-expandable valve, although it was
transient in more than one third. Longer baseline QRS
duration and a more ventricular positioning of the prosthesis
were associated with a higher rate of persistent LBBB,
which in turn determined higher risks for complete AVB
and PPI, but not mortality, at 1-year follow-up (19).Antiarrhythmic Potential of Mesenchymal Stem
Cell Is Modulated by Hypoxic Environment
Objectives The purpose of this study was to evaluate the
antiarrhythmic potential of mesenchymal stem cells (MSC)
under a different environment.
Background Little is known about how environmental
status affects antiarrhythmic potential of MSCs.
Methods To investigate the effect of paracrine factors
secreted from MSCs under different circumstances on
arrhythmogenicity in rats with myocardial infarction, we
injected paracrine media (PM) secreted under hypoxic,
normoxic conditions (hypoxic PM and normoxic PM), and
MSC into the border zone of infarcted myocardium in rats.
Results We found that the injection of hypoxic PM, but
not normoxic PM, markedly restored conduction velocities,
suppressed focal activity, and prevented sudden arrhythmic
deaths in rats. Underlying this electrophysiological alter-
ation was a decrease in ﬁbrosis, restoration of connexin 43,
alleviation of Ca2þ overload, and recovery of Ca2þ-
regulatory ion channels and proteins, all of which is sup-
ported by proteomic data showing that several paracrine
factors including basic ﬁbroblast growth factor, insulinlike
growth factor 1, hepatocyte growth factor, and EF-
hand domain-containing 2 are potential mediators. When
compared with PM, MSC injection did not reduce or pre-
vent arrhythmogenicity, suggesting that the antiarrhythmic
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paracrine factors.
Conclusions A hypoxic or normoxic environment
surrounding MSC affects the type and properties of the
growth factors or cytokines, and these secreted molecules
determine the characteristics of the electro-anatomical
substrate of the surrounding myocardium (20).
Left Ventricular Midwall Fibrosis as a Predictor of
Mortality and Morbidity After Cardiac
Resynchronization Therapy in Patients With
Nonischemic Cardiomyopathy
Objectives The aim of this study was to determine whether
left ventricular (LV) midwall ﬁbrosis, detected by midwall
hyperenhancement (MWHE) on late gadolinium enhance-
ment cardiovascular magnetic resonance (CMR) imaging,
predicts mortality and morbidity in patients with dilated
cardiomyopathy (DCM) undergoing cardiac resynchroni-
zation therapy (CRT).
Background Midwall ﬁbrosis predicts mortality and
morbidity in patients with DCM.
Methods Patients with DCM with (þ) or without ()
MWHE (n ¼ 20 and n ¼ 77, respectively) as well as
161 patients with ischemic cardiomyopathy (ICM) under-
going CRT (n ¼ 258) were followed up for a maximum of
8.7 years.
Results Among patients with DCM, þMWHE predicted
cardiovascular mortality (hazard ratio [HR]: 18.6; 95%
conﬁdence intervals [CI]: 3.51 to 98.5; p ¼ 0.0008), total
mortality or hospitalization for major adverse cardiovascular
events (HR: 7.57; 95% CI: 2.71 to 21.2; p < 0.0001), and
cardiovascular mortality or heart failure hospitalizations
(HR: 9.56; 95% CI: 2.72 to 33.6; p ¼ 0.0004), independent
of New York Heart Association class, QRS duration,
atrial ﬁbrillation, LV volumes, LV ejection fraction, and a
CMR-derived measure of dyssynchrony. Among patients
with DCM and ICM, the risk of cardiovascular mortality for
DCMþMWHE (adjusted HR: 18.5; 95% CI: 3.93 to 87.3;
p¼ 0.0002) was similar to that for ICM (adjusted HR: 21.0;
95% CI: 5.06 to 87.2; p < 0.0001). Both DCM þMWHE
and ICM were predictors of pump failure death as well as
sudden cardiac death. LV reverse remodeling was observed in
DCM MWHE and in ICM but not in DCM þMWHE.
Conclusions Midwall ﬁbrosis is an independent predictor
of mortality and morbidity in patients with DCM under-
going CRT. The outcome of DCM with midwall ﬁbrosis is
similar to that of ICM. This relationship is mediated by
both pump failure and sudden cardiac death (21).
Prediction of Mortality in Clinical Practice for
Medicare Patients Undergoing Deﬁbrillator
Implantation for Primary Prevention of Sudden
Cardiac Death
Objectives The aim of this study was to derive and validate
a practical risk model to predict death within 4 years ofprimary prevention implantable cardioverter-deﬁbrillator
(ICD) implantation.
Background ICDs for the primary prevention of sudden
cardiac death improve survival, but recent data suggest that
a patient subset with high mortality and minimal ICD
beneﬁt may be identiﬁed.
Methods Data from a development cohort (n ¼ 17,991)
and validation cohort (n ¼ 27,893) of Medicare beneﬁciaries
receiving primary prevention ICDs from 2005 to 2007 were
merged with outcomes data through mid-2010 to construct
and validate complete and abbreviated risk models for all-
cause mortality using Cox proportional hazards regression.
Results Over a median follow-up period of 4 years, 6,741
(37.5%) development and 8,595 (30.8%) validation cohort
patients died. The abbreviated model was based on 7 clin-
ically relevant predictors of mortality identiﬁed from
complete model results, referred to as the “SHOCKED”
predictors: 75 years of age or older (hazard ratio [HR]: 1.70;
95% conﬁdence interval [CI]: 1.62 to 1.79), heart failure
(New York Heart Association functional class III) (HR:
1.35; 95% CI: 1.29 to 1.42), out of rhythm because of atrial
ﬁbrillation (HR: 1.26; 95% CI: 1.19 to 1.33), chronic
obstructive pulmonary disease (HR: 1.70; 95% CI: 1.61 to
1.80), kidney disease (chronic) (HR: 2.33; 95% CI: 2.20 to
2.47), ejection fraction (left ventricular)  20% (HR: 1.26;
95% CI: 1.20 to 1.33), and diabetes mellitus (HR: 1.43; 95%
CI: 1.36 to 1.50). This model had C-statistics of 0.75 (95%
CI: 0.75 to 0.76) and 0.74 (95% CI: 0.74 to 0.75) in the
development and validation cohorts, respectively. Validation
patients in the highest risk decile on the basis of the
SHOCKED predictors had a 65% 3-year mortality rate. A
nomogram is provided for survival probabilities 1 to 4 years
after ICD implantation.
Conclusions This useful model, based on more than 45,000
primary prevention ICD patients, accurately identiﬁes
patients at highest risk for death after device implantation and
may signiﬁcantly inﬂuence clinical decision making (22).Radiofrequency Ablation of Premature Ventricular
Ectopy Improves the Efﬁcacy of Cardiac
Resynchronization Therapy in Nonresponders
Objectives This study sought to examine whether sup-
pressing premature ventricular contractions (PVC) using
radiofrequency ablation improves effectiveness of the cardiac
resynchronization therapy (CRT) in nonresponders.
Background CRT is an effective strategy for drug refrac-
tory congestive heart failure. However, one-third of patients
with CRT do not respond clinically, and the causes for
nonresponse are poorly understood. Whether frequent PVC
contribute to CRT nonresponse remains unknown.
Methods In this multicenter study, CRT nonresponders
with >10,000 PVC in 24 h who underwent PVC ablation
were enrolled from a prospective database.
Results Sixty-ﬁve subjects (age 66.6  12.4 years, 78% men,
QRS duration of 155  18 ms) had radiofrequency ablation
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ablation were 91% and 88% in 12  4 months of follow-up.
There was signiﬁcant improvement in left ventricular (LV)
ejection fraction (26.2  5.5% to 32.7  6.7 %, p < 0.001),
LV end-systolic diameter (5.93  0.55 cm to 5.62  0.32
cm, p < 0.001), LV end-diastolic diameter (6.83  0.83 cm
to 6.51  0.91 cm, p < 0.001), LV end-systolic volume (178
 72 to 145  23 ml, p < 0.001), LV end-diastolic volume
(242  85 ml to 212  63 ml, p < 0.001), and median New
York Heart Association functional class (3.0 to 2.0, p <
0.001). Modeling of pre-ablation PVC burden revealed an
improvement in ejection fraction when the pre-ablation PVC
burden was >22% in 24 h.
Conclusions Frequent PVC is an uncommon yet signiﬁ-
cant cause of CRT nonresponse. Radiofrequency ablation of
PVC foci improves LV function and New York Heart
Association class and promotes reverse remodeling in CRT
nonresponders. PVC ablation may be used to enhance CRT
efﬁcacy in nonresponders with signiﬁcant PVC burden (23).R222Q SCN5A Mutation Is Associated With
Reversible Ventricular Ectopy and Dilated
Cardiomyopathy
Objectives The goal of this study was to characterize
a variant in the SCN5A gene that encodes the alpha-subunit
of the cardiac sodium channel, Nav1.5, which was identiﬁed
in 1 large kindred with dilated cardiomyopathy (DCM) and
multiple arrhythmias, including premature ventricular
complexes (PVCs).
Background Treatment guidelines for familial DCM are
based on conventional heart failure therapies, and no gene-
based interventions have been established.
Methods Family members underwent clinical evaluation
and screening of the SCN5A and LMNA genes. Cellular
electrophysiology and computational modeling were used to
determine the functional consequences of the mutant
Nav1.5 protein.
Results An R222Q missense variant located in a Nav1.5
voltage-sensing domain was identiﬁed in affected family
members. Patch-clamp studies showed that R222Q Nav1.5
did not alter sodium channel current density, but did left
shift steady-state parameters of activation and inactivation.
Using a voltage ramp protocol, normalized current responses
of R222Q channels were of earlier onset and greater
magnitude than wild-type channels. Action potential
modeling using Purkinje ﬁber and ventricular cell models
suggested that rate-dependent ectopy of Purkinje ﬁber
origin is the predominant ventricular effect of the R222Q
variant and a potential cause of DCM. In R222Q carriers,
there were only modest responses to heart failure therapies,
but PVCs and DCM were substantially reduced by amio-
darone or ﬂecainide, which are drugs that have sodium
channel-blocking properties.
Conclusions The R222Q SCN5A variant has an activating
effect on sodium channel function and is associated withreversible ventricular ectopy and DCM. Elucidation of the
genetic basis of familial DCM can enable effective gene-
targeted therapy to be implemented (24).Trends in Permanent Pacemaker Implantation in
the United States From 1993 to 2009: Increasing
Complexity of Patients and Procedures
Objectives This study sought to deﬁne contemporary
trends in permanent pacemaker use by analyzing a large
national database.
Background The Medicare National Coverage Determi-
nation for permanent pacemaker, which emphasized single-
chamber pacing, has not changed signiﬁcantly since 1985.
We sought to deﬁne contemporary trends in permanent
pacemaker use by analyzing a large national database.
Methods We queried the Nationwide Inpatient Sample to
identify permanent pacemaker implants between 1993 and
2009 using the International Classiﬁcation of Diseases-
Ninth Revision-Clinical Modiﬁcation procedure codes for
dual-chamber (DDD), single-ventricular (VVI), single-atrial
(AAI), or biventricular (BiV) devices. Annual permanent
pacemaker implantation rates and patient demographics
were analyzed.
Results Between 1993 and 2009, 2.9 million patients
received permanent pacemakers in the United States.
Overall use increased by 55.6%. By 2009, DDD use
increased from 62% to 82% (p < 0.001), whereas single-
chamber ventricular pacemaker use fell from 36% to 14%
(p ¼ 0.01). Use of DDD devices was higher in urban,
nonteaching hospitals (79%) compared with urban teaching
hospitals (76%) and rural hospitals (72%). Patients with
private insurance (83%) more commonly received DDD
devices than Medicaid (79%) or Medicare (75%) recipients
(p < 0.001). Patient age and Charlson comorbidity index
increased over time. Hospital charges ($2011) increased
45.3%, driven by the increased cost of DDD devices.
Conclusions There is a steady growth in the use of
permanent pacemakers in the United States. Although
DDD device use is increasing, whereas single-chamber
ventricular pacemaker use is decreasing. Patients are
becoming older and have more medical comorbidities. These
trends have important health care policy implications (25).Type 2 Diabetes Mellitus and Risk of Incident Atrial
Fibrillation in Women
Objectives The purpose of this study was to assess whether
changes of major atrial ﬁbrillation (AF) risk factors and/or
intercurrent cardiovascular events could explain the rela-
tionship between type 2 diabetes mellitus (T2D) and inci-
dent AF.
Background Previous studies found an increased risk of
incident AF among individuals with T2D, but few, if any, of
these studies took into account changes of AF risk factors
over time.
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participated in the Women’s Health Study, and who were
free of cardiovascular disease and AF at baseline were fol-
lowed for a median of 16.4 years. Cox proportional-hazards
models were constructed to assess the relationship between
T2D and incident AF, using either information at baseline
or time-varying covariates for both T2D and potential
confounders.
Results At baseline, 937 (2.7 %) women had T2D.
Compared with women without T2D, women with T2D
had an age-adjusted hazard ratio (HR) for new-onset AF of
1.95 (95% conﬁdence interval [CI]: 1.49 to 2.56; p <
0.0001). In multivariable analyses adjusting for baseline
confounders, this HR was substantially attenuated, but
baseline T2D remained a signiﬁcant predictor of incident
AF (HR: 1.37, 95% CI: 1.03 to 1.83; p ¼ 0.03). In time-
updated models that adjusted for changes in AF risk
factors and intercurrent cardiovascular events, the HR for
T2D was attenuated further and became nonsigniﬁcant
(HR: 1.14; 95% CI: 0.93 to 1.40; p ¼ 0.20).
Conclusions Although this study conﬁrms a signiﬁcant
relationship between baseline T2D and incident AF, our
data suggest that the increased risk associated with T2D is
mainly mediated by changes of other AF risk factors (26).Clinical Efﬁcacy of Ivabradine in Patients With
Inappropriate Sinus Tachycardia: A Prospective,
Randomized, Placebo-Controlled, Double-Blind,
Crossover Evaluation
Objectives The purpose of this study was to investigate the
role of ivabradine in the treatment of symptomatic inap-
propriate sinus tachycardia using a double-blind, placebo-
controlled, crossover design.
Background Due to its If blocking properties, ivabradine
can selectively attenuate the high discharge rate from sinus
node cells, causing inappropriate sinus tachycardia.
Methods Twenty-one patients were randomized to receive
placebo (n ¼ 10) or ivabradine 5 mg twice daily (n ¼ 11) for
6 weeks. After a washout period, patients crossed over for an
additional 6 weeks. Each patient underwent symptom
evaluation and heart rate assessment at the start and ﬁnish of
each phase.
Results After taking ivabradine, patients reported elimi-
nation of >70% of symptoms (relative risk: 0.25; 95% CI:
0.18 to 0.34; p < 0.001), with 47% of them experiencing
complete elimination. These effects were associated with
a signiﬁcant reduction of heart rate at rest (from 88  11
beats/min to 76  11 beats/min, p ¼ 0.011), on standing
(from 108  12 beats/min to 92  11 beats/min, p <
0.0001), during 24 h (from 88  5 beats/min to 77  9
beats/min, p ¼ 0.001), and during effort (from 176  17
beats/min to 158  16 beats/min, p ¼ 0.001). Ivabradine
administration was also associated with a signiﬁcant increase
in exercise performance. No cardiovascular side effects were
observed in any patients while taking ivabradine.Conclusions In this cohort, ivabradine signiﬁcantly
improved symptoms associated with inappropriate sinus
tachycardia and completely eliminated them in approxi-
mately half of the patients. These ﬁndings suggest that
ivabradine may be an important agent for improving
symptoms in patients with inappropriate sinus tachycardia
(27).
Spectrum and Prevalence of Mutations Involving
BrS1- Through BrS12-Susceptibility Genes in
a Cohort of Unrelated Patients Referred for
Brugada Syndrome Genetic Testing: Implications
for Genetic Testing
Objectives The aim of this study was to provide the
spectrum and prevalence of mutations in the 12 Brugada
syndrome (BrS)–susceptibility genes discovered to date in
a single large cohort of unrelated BrS patients.
Background BrS is a potentially lethal heritable arrhythmia
syndrome diagnosed electrocardiographically by coved-type
ST-segment elevation in the right precordial leads (V1 to
V3; type 1 Brugada electrocardiographic [ECG] pattern)
and the presence of a personal/family history of cardiac
events.
Methods Using polymerase chain reaction, denaturing
high-performance liquid chromatography, and DNA
sequencing, comprehensive mutational analysis of BrS1-
through BrS12-susceptibility genes was performed in 129
unrelated patients with possible/probable BrS (46 with
clinically diagnosed BrS [ECG pattern plus personal/family
history of a cardiac event] and 83 with a type 1 BrS ECG
pattern only).
Results Overall, 27 patients (21%) had a putative patho-
genic mutation, absent in 1,400 Caucasian reference alleles,
including 21 patients with an SCN5A mutation, 2 with
a CACNB2B mutation, and 1 each with a KCNJ8 muta-
tion, a KCND3 mutation, an SCN1Bb mutation, and an
HCN4 mutation. The overall mutation yield was 23% in the
type 1 BrS ECG pattern-only patients versus 17% in the
clinically diagnosed BrS patients and was signiﬁcantly
greater among young men <20 years of age with clinically
diagnosed BrS and among patients who had a prolonged PQ
interval.
Conclusions We identiﬁed putative pathogenic mutations
in w20% of our BrS cohort, with BrS genes 2 through 12
accounting for <5%. Importantly, the yield was similar
between patients with only a type 1 BrS ECG pattern and
those with clinically established BrS. The yield approaches
40% for SCN5A-mediated BrS (BrS1) when the PQ
interval exceeds 200 ms. Calcium channel–mediated BrS is
extremely unlikely in the absence of a short QT interval (28).
The Limit of Plausibility for Predictors of
Response: Application to Biventricular Pacing
Objectives We sought a method for any reader to quantify
the limit, imposed by variability, to sustainably observable
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We then apply this to echocardiographic measurements of
mechanical dyssynchrony and response.
Background Can mechanical dyssynchrony markers stro-
ngly predict ventricular remodeling by biventricular pacing
(cardiac resynchronization therapy)?
Methods First, we established the mathematical depression
of observable R2 arising from: 1) spontaneous variability of
response markers; and 2) test–retest variability of dyssyn-
chrony measurements. Second, we contrasted published R2
values between externally monitored randomized controlled
trials and highly skilled single-center studies (HSSCSs).
Results Inherent variability of response markers causes
a contraction factor in R2 of 0.48 (change in left ventricular
ejection fraction [DLVEF]), 0.50 (change in end-systolic
volume [DESV]), and 0.40 (change in end-diastolic
volume [DEDV]). Simultaneously, inherent variability of
mechanical dyssynchrony markers causes a contraction factor
of between 0.16 and 0.92 (average, 0.6). Therefore the
combined contraction factor, that is, limit on sustainably
observable R2 between mechanical dyssynchrony markers
and response, is w0.29 (DLVEF), w0.24 (DESV), and
w0.30 (DEDV). Many R2 values published in HSSCSs
exceeded these mathematical limits; none in externally
monitored trials did so. Overall, HSSCSs overestimate R2
by 5- to 20-fold (p ¼ 0.002). Absence of bias-resistance
features in study design (formal enrollment and blinded mea-
surements) was associated with more overstatement of R2.
Conclusions Reports of R2 > 0.2 in response prediction
arose exclusively from studies without formally documented
enrollment and blinding. The HSSCS approach over-
estimates R2 values, frequently breaching the mathematical
ceiling on sustainably observable R2, which is far below 1.0,
and can easily be calculated by readers using formulas pre-
sented here. Community awareness of this low ceiling may
help resist future claims. Reliable individualized response
prediction, using methods originally designed for group-
mean effects, may never be possible because it has 2
currently unavailable and perhaps impossible prerequisites:
1) excellent blinded test–retest reproducibility of dyssyn-
chrony; and 2) response markers reproducible over time
within nonintervened individuals. Dispassionate evaluation,
and improvement, of test–retest reproducibility is required
before any further claims of strong prediction. Prediction
studies should be designed to resist bias (29).Chromosome 4q25 Variants Are Genetic Modiﬁers
of Rare Ion Channel Mutations Associated With
Familial Atrial Fibrillation
Objectives The aim of this study was to test the hypothesis
that 2 common polymorphisms in the chromosome 4q25
region that have been associated with atrial ﬁbrillation (AF)
contribute to the variable penetrance of familial AF.
Background Although mutations in ion channels, gap
junction proteins, and signaling molecules have beendescribed for Mendelian forms of AF, penetrance is highly
variable. Recent studies have consistently identiﬁed 2
common single-nucleotide polymorphisms in the chromo-
some 4q25 region as independent AF susceptibility alleles.
Methods Eleven families in which AF was present in 2
members who also shared a candidate gene mutation were
studied. These mutations were identiﬁed in all subjects with
familial lone AF (n ¼ 33) as well as apparently unaffected
family members (age >50 years with no AF; n ¼ 17).
Results Mutations were identiﬁed in SCN5A (n ¼ 6),
NPPA (n ¼ 2), KCNQ1 (n ¼ 1), KCNA5 (n ¼ 1), and
NKX2.5 (n ¼ 1). In genetic association analyses, unstratiﬁed
and stratiﬁed according to age of onset of AF and unaffected
age >50 years, there was a highly statistically signiﬁcant
association between the presence of both common
(rs2200733 and rs10033464) and rare variants and AF
(unstratiﬁed p ¼ 1  108, stratiﬁed [age of onset <50
years and unaffected age >50 years] p ¼ 7.6  105)
(unstratiﬁed p < 0.0001, stratiﬁed [age of onset <50 years
and unaffected age >50 years] p < 0.0001). Genetic asso-
ciation analyses showed that the presence of common 4q25
risk alleles predicted whether carriers of rare mutations
developed AF (p ¼ 2.2  104).
Conclusions Common AF-associated 4q25 poly-
morphisms modify the clinical expression of latent cardiac
ion channel and signaling molecule gene mutations associ-
ated with familial AF. These ﬁndings support the idea that
the genetic architecture of AF is complex and includes both
rare and common genetic variants (30).A Randomized Comparison of Pulmonary Vein
Isolation With Versus Without Concomitant Renal
Artery Denervation in Patients With Refractory
Symptomatic Atrial Fibrillation and Resistant
Hypertension
Objectives The aim of this prospective randomized study
was to assess the impact of renal artery denervation in
patients with a history of refractory atrial ﬁbrillation (AF)
and drug-resistant hypertension who were referred for
pulmonary vein isolation (PVI).
Background Hypertension is the most common cardio-
vascular condition responsible for the development and
maintenance of AF. Treating drug-resistant hypertension
with renal denervation has been reported to control blood
pressure, but any effect on AF is unknown.
Methods Patients with a history of symptomatic parox-
ysmal or persistent AF refractory to2 antiarrhythmic drugs
and drug-resistant hypertension (systolic blood pressure
>160 mm Hg despite triple drug therapy) were eligible for
enrolment. Consenting patients were randomized to PVI
only or PVI with renal artery denervation. All patients were
followed 1 year to assess maintenance of sinus rhythm and
to monitor changes in blood pressure.
Results Twenty-seven patients were enrolled, and 14 were
randomized to PVI only, and 13 were randomized to PVI
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signiﬁcant reductions in systolic (from 181  7 to 156 
5, p < 0.001) and diastolic blood pressure (from 97  6
to 87  4, p < 0.001) were observed in patients treated
with PVI with renal denervation without signiﬁcant
change in the PVI only group. Nine of the 13 patients
(69%) treated with PVI with renal denervation were
AF-free at the 12-month post-ablation follow-up exami-
nation versus 4 (29%) of the 14 patients in the PVI-only
group (p ¼ 0.033).
Conclusions Renal artery denervation reduces systolic and
diastolic blood pressure in patients with drug-resistant
hypertension and reduces AF recurrences when combined
with PVI. (Combined Treatment of Resistant Hypertension
and Atrial Fibrillation; NCT01117025) (31).Connexin43 Gene Transfer Reduces Ventricular
Tachycardia Susceptibility After Myocardial
Infarction
Objectives The aim of this study was to evaluate the links
between connexin43 (Cx43) expression, myocardial
conduction velocity, and ventricular tachycardia in a model
of healed myocardial infarction.
Background Post-infarction ventricular arrhythmias fre-
quently cause sudden death. Impaired myocardial conduc-
tion has previously been linked to ventricular arrhythmias.
Altered connexin expression is a potential source of
conduction slowing identiﬁed in healed scar border tissues.
The functional effect of increasing border-zone Cx43 has
not been previously evaluated.
Methods Twenty-ﬁve Yorkshire pigs underwent anterior
infarction by transient left anterior descending coronary
artery occlusion, followed by weekly testing for arrhythmia
inducibility. Twenty animals with reproducibly inducible
sustained monomorphic ventricular tachycardia were
randomized 2:1:1 to receive AdCx43, Adbgal, or no gene
transfer. One week later, animals underwent follow-up
electrophysiologic study and tissue assessment for several
functional and molecular measures.
Results Animals receiving AdCx43 had less electrogram
fractionation and faster conduction velocity in the anterior-
septal border zone. Only 40% of AdCx43 animals
remained inducible for ventricular tachycardia, while 100%
of controls were inducible after gene transfer. AdCx43
animals had 2-fold higher Cx43 protein levels in the
anterior-septal infarct border, with similar percents of
phosphorylated and intercalated disk-localized Cx43
compared with controls.
Conclusions These data mechanistically link Cx43
expression to slow conduction and arrhythmia susceptibility
in the healed scar border zone. Targeted manipulation of
Cx43 levels improved conduction velocity and reduced
ventricular tachycardia susceptibility. Cx43 gene transfer
represents a novel treatment strategy for post-infarction
arrhythmias (32).Clinical Evaluation of Deﬁbrillation Testing in an
Unselected Population of 2,120 Consecutive
Patients Undergoing First Implantable
Cardioverter-Deﬁbrillator Implant
Objectives The purpose of this study is to assess the
effectiveness of deﬁbrillation testing (DT) in patients
undergoing implantable cardioverter-deﬁbrillator (ICD)
insertion.
Background Although DT is considered a standard
procedure during ICD implantation, its usefulness has not
been deﬁnitively proven.
Methods The SAFE-ICD (Safety of Two Strategies of
ICD Management at Implantation) study is a prospective
observational study designed to evaluate the outcome of 2
strategies: performing deﬁbrillation testing (DTþ) versus
not performing deﬁbrillation testing (DT) during de novo
ICD implants. No deviation from the centers’ current
practice was introduced. In all, 2,120 consecutive patients
(836 DTþ and 1,284 DT) age 18 years were enrolled at
41 Italian centers from April 2008 to May 2009 and fol-
lowed up for 24 months until June 2011. The primary
endpoint was a composite of severe complications at ICD
implant and sudden cardiac death or resuscitation at 2 years.
Results The primary endpoint occurred in 34 patients: 12
intraoperative complications (8 in DTþ group; 4 in DT
group) and 22 during follow-up (10 in DTþ group; 12 in
DT group). Overall, the estimated yearly incidence (95%
conﬁdence interval) was DTþ 1.15% (0.73 to 1.83) and
DT 0.68% (0.42 to 1.12). The difference between the 2
groups was negligible: 0.47% per year (0.15 to 1.10).
Mortality from any cause was similar at 2 years (adjusted
hazard ratio: 0.97 [0.76 to 1.23], p ¼ 0.80).
Conclusions In this large cohort of new ICD implants,
event rates were similar and extremely low in both groups.
These data indicate a limited clinical relevance for DT
testing, thus supporting a strategy of omitting DT during an
ICD implant. (Safety of Two Strategies of ICD Manage-
ment at Implantation [SAFE-ICD]; NCT00661037) (33).
Modeling of Catecholaminergic Polymorphic
Ventricular Tachycardia With Patient-Speciﬁc
Human-Induced Pluripotent Stem Cells
Objectives The goal of this study was to establish a patient-
speciﬁc human-induced pluripotent stem cells (hiPSCs)
model of catecholaminergic polymorphic ventricular tachy-
cardia (CPVT).
Background CPVT is a familial arrhythmogenic syndrome
characterized by abnormal calcium (Ca2þ) handling,
ventricular arrhythmias, and sudden cardiac death.
Methods Dermal ﬁbroblasts were obtained from a CPVT
patient due to the M4109R heterozygous point RYR2
mutation and reprogrammed to generate the CPVT-hiPSCs.
The patient-speciﬁc hiPSCs were coaxed to differentiate into
the cardiac lineage and compared with healthy control
hiPSCs-derived cardiomyocytes (hiPSCs-CMs).
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monstrated the development of delayed afterdepolarizations
in 69% of the CPVT-hiPSCs-CMs compared with 11% in
healthy control cardiomyocytes. Adrenergic stimulation by
isoproterenol (1 mM) or forskolin (5 mM) increased the
frequency and magnitude of afterdepolarizations and also
led to development of triggered activity in the CPVT-
hiPSCs-CMs. In contrast, ﬂecainide (10 mM) and thap-
sigargin (10 mM) eliminated all afterdepolarizations in
these cells. The latter ﬁnding suggests an important role
for internal Ca2þ stores in the pathogenesis of delayed
afterdepolarizations. Laser-confocal Ca2þ imaging revealed
signiﬁcant whole-cell [Ca2þ] transient irregularities
(frequent local and large-storage Ca2þ-release events,
broad and double-humped transients, and triggered
activity) in the CPVT cardiomyocytes that worsened with
adrenergic stimulation and Ca2þ overload and improved
with beta-blockers. Store-overload–induced Ca2þ release
was also identiﬁed in the hiPSCs-CMs and the threshold
for such events was signiﬁcantly reduced in the CPVT
cells.
Conclusions This study highlights the potential of hiPSCs
for studying inherited arrhythmogenic syndromes, in
general, and CPVT speciﬁcally. As such, it represents
a promising paradigm to study disease mechanisms, opti-
mize patient care, and aid in the development of new
therapies (34).Familial Aggregation of Lone Atrial Fibrillation in
Young Persons
Objectives This study investigated whether an individual’s
risk of developing lone atrial ﬁbrillation (AF) before age 60
years is associated with lone AF in relatives.
Background Genetic factors may play a role in the devel-
opment of lone AF.
Methods Using Danish national registers, a cohort was
established of w4 million persons born between 1950 and
2008, and those with a family history of lone AF (AF
without preceding cardiovascular/endocrine diagnoses) were
identiﬁed. Individuals were followed up until the ﬁrst
diagnosis of lone AF. Poisson regression was used to esti-
mate incidence rate ratios (IRRs).
Results In w92 million person-years of follow-up, 9,507
persons were identiﬁed as having lone AF. The IRRs for
lone AF given an affected ﬁrst- or second-degree relative
were 3.48 (95% conﬁdence interval [CI]: 3.08 to 3.93) and
1.64 (95% CI: 1.04 to 2.59), respectively. IRRs were higher
for men than for women but were not associated with the
affected relative’s sex. IRR for lone AF was 6.24 (95% CI:
2.59 to 15.0), given at least 2 ﬁrst-degree relatives affected
with lone AF. The IRR for lone AF in persons aged <40
years given a ﬁrst-degree relative affected at age <40 years
was 5.42 (95% CI: 3.80 to 7.72), and 8.53 (95% CI: 3.82 to
19.0) in persons age <30 years given a ﬁrst-degree relative
affected at age <30 years.Conclusions A family history of lone AF is associated with
substantial risk of lone AF, with the strongest risks associ-
ated with young age at onset, multiple affected relatives, and
in ﬁrst-degree relatives. These results suggest routine eval-
uation of the families of at least certain types of patients with
lone AF (35).
Clinical Implications of an Implantable
Cardioverter-Deﬁbrillator in Patients With
Vasospastic Angina and Lethal Ventricular
Arrhythmia
Objectives The present study was performed to investigate
the clinical implications of an implantable cardioverter-
deﬁbrillator (ICD) in patients with vasospastic angina
(VSA) resuscitated from lethal ventricular arrhythmia.
Background The prognosis of VSA is known to be good
with medication; however, ventricular arrhythmia and
cardiopulmonary arrest are rare but life-threatening
complications of this disease. The ICD is a proven
modality for patients with ventricular arrhythmia, but the
clinical implications in this population remain to be
elucidated.
Methods We conducted a retrospective, observational,
multicenter study involving patients with an ICD due to
documented ventricular arrhythmia and VSA diagnosed by
acetylcholine provocation test. All patients were followed up
for appropriate ICD therapy, sudden cardiac arrest, or death
from all causes.
Results Twenty-three patients were included in the present
study and completely followed up. All patients are still alive.
During a follow-up of 2.9 years (median 2.1 years), 4
ventricular ﬁbrillations and 1 episode of pulseless electrical
activity occurred in 5 patients (21.7%). There were no
statistically signiﬁcant differences in patient characteristics
between the recurrence and nonrecurrence groups, including
medication, smoking status, and whether the patient was or
was not free of symptoms after ICD implantation.
Conclusions Patients with VSA and lethal ventricular
arrhythmia are a population at high risk for recurrence of
cardiopulmonary arrest, and there is no reliable indicator for
predicting recurrence of ventricular arrhythmia. Insertion of
an ICD with medication for VSA is appropriate for this
high-risk population (36).
Performance of the HEMORR2HAGES, ATRIA, and
HAS-BLED Bleeding Risk–Prediction Scores in
Patients With Atrial Fibrillation Undergoing
Anticoagulation: The AMADEUS (Evaluating the
Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation)
Study
Objectives The objective of this study was to compare the
predictive performance of bleeding risk–estimation tools in
a cohort of patients with atrial ﬁbrillation (AF) undergoing
anticoagulation.
The Editors JACC Vol. 62, No. 21, 2013
JACC Topic Collection: Heart Rhythm Disorders November 19/26, 2013:e451–519
e464Background Three bleeding risk–prediction schemes have
been derived for and validated in patients with AF:
HEMORR2HAGES (Hepatic or Renal Disease, Ethanol
Abuse, Malignancy, Older Age, Reduced Platelet Count or
Function, Re-Bleeding, Hypertension, Anemia, Genetic
Factors, Excessive Fall Risk and Stroke), ATRIA (Anti-
coagulation and Risk Factors in Atrial Fibrillation), and
HAS-BLED (Hypertension, Abnormal Renal/Liver Func-
tion, Stroke, Bleeding History or Predisposition, Labile
International Normalized Ratio, Elderly, Drugs/Alcohol).
The relative predictive values of these bleeding scores have
not previously been compared.
Methods We analyzed the dataset from the AMADEUS
(Evaluating the Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation) trial,
a multicenter, randomized, open-label noninferiority study
that compared ﬁxed-dose idraparinux with adjustable-dose
oral vitamin K antagonist therapy in patients with AF.
The principal safety outcome was any clinically relevant
bleeding event, which was a composite of major bleeding
plus clinically relevant nonmajor bleeding.
Results The HAS-BLED score performed best in pre-
dicting any clinically relevant bleeding, reﬂected both in net
reclassiﬁcation improvement (10.3% and 13% improvement
compared with HEMORR2HAGES and ATRIA, respec-
tively) and receiver-operating characteristic (ROC) analyses
(c-indexes: 0.60 vs. 0.55 and 0.50 for HAS-BLED vs.
HEMORR2AGES and ATRIA, respectively). Using
decision-curve analysis, the HAS-BLED score demon-
strated superior performance compared with ATRIA and
HEMORR2HAGES at any threshold probability for clin-
ically relevant bleeding. HAS-BLED was the only score that
demonstrated a signiﬁcant predictive performance for
intracranial hemorrhage (c-index: 0.75; p ¼ 0.03). An
ATRIA score >3 was not signiﬁcantly associated with the
risk for any clinically relevant bleeding on Cox regression or
on ROC analysis (c-index: 0.50; p ¼ 0.87).
Conclusions All 3 tested bleeding risk–prediction scores
demonstrated only modest performance in predicting any
clinically relevant bleeding, although the HAS-BLED score
performed better than the HEMORR2HAGES and
ATRIA scores, as reﬂected by ROC analysis, reclassiﬁcation
analysis, and decision-curve analysis. Only HAS-BLED
demonstrated a signiﬁcant predictive performance for
intracranial hemorrhage. Given its simplicity, the HAS-
BLED score may be an attractive method for the estima-
tion of oral anticoagulant–related bleeding risk for use in
clinical practice, supporting recommendations in interna-
tional guidelines (37).Family History of Premature Death and Risk of
Early Onset Cardiovascular Disease
Objectives The purpose of this study was to examine the
effect of a family history of premature death, cardiovascular
death in particular, on the risk of early cardiovascular disease.Background Studies suggest that fatal cardiovascular events
and less severe cardiovascular diseases may co-occur in
families. Consequently, a family history of premature death
may indicate a familial cardiac frailty that predisposes to
early cardiovascular disease.
Methods We ascertained family history of premature death
(age <60 years) in all individuals born in Denmark from
1950 to 2008 and followed this cohort for early cardiovas-
cular disease (age <50 years). Using Poisson regression, we
estimated incidence rate ratios (IRRs) reﬂecting the effect of
premature death in the family on early cardiovascular disease
risk.
Results Among 3,985,301 persons followed up for
89,294,258 person-years, 129,825, 31,172, and 5,214 were
diagnosed with any early cardiovascular disease, ischemic
heart disease, and ventricular arrhythmia, respectively. IRRs
for these conditions given a history of premature cardiovas-
cular death in ﬁrst-degree relatives were 1.72 (95% conﬁdence
interval [CI]: 1.68 to 1.77), 2.21 (95% CI: 2.11 to 2.31), and
1.94 (95% CI: 1.70 to 2.20), respectively. With 2 cardio-
vascular deaths in a family, corresponding IRRs were 3.30
(95% CI: 2.77 to 3.94), 5.00 (95% CI: 3.87 to 6.45), and 6.18
(95%CI: 3.32 to 11.50). The IRR for any early cardiovascular
disease given a family history of premature noncardiovascular
death was signiﬁcantly lower, 1.12 (95% CI: 1.10 to 1.14)
(pcardiac vs. noncardiac < 0.0001).
Conclusions Family history of premature cardiovascular
death was consistently and signiﬁcantly associated with a risk
of early cardiovascular disease, suggesting an inherited
cardiac vulnerability. These results should be kept in mind
when assessing cardiovascular disease risk in persons with
a family history of premature cardiovascular death (38).Common Variation in the NOS1AP Gene Is
Associated With Drug-Induced QT Prolongation and
Ventricular Arrhythmia
Objectives This study sought to determine whether varia-
tions in NOS1AP affect drug-induced long QT syndrome
(LQTS).
Background Use of antiarrhythmic drugs is limited by the
high incidence of serious adverse events including QT
prolongation and torsades de pointes. NOS1AP gene vari-
ants play a role in modulating QT intervals in healthy
subjects and severity of presentation in LQTS.
Methods This study carried out an association study using
167 single nucleotide polymorphisms (SNP) spanning the
NOS1AP gene in 58 Caucasian patients experiencing drug-
induced LQTS (dLQTS) and 87 Caucasian controls from
the DARE (Drug-Induced Arrhythmia Risk Evaluation)
study.
Results The rs10800397 SNP was signiﬁcantly associated
with dLQTS (odds ratio [OR]: 3.3, 99.95% conﬁdence
interval [CI]: 1.0 to 10.8, p ¼ 3.7  10–4). The associations
were more pronounced in the subgroup of amiodarone users,
in which 3 SNPs, including rs10800397, were signiﬁcantly
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99.95% CI: 1.1 to 27.9, p ¼ 3.0  10–4). We genotyped
rs10919035 in an independent replication cohort of 28
amiodarone dLQTS cases versus 173 control subjects (meta-
analysis of both studies: OR: 2.81, 99.95% CI: 1.62 to 4.89,
p ¼ 2.4  10–4). Analysis of corrected QT interval among
74 control subjects from our dataset showed a similar pattern
of signiﬁcance over the gene region as the case-control
analysis. This pattern was conﬁrmed in 1,480 control
subjects from the BRIGHT (British Genetics of Hyper-
tension Study) cohort (top SNP from DARE: rs12734991
in meta-analysis: increase in corrected QT interval per C
allele: 9.1  3.2 ms, p ¼ 1.7  10–4).
Conclusions These results provide the ﬁrst demonstration
that common variations in the NOS1AP gene are associ-
ated with a signiﬁcant increase in the risk of dLQTS. This
study suggests that common variations in the NOS1AP
gene may have relevance for future pharmacogenomic
applications in clinical practice permitting safer prescription
of drugs for vulnerable patients (39).Electrophysiological and Hemodynamic
Characteristics Associated With Obesity in
Patients With Atrial Fibrillation
Objectives The authors sought to characterize the left atrial
(LA) and pulmonary vein (PV) electrophysiological and
hemodynamic features in obese patients with atrial ﬁbrilla-
tion (AF).
Background Obesity is associated with increased risk for
AF.
Methods A total of 63 consecutive patients with AF who
had normal left ventricular (LV) ejection fraction and who
underwent catheter ablation were studied. Atrial and PV
electrophysiological studies were performed at the time of
ablation with hemodynamic assessment by cardiac cathe-
terization, and LA/LV structure and function by echocar-
diography. Patients were compared on the basis of body
mass index (BMI): <25 kg/m2 (n ¼ 19) and BMI 30 kg/
m2 (n ¼ 44).
Results At a 600-ms pacing cycle length, obese patients
had shorter effective refractory period (ERP) in the left
atrium (251  25 ms vs. 233  32 ms, p ¼ 0.04), and in
the proximal (207  33 ms vs. 248  34 ms, p < 0.001)
and distal (193  33 ms vs. 248  44 ms, p < 0.001) PV
than normal BMI patients. Obese patients had higher
mean LA pressure (15  5 mm Hg vs. 10  5 mm Hg,
p < 0.001) and LA volume index (28  12 ml/m2 vs. 21
 14 ml/m2, p ¼ 0.006), and lower LA strain (5.5 
3.1% vs. 8.8  2.8%; p < 0.001) than normal BMI
patients.
Conclusions Increased LA pressure and volume, and
shortened ERP in the left atrium and PV are potential
factors facilitating and perpetuating AF in obese patients
with AF (40).Reduction in Life-Threatening Ventricular
Tachyarrhythmias in Statin-Treated Patients With
Nonischemic Cardiomyopathy Enrolled in the
MADIT-CRT (Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac Resynchronization
Therapy)
Objectives This study hypothesized that time-dependent
statin therapy will reduce the risk of life-threatening
ventricular tachyarrhythmias among patients with non-
ischemic cardiomyopathy (NICM) enrolled in the MADIT-
CRT (Multicenter Automatic Deﬁbrillator Implantation
Trial with Cardiac Resynchronization Therapy).
Background Prior studies suggested that statin therapy
exerts antiarrhythmic properties among patients with coro-
nary artery disease. However, data regarding the effect of
statins on arrhythmic risk among patients with NICM are
limited.
Methods Multivariate Cox proportional hazards regression
modeling was used to assess the effect of statin therapy,
evaluated as a time-dependent covariate, on the risk of
appropriate deﬁbrillator therapy for fast ventricular tachy-
cardia (VT) (deﬁned as a rate faster than 180 beats/min)/
ventricular ﬁbrillation (VF) or death (primary endpoint) and
appropriate deﬁbrillator shocks (secondary endpoint) among
821 patients with NICM enrolled in theMADIT-CRT trial.
Results Statin users (n ¼ 499) were older and had a higher
prevalence of diabetes and hypertension yet were less
frequently smokers. Multivariate analysis showed that time-
dependent statin therapy was independently associated with
a signiﬁcant 77% reduction in the risk of fast VT/VF or
death (p < 0.001) and with a signiﬁcant 46% reduction in
the risk of appropriate implantable cardioverter deﬁbrillator
shocks (p ¼ 0.01). Consistent with these ﬁndings, the
cumulative probability of fast VT/VF or death at 4 years of
follow-up was signiﬁcantly lower among patients who were
treated with statins (11%) as compared with study patients
who were not treated with statins (19%; p ¼ 0.006 for the
overall difference during follow-up).
Conclusions Statin use was associated with a signiﬁcant
reduction in the risk of life-threatening ventricular tachyar-
rhythmias among patients with NICM (41).
Indirect Comparisons of New Oral Anticoagulant
Drugs for Efﬁcacy and Safety When Used for
Stroke Prevention in Atrial Fibrillation
Objectives This study sought to perform an indirect
comparison analysis of dabigatran etexilate (2 doses), rivar-
oxaban, and apixaban for their relative efﬁcacy and safety
against each other.
Background Data for warfarin compared against the new
oral anticoagulants (OACs) in large phase III clinical trials
of stroke prevention in atrial ﬁbrillation (AF) are now
available for the oral direct thrombin inhibitor, dabigatran
etexilate, in 2 doses (150 mg twice daily [BID], 110 mg
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apixaban. A “head-to-head” direct comparison of drugs is
the standard method for comparing different treatments, but
in the absence of such head-to-head direct comparisons,
another alternative to assess the relative effect of different
treatment interventions would be to perform indirect
comparisons, using a common comparator. Nonetheless, any
inter-trial comparison is always fraught with major difﬁ-
culties, and an indirect comparison analysis has many limi-
tations, especially with the inter-trial population differences
and thus, should not be overinterpreted.
Methods Indirect comparison analysis was performed using
data from the published trials.
Results There was a signiﬁcantly lower risk of stroke and
systemic embolism (by 26%) for dabigatran (150 mg BID)
compared with rivaroxaban, as well as hemorrhagic stroke
and nondisabling stroke. There were no signiﬁcant differ-
ences for apixaban versus dabigatran (both doses) or rivar-
oxaban; or rivaroxaban versus dabigatran 110 mg BID in
preventing stroke and systemic embolism. For ischemic
stroke, there were no signiﬁcant differences between the new
OACs. Major bleeding was signiﬁcantly lower with apix-
aban compared with dabigatran 150 mg BID (by 26%) and
rivaroxaban (by 34%), but not signiﬁcantly different from
dabigatran 110 mg BID. There were no signiﬁcant differ-
ences between apixaban and dabigatran 110 mg BID in
safety endpoints. Apixaban also had lower major or clinically
relevant bleeding (by 34%) compared with rivaroxaban.
When compared with rivaroxaban, dabigatran 110 mg BID
was associated with less major bleeding (by 23%) and
intracranial bleeding (by 54%). There were no signiﬁcant
differences in myocardial infarction events between the
dabigatran (both doses) and apixaban.
Conclusions Notwithstanding the limitations of an indi-
rect comparison study, we found no profound signiﬁcant
differences in efﬁcacy between apixaban and dabigatran
etexilate (both doses) or rivaroxaban. Dabigatran 150 mg
BID was superior to rivaroxaban for some efﬁcacy
endpoints, whereas major bleeding was signiﬁcantly lower
with dabigatran 110 mg BID or apixaban. Only a head-
to-head direct comparison of the different new OACs
would fully answer the question of efﬁcacy/safety differences
between the new drugs for stroke prevention in AF (42).Treatment of Atrial Fibrillation by the Ablation of
Localized Sources: CONFIRM (Conventional
Ablation for Atrial Fibrillation With or Without
Focal Impulse and Rotor Modulation) Trial
Objectives We hypothesized that human atrial ﬁbrillation
(AF) may be sustained by localized sources (electrical rotors
and focal impulses), whose elimination (focal impulse and
rotor modulation [FIRM]) may improve outcome from AF
ablation.
Background Catheter ablation for AF is a promising
therapy, whose success is limited in part by uncertainty inthe mechanisms that sustain AF. We developed a compu-
tational approach to map whether AF is sustained by several
meandering waves (the prevailing hypothesis) or localized
sources, then prospectively tested whether targeting patient-
speciﬁc mechanisms revealed by mapping would improve
AF ablation outcome.
Methods We recruited 92 subjects during 107 consecutive
ablation procedures for paroxysmal or persistent (72%) AF.
Cases were prospectively treated, in a 2-arm 1:2 design, by
ablation at sources (FIRM-guided) followed by conventional
ablation (n ¼ 36), or conventional ablation alone (n ¼ 71;
FIRM-blinded).
Results Localized rotors or focal impulses were detected in
98 (97%) of 101 cases with sustained AF, each exhibiting
2.1  1.0 sources. The acute endpoint (AF termination or
consistent slowing) was achieved in 86% of FIRM-guided
cases versus 20% of FIRM-blinded cases (p < 0.001).
FIRM ablation alone at the primary source terminated AF
in a median 2.5 min (interquartile range: 1.0 to 3.1 min).
Total ablation time did not differ between groups (57.8 
22.8 min vs. 52.1  17.8 min, p ¼ 0.16). During a median
273 days (interquartile range: 132 to 681 days) after a single
procedure, FIRM-guided cases had higher freedom from
AF (82.4% vs. 44.9%; p < 0.001) after a single procedure
than FIRM-blinded cases with rigorous, often implanted,
electrocardiography monitoring. Adverse events did not
differ between groups.
Conclusions Localized electrical rotors and focal impulse
sources are prevalent sustaining mechanisms for human AF.
FIRM ablation at patient-speciﬁc sources acutely terminated
or slowed AF, and improved outcome. These results offer
a novel mechanistic framework and treatment paradigm for
AF. (Conventional Ablation for Atrial Fibrillation With or
Without Focal Impulse and Rotor Modulation
[CONFIRM]; NCT01008722) (43).Differential Response to Cardiac
Resynchronization Therapy and Clinical Outcomes
According to QRS Morphology and QRS Duration
Objectives The goal of this study was to examine the
relative impact of QRS morphology and duration in echo-
cardiographic responses to cardiac resynchronization therapy
(CRT) and clinical outcomes.
Background At least one-third of all patients treated with
CRT fail to derive beneﬁt. Patients without left bundle
branch block (LBBB) or patients with smaller QRS duration
(QRSd) respond less or not at all to CRT.
Methods We retrospectively assessed baseline characteris-
tics, clinical and echocardiographic response, and outcomes
of all patients who received CRT at our institution between
December 2003 and July 2007. Patients were stratiﬁed into
4 groups according to their baseline QRS morphology and
QRSd.
Results A total of 496 patients were included in the study;
216 (43.5%) had LBBB and a QRSd 150 ms, 85 (17.1%)
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LBBB and a QRSd 150 ms, and 103 (20.8%) had non-
LBBB and QRSd <150 ms. Echocardiographic response
(change in ejection fraction) was better in patients with
LBBB and QRSd 150 ms (12  12%) than in those with
LBBB and QRSd <150 ms (8  10%), non-LBBB and
QRSd 150 ms (5  9%), and non-LBBB and
QRSd <150 ms (3  11%) (p < 0.0001). In a multivariate
stepwise model with change in ejection fraction as the
dependent variable, the presented classiﬁcation was the most
important independent variable (p ¼ 0.0003). Long-term
survival was better in LBBB patients with QRSd 150
ms (p ¼ 0.02), but this difference was not signiﬁcant after
adjustment for other baseline characteristics (p ¼ 0.15).
Conclusions QRS morphology is a more important base-
line electrocardiographic determinant of CRT response than
QRSd (44).MR Cine DENSE Dyssynchrony Parameters for the
Evaluation of Heart Failure: Comparison With
Myocardial Tissue Tagging
Objectives We sought to assess the effectiveness of auto-
mated mechanical dyssynchrony (MD) parameters based on
regional heterogeneity of strain (circumferential [CURE],
longitudinal [LURE], and radial uniformity ratio estimates)
relative to parameters based on regional time to peak
contraction with cardiac magnetic resonance (CMR) cine
DENSE (Displacement Encoding with Stimulated Echoes)
validated with myocardial tissue tagging (MTT) strain data.
Background Dyssynchrony measures based on the Fourier
transformation (FT) of regional strain, such as CURE
(previously evaluated in cardiac resynchronization therapy
candidates), directly assess MD and yield straightforward
global dyssynchrony indexes; however, performance relative
to the 12-segment standard deviation of time to peak strain
(SD12) or maximal regional delay in time to peak strain is
unknown.
Methods Cine DENSE and MTT were obtained with
CMR (1.5-T Siemens Avanto, Siemens, Erlangen,
Germany) in 13 canines: 3 normal control subjects, 5 with
tachycardia pacing-induced heart failure (HF) and left
bundle branch ablation (LBBB-HF), and 5 with HF and
narrow QRS (NQRS-HF). Strain and dyssynchrony
parameters were determined with both CMR methods.
Results Both HF groups had reduced peak strains and
left ventricular ejection fraction compared with normal
cases. There was strong agreement between cine DENSE
and MTT on the basis of intraclass correlation coefﬁcients
(CURE: 0.99, 95% CI: 0.96 to 1.00; LURE: 0.92, 95%
CI: 0.77 to 0.98; circumferential strain [ECC]: 0.95, 95%
CI: 0.72 to 0.99; longitudinal strain [ELL]: 0.82, 95% CI:
0.42 to 0.97). The FT-based metrics (scale 0 to 1), in
particular CURE, discriminated highly between LBBB-
HF and NQRS-HF groups (median difference): CURE:
0.60, 95% CI: 0.43 to 0.76; LURE: 0.39, 95% CI: 0.19 to0.58; radial uniformity ratio estimate: 0.22, 95% CI: 0.04
to 0.40). In contrast, relative conﬁdence intervals for group
differences in time-to-peak parameters were wide, indi-
cating less consistent discrimination (median difference):
SD12-ECC: 52.5, 95% CI: 4.0 to 109.2; SD12-ELL:
40.9, 95% CI: 5.3 to 87.1; SD12-radial strain: 42.0,
95% CI: 0.4 to 83.6). Correlations between FT-based
and time-to-peak parameters were signiﬁcant (CURE/
SD12-ECC: r ¼ 0.62, p ¼ 0.03; LURE/SD12-ELL:
r ¼ 0.76, p ¼ 0.005) but not as tight as correlations
between time-to-peak parameters.
Conclusions Automated FT-based circumferential, radial,
and longitudinal dyssynchrony measures compare favorably
with time-to-peak parameters. Cine DENSE was effective
for this application and validated with MTT. Further
clinical evaluation in cardiac resynchronization therapy
candidates with CMR or other imaging modalities is
warranted (45).Assessment of Myocardial Scarring Improves Risk
Stratiﬁcation in Patients Evaluated for Cardiac
Deﬁbrillator Implantation
Objectives We tested whether an assessment of myocardial
scarring by cardiac magnetic resonance imaging (MRI)
would improve risk stratiﬁcation in patients evaluated for
implantable cardioverter-deﬁbrillator (ICD) implantation.
Background Current sudden cardiac death risk stratiﬁca-
tion emphasizes left ventricular ejection fraction (LVEF);
however, most patients suffering sudden cardiac death have
a preserved LVEF, and many with poor LVEF do not
beneﬁt from ICD prophylaxis.
Methods One hundred thirty-seven patients undergoing
evaluation for possible ICD placement were prospectively
enrolled and underwent cardiac MRI assessment of LVEF
and scar. The pre-speciﬁed primary endpoint was death or
appropriate ICD discharge for sustained ventricular
tachyarrhythmia.
Results During a median follow-up of 24 months the
primary endpoint occurred in 39 patients. Whereas the rate
of adverse events steadily increased with decreasing LVEF,
a sharp step-up was observed for scar size >5% of left
ventricular mass (hazard ratio [HR]: 5.2; 95% conﬁdence
interval [CI]: 2.0 to 13.3). On multivariable Cox propor-
tional hazards analysis, including LVEF and
electrophysiological-study results, scar size (as a continuous
variable or dichotomized at 5%) was an independent
predictor of adverse outcome. Among patients with LVEF
>30%, those with signiﬁcant scarring (>5%) had higher risk
than those with minimal or no (5%) scarring (HR: 6.3;
95% CI: 1.4 to 28.0). Those with LVEF >30% and
signiﬁcant scarring had risk similar to patients with
LVEF 30% (p ¼ 0.56). Among patients with
LVEF 30%, those with signiﬁcant scarring again had
higher risk than those with minimal or no scarring (HR: 3.9;
95% CI: 1.2 to 13.1). Those with LVEF 30% and
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>30% (p ¼ 0.71).
Conclusions Myocardial scarring detected by cardiac MRI
is an independent predictor of adverse outcome in patients
being considered for ICD placement. In patients with
LVEF >30%, signiﬁcant scarring (>5% LV) identiﬁes
a high-risk cohort similar in risk to those with LVEF 30%.
Conversely, in patients with LVEF 30%, minimal or no
scarring identiﬁes a low-risk cohort similar to those with
LVEF >30% (46).Modeling Serum Biomarkers S100 Beta and
Neuron-Speciﬁc Enolase as Predictors of Outcome
After Out-of-Hospital Cardiac Arrest: An Aid to
Clinical Decision Making
Objectives The aim of this study was to determine the
added value of the serum biomarkers S100 and neuron-
speciﬁc enolase to clinical characteristics for predicting
outcome after out-of-hospital cardiac arrest.
Background Serum S100 beta (S100B) and neuron-
speciﬁc enolase concentrations rise after brain injury.
Methods A prolective observational study was conducted
among all adult survivors of nontraumatic out-of-hospital
cardiac arrest admitted to 1 hospital (April 3, 2008 to
April 3, 2011). Three blood samples (on arrival and on days
1 and 3) were drawn for biomarkers, contingent on survival.
Follow-up continued until in-hospital death or discharge.
Outcomes were deﬁned as good (Cerebral Performance
Category score 1 or 2) or poor (Cerebral performance
category score 3 to 5).
Results A total of 195 patients were included (65.6% men,
mean age 73  16 years), with presenting rhythms of
asystole in 61.5% and ventricular tachycardia or ventricular
ﬁbrillation in 24.1%. Only 43 patients (22.0%) survived to
hospital discharge, 26 (13.3%) with good outcomes. Patients
with good outcomes had signiﬁcantly lower S100B levels at
all time points and lower neuron-speciﬁc enolase levels on
days 1 and 3 compared with those with poor outcomes.
Independent predictors at admission of a good outcome
were younger age, a presenting rhythm of ventricular
tachycardia or ventricular ﬁbrillation, and lower S100B level.
Predictors on day 3 were younger age and lower day 3
S100B level. The area under the receiver-operating charac-
teristic curve of the admission-day model was 0.932 with
and 0.880 without biomarker data (p ¼ 0.027 for the
difference).
Conclusions Risk stratiﬁcation after out-of-hospital cardiac
arrest using both clinical and biomarker data is feasible. The
biomarkers, although adding an ostensibly modest 5.2% to
the area under the receiver-operating characteristic curve,
substantially reduced the level of uncertainty in decision
making. Nevertheless, current biomarkers cannot replace
societal considerations in determining acceptable levels of
uncertainty. (Protein S100 Beta as a Predictor of Resusci-
tation Outcome; NCT00814814) (47).Midregional Pro-Adrenomedullin as a Predictor for
Therapeutic Response to Midodrine Hydrochloride
in Children With Postural Orthostatic Tachycardia
Syndrome
Objectives This study was designed to explore the
predictive value of the midregional fragment of pro-
adrenomedullin (MR-proADM) in assessing the thera-
peutic efﬁcacy of midodrine hydrochloride for children with
postural orthostatic tachycardia syndrome (POTS).
Background Midodrine hydrochloride is an important
therapeutic option for children with POTS. However, there
has not been any method to predict response to the drug.
The MR-proADM is produced in equimolar amounts to
adrenomedullin (ADM), and directly reﬂects levels of the
rapidly degraded active peptide, ADM.
Methods Fifty-seven children with POTS were designated
as the POTS group. Twenty healthy children served as the
control group. The children in the POTS group received
midodrine hydrochloride treatment. The plasma concen-
tration of MR-proADM was measured, using a sandwich
immunoluminometric assay. A receiver-operating charac-
teristic curve was used to explore the predictive value of
MR-proADM.
Results Plasma levels of MR-proADM were signiﬁcantly
higher in children with POTS (75.0 [62.5 to 96.0] pg/ml)
than in the control group (58.5 [50.3 to 69.0] pg/ml).
Plasma levels of MR-proADM in responders to midodrine
hydrochloride was signiﬁcantly higher than that of nonre-
sponders (76.0 [66.0 to 91.0] pg/ml vs. 59.0 [54.0 to 65.5]
pg/ml, p < 0.01]. A receiver-operating characteristic curve
on the predictive value of MR-proADM showed that the
area under the curve was 0.879 with a 95% conﬁdence
interval of 0.761 to 0.997. Using a cutoff value for MR-
proADM of 61.5 pg/ml produced both high sensitivity
(100%) and speciﬁcity (71.6%) in predicting the efﬁcacy of
midodrine hydrochloride therapy for treating POTS.
Conclusions MR-proADM can help guide midodrine
hydrochloride therapy in the management of POTS in
children (48).Clinical Application of Cardiovascular
Pharmacogenetics
Pharmacogenetics primarily uses genetic variation to identify
subgroups of patients who may respond differently to
a certain medication. Since its ﬁrst description, the ﬁeld of
pharmacogenetics has expanded to study a broad range of
cardiovascular drugs and has become a mainstream research
discipline. Three principle classes of pharmacogenetic
markers have emerged: 1) pharmacokinetic; 2) pharmaco-
dynamic; and 3) underlying disease mechanism. In the realm
of cardiovascular pharmacogenetics, signiﬁcant advances
have identiﬁed markers in each class for a variety of thera-
peutics, some with a potential for improving patient
outcomes. While ongoing clinical trials will determine if
JACC Vol. 62, No. 21, 2013 The Editors
November 19/26, 2013:e451–519 JACC Topic Collection: Heart Rhythm Disorders
e469routine use of pharmacogenetic testing may be beneﬁcial,
the data today support pharmacogenetic testing for certain
variants on an individualized, case-by-case basis. Our
primary goal is to review the association data for the major
pharmacogenetic variants associated with commonly used
cardiovascular medications: antiplatelet agents, warfarin,
statins, beta-blockers, diuretics, and antiarrhythmic drugs.
In addition, we highlight which variants and in which
contexts pharmacogenetic testing can be implemented by
practicing clinicians. The pace of genetic discovery has
outstripped the generation of the evidence justifying its
clinical adoption. Until the evidentiary gaps are ﬁlled,
however, clinicians may choose to target therapeutics to
individual patients whose genetic background indicates
that they stand to beneﬁt the most from pharmacogenetic
testing (49).Long-Term Prognosis Following Resuscitation From
Out of Hospital Cardiac Arrest: Role of
Percutaneous Coronary Intervention and
Therapeutic Hypothermia
Objectives The aim of the study was to assess the inﬂuence
of percutaneous coronary intervention (PCI) and therapeutic
hypothermia (TH) on long-term prognosis.
Background Although hospital care consisting of TH
and/or PCI in particular patients resuscitated following
out-of-hospital cardiac arrest (OHCA) can improve survival
to hospital discharge, there is little evidence regarding how
these therapies may impact long-term prognosis.
Methods We performed a cohort investigation of all
persons >18 years of age who suffered nontraumatic OHCA
and were resuscitated and discharged alive from the hospital
between January 1, 2001, and December 31, 2009, in
a metropolitan emergency medical service (EMS) system.
We reviewed EMS and hospital records, state death certif-
icates, and the national death index to determine clinical
characteristics and vital status. Survival analyses were con-
ducted using Kaplan-Meier estimates and multivariable Cox
regression. Analyses of TH were restricted to those patients
who were comatose at hospital admission.
Results Of the 5,958 persons who received EMS-attempted
resuscitation, 1,001 (16.8%) were discharged alive from the
hospital. PCI was performed in 384 of 1,001 (38.4%),
whereas TH was performed in 241 of 941 (25.6%) persons
comatose at hospital admission. Five-year survival was 78.7%
among those treated with PCI compared with 54.4%
among those not receiving PCI and 77.5% among those
treated with TH compared with 60.4% among those not
receiving TH (both p < 0.001). After adjustment for
confounders, PCI was associated with a lower risk of death
(hazard ratio [HR]: 0.46 [95% conﬁdence interval [CI]: 0.34
to 0.61]; p< 0.001). Likewise, THwas associated with a lower
risk of death (HR: 0.70 [95% CI: 0.50 to 0.97]; p ¼ 0.04).
Conclusions The ﬁndings suggested that effects of
acute hospital interventions for post-resuscitation treatmentextend beyond hospital survival and can positively inﬂuence
prognosis following the arrest hospitalization (50).Hybrid Thoracoscopic Surgical and Transvenous
Catheter Ablation of Atrial Fibrillation
Objectives The purpose of this study was to evaluate the
feasibility, safety, and clinical outcomes up to 1 year in
patients undergoing combined simultaneous thoracoscopic
surgical and transvenous catheter atrial ﬁbrillation (AF)
ablation.
Background The combination of the transvenous endo-
cardial approach with the thoracoscopic epicardial approach
in a single AF ablation procedure overcomes the limitations
of both techniques and should result in better outcomes.
Methods A cohort of 26 consecutive patients with AF who
underwent hybrid thoracoscopic surgical and transvenous
catheter ablation were followed, with follow-up of up to 1
year.
Results Twenty-six patients (42% with persistent AF)
underwent successful hybrid procedures. There were no
complications. The mean follow-up period was 470  154
days. In 23% of the patients, the epicardial lesions were
not transmural, and endocardial touch-up was necessary.
One-year success, deﬁned according to the Heart Rhythm
Society, European Heart Rhythm Association, and Euro-
pean Cardiac Arrhythmia Society consensus statement for
the catheter and surgical ablation of AF, was 93% for
patients with paroxysmal AF and 90% for patients with
persistent AF. Two patients underwent catheter ablation for
recurrent AF or left atrial ﬂutter after the hybrid procedure.
Conclusions A combined transvenous endocardial and
thoracoscopic epicardial ablation procedure for AF is feasible
and safe, with a single-procedure success rate of 83% at 1
year (51).Medical Device Innovation: Prospective Solutions
for an Ecosystem in Crisis: Adding a Professional
Society Perspective
Barriers to medical device innovation compromise timelines
and costs from bench to bedside. Fragmented strategies by
individual competitors are no longer sustainable. Pragmati-
cally focused pre-competitive collaboration across stake-
holders approaches innovation as an ecosystem. Desiloing
experience and expertise encourages high-impact infra-
structure efﬁciencies unique to pre-competitive constructs.
Alignment of processes and objectives across the regulatory,
reimbursement, clinical research, and clinical practice
enterprises, with particular attention to the total product life
cycle and continuous accrual of safety information, promotes
more predictable equipoise for speed of access relative to
residual safety concerns. Professional societies are well
positioned to convene pre-competitive dialogue, facilitate
alignment, and add perspective to equipoise within the
innovation ecosystem (52).
The Editors JACC Vol. 62, No. 21, 2013
JACC Topic Collection: Heart Rhythm Disorders November 19/26, 2013:e451–519
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Phosphodiesterase Type 4 Protects Against Atrial
Arrhythmias
Objectives This study was designed to examine whether
a cyclic adenosine monophosphate (cAMP) phosphodies-
terase (PDE), PDE4, is expressed in human atrium and
contributes to the control of electrical stability.
Background Atrial ﬁbrillation is accompanied by
a profound remodeling of membrane receptors and alter-
ations in cAMP-dependent regulation of Ca2þ handling.
Being responsible for cAMP hydrolysis, PDEs are likely to
play a role in this setting. In the rodent heart, PDE4
contributes up to 60% of total cAMP-hydrolytic activity.
However, its role in the human heart remains controversial.
Methods L-type Ca2þ current and spontaneous Ca2þ
release were recorded in isolated human atrial myocytes.
Intracellular cAMP was measured by live cell imaging using
a ﬂuorescence resonance energy transfer-based sensor.
Contractile force and arrhythmias were recorded in human
atrial trabeculae. PDE activity was measured in human atrial
tissue from patients in sinus rhythm and permanent atrial
ﬁbrillation.
Results PDE4 is expressed in human atrial myocytes and
accounts for approximately 15% of total PDE activity.
PDE4D represents the major PDE4 subtype. PDE4 inhi-
bition increased intracellular cAMP and L-type Ca2þ
current and dramatically delayed their decay after a brief
b-adrenergic stimulation. PDE4 inhibition also increased
the frequency of spontaneous Ca2þ release at baseline, as
well as the contractile response and the incidence of
arrhythmias in human atrial strips during b-adrenergic
stimulation. Total PDE activity decreased with age, and the
relative PDE4 activity was lower in patients with permanent
atrial ﬁbrillation than in age-matched sinus rhythm controls.
Conclusions PDE4 is critical in controlling cAMP levels
and thereby Ca2þ inﬂux and release in human atrial muscle,
hence limiting the susceptibility to arrhythmias (53).
Applicability of a Risk Score for Prediction of the
Long-Term (8-Year) Beneﬁt of the Implantable
Cardioverter-Deﬁbrillator
Objectives The present study was designed to explore the
8-year survival beneﬁt of a nonresynchronization implant-
able cardioverter-deﬁbrillator (ICD) according to a simple
risk stratiﬁcation score.
Background There is limited information regarding factors
that predict the beneﬁt of primary prevention with an ICD
during long-term follow-up.
Methods This study used a previously developed risk score
including 5 clinical factors (New York Heart Association
functional class >II, age >70 years, blood urea nitrogen >26
mg/dl, QRS duration >0.12 s, and atrial ﬁbrillation) to
evaluate 8-year ICD survival beneﬁt within risk score cate-
gories among 1,191 MADIT-II (Multicenter Automatic
Deﬁbrillator Implantation Trial II) patients.Results Patients with low (0 risk factors, n ¼ 345) and
intermediate risk (1 to 2 risk factors, n ¼ 646) demonstrated
a signiﬁcantly higher probability of survival at 8-year follow-
up when treated by ICD as compared with non-ICD
therapy (75% vs. 58%, p ¼ 0.004; and 47% vs. 31%, p <
0.001, respectively). By contrast, among high-risk patients
(3 or more risk factors, n ¼ 200), there was no signiﬁcant
difference in 8-year survival between the ICD and non-ICD
subgroups (19% vs. 17%, p ¼ 0.50). Consistently, multi-
variate analysis showed that ICD therapy was associated
with a signiﬁcant long-term survival beneﬁt among low- and
intermediate-risk patients (hazard ratio [HR]: 0.52, p <
0.001, and HR: 0.66, p < 0.001, respectively), whereas
treatment with an ICD was not associated with a signiﬁcant
beneﬁt among high-risk patients (HR: 0.84, p ¼ 0.25).
Conclusions These ﬁndings suggest that a simple risk score
can identify patients who derive signiﬁcant long-term
beneﬁt from primary ICD therapy. High-risk patients
with multiple comorbidities composed 17% of the MADIT-
II population and did not derive long-term beneﬁt from
nonresynchronization device therapy (54).Outcome of Cardiac Surgery in Patients 50 Years
of Age or Older With Ebstein Anomaly: Survival and
Functional Improvement
Objectives This study sought to analyze the presentation,
surgical procedures, and outcomes in patients 50 years of
age with Ebstein anomaly (EA).
Background Data on management and surgical outcomes
in older patients with EA are limited.
Methods Operative and clinical data from patients with
EA 50 years of age undergoing cardiac surgery at our
center between October 1980 and January 2010 were
analyzed.
Results During the study period, 89 procedures were per-
formed in 81 patients with EA (63% women; mean [range]
age 59 [50 to 79] years). Pre-operative symptoms included
palpitations (n ¼ 69), edema (n ¼ 30), and previous stroke/
transient ischemic attack (n ¼ 21). Seventy-six patients
(85%) had functional class III or IV symptoms, and 13
(16%) had previous cardiac surgery. Tricuspid valve surgery
was necessary in 87 of the 89 procedures (98%): replacement
in 65 (73%) and repair in 22 (25%). Three early deaths
occurred (4%). On long-term follow-up (available in 73 of
78 early survivors), 63 patients (89%) had improved func-
tional class and 13 patients died (19%). The 20-year survival
was 65% versus 74% for age- and sex-matched controls
(p ¼ 0.001). The best predictors of late death were lack of
post-operative improvement and older age at surgery.
Conclusions Although cardiac surgery in patients with
EA 50 years of age was often complex, early mortality was
low (4%) when surgery was performed at an experienced
center. Long-term survival was good, although less than
expected. These data suggested that surgery in older patients
with EA may have to be performed earlier (55).
JACC Vol. 62, No. 21, 2013 The Editors
November 19/26, 2013:e451–519 JACC Topic Collection: Heart Rhythm Disorders
e471Optimal Treatment of Patients Surviving Out-of-
Hospital Cardiac Arrest
Interest in post-resuscitation care has risen with the devel-
opment of treatment modalities that can affect long-term
survival rates even when begun after the systematic
ischemia/reperfusion insult associated with cardiac arrest.
Mild therapeutic hypothermia has become the foundation
for improvement of neurologically favorable survival after
cardiac arrest. Reperfusion therapy, speciﬁcally early percu-
taneous coronary intervention, is becoming an important
adjunct to therapeutic hypothermia. Identifying which post–
cardiac arrest patient had an occluded or unstable coronary
vessel is difﬁcult because such events are not reliably pre-
dicted by precedent symptoms or standard electrocardio-
graphic analysis. Increasing clinical experience suggests that
resuscitated cardiac arrest victims without an obvious
noncardiac etiology should undergo emergency coronary
angiography and, where indicated, percutaneous coronary
intervention. If comatose, they should receive concurrent
therapeutic hypothermia. Such an approach can double
long-term survival rates among those successfully resusci-
tated after out-of-hospital cardiac arrest (56).Dynamicity of the J-Wave in Idiopathic Ventricular
Fibrillation With a Special Reference to Pause-
Dependent Augmentation of the J-Wave
Objectives This study evaluated the pause-dependency of
the J-wave to characterize this phenomenon in idiopathic
ventricular ﬁbrillation (VF).
Background The J-wave can be found in apparently
healthy subjects and in patients at risk for sudden cardiac
death, and risk stratiﬁcation is therefore needed.
Methods Forty patients with J-wave–associated idiopathic
VF were studied for J waves with special reference concerning
pause-dependent augmentation. J waves were deﬁned as
those 0.1 mV above the isoelectric line and were compared
with 76 non-VF patients of comparable age and sex.
Results The J-wave was larger in patients with idiopathic
VF than in the controls: 0.360  0.181 mV versus 0.192 
0.064 mV (p ¼ 0.0011). J waves were augmented during
storms of VF (n ¼ 9 [22.5%]), which was controlled by
isoproterenol; they disappeared within weeks in 5 patients.
In addition, sudden prolongation of the R-R interval was
observed in 27 patients induced by benign arrhythmia, and
15 patients (55.6%) demonstrated pause-dependent aug-
mentation (from 0.391  0.126 mV to 0.549  0.220 mV;
p < 0.0001). In the other 12 experimental subjects and in
the 76 control subjects, J waves remained unchanged. Pause-
dependent augmentation of J waves was detected in 55.6%
(sensitivity) but was speciﬁc (100%) in the patients with
idiopathic VF with high positive (100%) and negative
(86.4%) predictive values.
Conclusions Pause-dependent augmentation of J waves
was conﬁrmed in about one-half of the patients withidiopathic VF after sudden R-R prolongation. Such
dynamicity of J waves was speciﬁc to idiopathic VF and may
be used for risk stratiﬁcation (57).
Sudden Cardiac Death in Patients With Human
Immunodeﬁciency Virus Infection
Objectives The aim of this study was to determine the
incidence and clinical characteristics of sudden cardiac death
(SCD) in patients with human immunodeﬁciency virus
(HIV) infection.
Background As the HIV-infected population ages,
cardiovascular disease prevalence and mortality are
increasing, but the incidence and features of SCD have not
yet been described.
Methods The records of 2,860 consecutive patients in
a public HIV clinic in San Francisco between April 2000 and
August 2009 were examined. Identiﬁcation of deaths, causes
of death, and clinical characteristics were obtained by search
of the National Death Index and/or clinic records. SCDs
were determined using published retrospective criteria: 1) the
International Classiﬁcation of Diseases-10th Revision, code
for all cardiac causes of death; and (2) circumstances of death
meeting World Health Organization criteria.
Results Of 230 deaths over a median of 3.7 years of follow-
up, 30 (13%) met SCD criteria, 131 (57%) were due to
acquired immune deﬁciency syndrome (AIDS), 25 (11%)
were due to other (natural) diseases, and 44 (19%) were due
to overdoses, suicides, or unknown causes. SCDs accounted
for 86% of all cardiac deaths (30 of 35). The mean SCD rate
was 2.6 per 1,000 person-years (95% conﬁdence interval: 1.8
to 3.8), 4.5-fold higher than expected. SCDs occurred in
older patients than did AIDS deaths (mean 49.0 vs. 44.9
years, p ¼ 0.02). Compared with AIDS and natural deaths
combined, SCDs had a higher prevalence of prior myocar-
dial infarction (17% vs. 1%, p < 0.0005), cardiomyopathy
(23% vs. 3%, p < 0.0005), heart failure (30% vs. 9%, p ¼
0.004), and arrhythmias (20% vs. 3%, p ¼ 0.003).
Conclusions SCDs account for most cardiac and many
non-AIDS natural deaths in HIV-infected patients. Further
investigation is needed to ascertain underlying mechanisms,
which may include inﬂammation, antiretroviral therapy
interruption, and concomitant medications (58).
Ventricular Arrhythmias in the Absence of
Structural Heart Disease
Ventricular arrhythmia (VA) in structurally normal hearts
can be broadly considered under non–life-threatening
monomorphic and life-threatening polymorphic rhythms.
Monomorphic VA is classiﬁed on the basis of site of origin
in the heart, and the most common areas are the ventricular
outﬂow tracts and left ventricular fascicles. The morphology
of the QRS complexes on electrocardiogram is an excellent
tool to identify the site of origin of the rhythm. Although
these arrhythmias are common and generally carry an
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ported. Very frequent ventricular ectopy may also result in
a cardiomyopathy in a minority of patients. Suppression of
VA may be achieved using calcium-channel blockers, beta-
adrenergic blockers, and class I or III antiarrhythmic
drugs. Radiofrequency ablation has emerged as an excellent
option to eliminate these arrhythmias, although certain foci
including aortic cusps and epicardium may be technically
challenging. Polymorphic ventricular tachycardia (VT) is
rare and generally occurs in patients with genetic ion channel
disorders including long QT syndrome, Brugada syndrome,
catecholaminergic polymorphic VT, and short QT
syndrome. Unlike monomorphic VT, these arrhythmic
syndromes are associated with sudden death. While the
cardiac gross morphology is normal, suggesting a structurally
normal heart, abnormalities exist at the molecular level and
predispose them to arrhythmias. Another fascinating area,
idiopathic ventricular ﬁbrillation and early repolarization
syndrome, are undergoing research for a genetic basis (59).New Concepts in the Assessment of Syncope
Signiﬁcant progress has been made in the past 3 decades in
our understanding of the various causes of loss of
consciousness thanks to the publication of several important
studies and guidelines. In particular, the recent European
Society of Cardiology guidelines provide a reference stan-
dard for optimal quality service delivery. This paper gives the
reader brief guidance on how to manage a patient with
syncope, with reference to the above guidelines. Despite the
progress made, the management of patients with syncope
remains largely unsatisfactory because of the presence of
a signiﬁcant gap between knowledge and its application.
Two new concepts aimed at ﬁlling that gap are currently
under evaluation: syncope facilities with specialist backup
and interactive decision-making software. Preliminary data
have shown that a standardized syncope assessment, espe-
cially when coupled with interactive decision-making soft-
ware, decreases admission rate and unnecessary testing and
improves diagnostic yield, thus reducing cost per diagnosis.
The long-term effects of such a new health care model on
the rate of diagnosis and survival await future studies (60).Eplerenone and Atrial Fibrillation in Mild Systolic
Heart Failure: Results From the EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization And
SurvIval Study in Heart Failure) Study
Objectives The purpose of this study was to analyze the
incidence of new atrial ﬁbrillation or ﬂutter (AFF) in the
EMPHASIS-HF (Eplerenone in Mild Patients Hospitali-
zation And SurvIval Study in Heart Failure) database.
Background Aldosterone antagonism in heart failure might
inﬂuence atrial ﬁbrosis and remodeling and, therefore, risk of
developing AFF. The development of new AFF was a pre-
speciﬁed secondary endpoint in the EMPHASIS-HF study.Methods Patients in New York Heart Association func-
tional class II and with ejection fraction 35% were eligible
for EMPHASIS-HF. History of AFF at baseline was re-
ported by investigators using the study case report form.
New onset AFF (in those with no history of AFF at base-
line) was reported using a speciﬁc endpoint form; in
a sensitivity analysis we also examined the effect of epler-
enone on AFF reported as an adverse event.
Results New onset AFF was signiﬁcantly reduced by
eplerenone: 25 of 911 (2.7%) versus 40 of 883 (4.5%) in the
placebo group (hazard ratio [HR]: 0.58, 95% conﬁdence
interval [CI]: 0.35 to 0.96; p ¼ 0.034). The reduction in the
primary endpoint with eplerenone was similar among
patients with and without AFF at baseline (HR: 0.60, 95%
CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to 0.85,
respectively; p for interaction ¼ 0.41). The risk of cardio-
vascular (CV) death or hospital admission for worsening
heart failure, the primary endpoint, was not signiﬁcantly
different in subjects with and without AFF at baseline (both
study groups combined: HR: 1.23, 95% CI: 0.81 to 1.86;
p ¼ 0.33).
Conclusions In patients with systolic heart failure and mild
symptoms, eplerenone reduced the incidence of new onset
AFF. The effects of eplerenone on the reduction of major
CV events were similar in patients with and without AFF at
baseline (61).Factors Predicting and Having an Impact on the
Need for a Permanent Pacemaker After CoreValve
Prosthesis Implantation Using the New Accutrak
Delivery Catheter System
Objectives The purpose of this study was to evaluate the
need for a permanent pacemaker after transcatheter aortic
valve implantation with the CoreValve prosthesis (Med-
tronic, Inc., Minneapolis, Minnesota) using the new
Accutrak delivery system (Medtronic, Inc.).
Background The need for a permanent pacemaker is
a recognized complication after transcatheter aortic valve
implantation with the CoreValve prosthesis.
Methods Between April 23, 2008 and May 31, 2011, 195
consecutive patients with symptomatic aortic valve stenosis
underwent transcatheter aortic valve implantation using the
self-expanding CoreValve prosthesis. In 124 patients, the
traditional delivery system was used, and in 71 patients, the
Accutrak delivery system was used.
Results There were no signiﬁcant differences in baseline
electrocardiographic characteristics between the traditional
system and the Accutrak patients: PR interval: 153  46 mm
versus 165  30 mm, p ¼ 0.12; left bundle branch block: 22
(20.2%) versus 8 (12.7%), p ¼ 0.21; right bundle branch
block: 21 (19.3%) versus 8 (12.7%), p ¼ 0.26. The depth of
the prosthesis in the left ventricular outﬂow tract was greater
with the traditional system than with the Accutrak system
(9.6  3.2 mm vs. 6.4  3 mm, p < 0.001) and the need for
a permanent pacemaker was higher with traditional system
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predictors of the need for a pacemaker were the depth of the
prosthesis in the left ventricular outﬂow tract (hazard ratio
[HR]: 1.2, 95% conﬁdence interval [CI]: 1.08 to 1.34, p <
0.001), pre-existing right bundle branch block (HR: 3.5, 95%
CI: 1.68 to 7.29, p¼ 0.001), and use of the traditional system
(HR: 27, 95% CI: 2.81 to 257, p ¼ 0.004).
Conclusions The new Accutrak delivery system was asso-
ciated with less deep prosthesis implantation in the left
ventricular outﬂow tract, which could be related to the lower
rate of permanent pacemaker requirement (62).Noninvasive Programmed Ventricular Stimulation
Early After Ventricular Tachycardia Ablation to
Predict Risk of Late Recurrence
Objectives The goal of this study was to evaluate the ability
of noninvasive programmed stimulation (NIPS) after
ventricular tachycardia (VT) ablation to identify patients at
high risk of recurrence.
Background Optimal endpoints for VT ablation are not
well deﬁned.
Methods Of 200 consecutive patients with VT and struc-
tural heart disease undergoing ablation, 11 had clinical VT
inducible at the end of ablation and 11 recurred spontane-
ously. Of the remaining 178 patients, 132 underwent NIPS
through their implantable cardioverter-deﬁbrillator 3.1 
2.1 days after ablation. At 2 drive cycle lengths, single,
double, and triple right ventricular extrastimuli were deliv-
ered to refractoriness. Clinical VT was deﬁned by compar-
ison with 12-lead electrocardiograms and stored implantable
cardioverter-deﬁbrillator electrograms from spontaneous VT
episodes. Patients were followed for 1 year.
Results Fifty-nine patients (44.7%) had no VT inducible at
NIPS; 49 (37.1%) had inducible nonclinical VT only; and
24 (18.2%) had inducible clinical VT. Patients with induc-
ible clinical VT at NIPS had markedly decreased 1-year VT-
free survival compared to those in whom no VT was
inducible (<30% vs. >80%; p ¼ 0.001), including 33%
recurring with VT storm. Patients with inducible nonclinical
VT only, had intermediate 1-year VT-free survival (65%).
Conclusions When patients with VT and structural heart
disease have noVT or nonclinical VT only inducible at the end
of ablation or their condition is too unstable to undergo ﬁnal
programmed stimulation, NIPS should be considered in the
following days to further deﬁne risk of recurrence. If clinical
VT is inducible at NIPS, repeat ablation may be considered
because recurrence over the following year is high (63).New Oral Anticoagulants in Atrial Fibrillation and
Acute Coronary Syndromes: ESC Working Group on
ThrombosisdTask Force on Anticoagulants in
Heart Disease Position Paper
Until recently, vitamin K antagonists were the only available
oral anticoagulants, but with numerous limitations thatprompted the introduction of new oral anticoagulants tar-
geting the single coagulation enzymes thrombin (dabigatran)
or factor Xa (apixaban, rivaroxaban, and edoxaban) and
given in ﬁxed doses without coagulation monitoring. Here
we review the pharmacology and the results of clinical trials
with these new agents in stroke prevention in atrial ﬁbril-
lation and secondary prevention after acute coronary
syndromes, providing perspectives on their future incorpo-
ration into clinical practice. In phase III trials in atrial
ﬁbrillation, compared with warfarin, dabigatran etexilate
150 mg B.I.D. reduced the rates of stroke/systemic
embolism without any difference in major bleeding; dabi-
gatran etexilate 110 mg B.I.D. had similar efﬁcacy with
decreased bleeding; apixaban 5 mg B.I.D. reduced stroke,
systemic embolism, and mortality as well as major bleeding;
and rivaroxaban 20 mg Q.D. was noninferior to warfarin
for stroke and systemic embolism without a difference in
major bleeding. All these agents reduced intracranial
hemorrhage. Edoxaban is currently being evaluated in
a further large phase III trial. Apixaban and rivaroxaban
were evaluated in phase III trials for prevention of recurrent
ischemia in patients with acute coronary syndromes who
were mostly receiving dual antiplatelet therapy, with con-
ﬂicting results on efﬁcacy but consistent results for
increased major bleeding. Overall, the new oral anticoagu-
lants are poised to replace vitamin K antagonists for many
patients with atrial ﬁbrillation and may have a role after
acute coronary syndromes. Although convenient to
administer and manage, they present challenges that need
to be addressed (64).Impact of Metabolic Syndrome on Procedural
Outcomes in Patients With Atrial Fibrillation
Undergoing Catheter Ablation
Objectives The aim of this study was to investigate impact
of metabolic syndrome (MS) on outcomes of catheter
ablation in patients with atrial ﬁbrillation (AF) in terms of
recurrence and quality of life (QoL).
Background MS, a proinﬂammatory state with hyperten-
sion, diabetes, dyslipidemia, and obesity, is presumed to be
a close associate of AF.
Methods In this prospective study, 1,496 consecutive
patients with AF undergoing ﬁrst ablation (29% with
paroxysmal AF, 26% with persistent AF, and 45% with
long-standing persistent AF) were classiﬁed into those
with MS (group 1; n ¼ 485) and those without MS
(group 2; n ¼ 1,011). Patients were followed for recur-
rence and QoL. The Medical Outcomes Study SF-36
Health Survey was used to assess QoL at baseline and
12 month after ablation.
Results After 21  7 months of follow-up, 189 patients
in group 1 (39%) and 319 in group 2 (32%) had
arrhythmia recurrence (p ¼ 0.005). When stratiﬁed
by AF type, patients with nonparoxysmal AF in group 1
failed more frequently compared with those in group 2
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existed in the subgroup with paroxysmal AF (39 [25%] vs.
62 [22%], p ¼ 0.295). Group 1 patients had signiﬁcantly
lower baseline scores on all SF-36 Health Survey subscales.
At follow-up, both mental component summary (D5.7 
2.5, p < 0.001) and physical component summary (D9.1 
3.7, p < 0.001) scores improved in group 1, whereas only
mental component summary scores (D4.6  2.8, p ¼
0.036) were improved in group 2. In the subgroup with
nonparoxysmal AF, MS, sex, C-reactive protein 0.9
mg/dl, and white blood cell count were independent
predictors of recurrence.
Conclusions Baseline inﬂammatory markers and the pres-
ence of MS predicted higher recurrence after single-catheter
ablation only in patients with nonparoxysmal AF. Addi-
tionally, signiﬁcant improvements in QoL were observed in
the post-ablation MS population (65).Effects of Atrial Fibrillation on Treatment of Mitral
Regurgitation in the EVEREST II (Endovascular
Valve Edge-to-Edge Repair Study) Randomized
Trial
Objectives The purpose of this study was to characterize
patients with mitral regurgitation (MR) and atrial ﬁbrillation
(AF) treated percutaneously using the MitraClip device
(Abbott Vascular, Abbott Park, Illinois) and compare the
results with surgery in this population.
Background The EVEREST II (Endovascular Valve
Edge-to-Edge Repair Study) randomized controlled trial
compared a less invasive catheter-based treatment for MR
with surgery, providing an opportunity to assess the impact
of AF on the outcomes of both the MitraClip procedure and
surgical repair.
Methods The study population included 264 patients
with moderately severe or severe MR assessed by an
independent echocardiographic core laboratory. Compar-
ison of safety and effectiveness study endpoints at 30 days
and 1 year were made using both intention-to-treat and
per-protocol (cohort of patients with MR 2þ at dis-
charge) analyses.
Results Pre-existing AF was present in 27% of patients.
These patients were older, had more advanced disease, and
were more likely to have a functional etiology. Similar
reduction of MR to 2þ before discharge was achieved in
patients with AF (83%) and in patients without AF (75%,
p ¼ 0.3). Freedom from death, mitral valve surgery for
valve dysfunction, and MR >2þ was similar at 12 months
for AF patients (64%) and for no-AF patients (61%, p ¼
0.3). At 12 months, MR reduction to <2þ was greater
with surgery than with MitraClip, but there was no
interaction between rhythm and MR reduction, and no
difference in all-cause mortality between patients with and
patients without AF.
Conclusions Atrial ﬁbrillation is associated with more
advanced valvular disease and noncardiac comorbidities.However, acute procedural success, safety, and 1-year
efﬁcacy with MitraClip therapy is similar for patients
with AF and without AF (66).The Federal Audit of Implantable Cardioverter-
Deﬁbrillator Implants: Lessons Learned
The federal government has investigated a large number
of institutions regarding concerns that implantable
cardioverter-deﬁbrillator procedures were performed in
violation of the criteria set forth in a National Coverage
Determination. We describe our experience and responses to
such an audit, as well as the complexities and nuances of
practicing evidence-based medicine in the setting of heavy
regulatory oversight (67).Risk Factors and Outcomes of Post-Procedure
Heart Blocks After Transcatheter Device
Closure of Perimembranous Ventricular
Septal Defect
Objectives The aim of this study was to analyze the
risk factors and mid-term outcomes associated with
post-procedure heart blocks (PPHBs) after transcatheter
closure of perimembranous ventricular septal defect
(pmVSD).
Background The development of heart blocks remains
a major challenge for transcatheter closure of pmVSD.
Methods Transcatheter closure of pmVSD was carried out
in 228 patients. Electrocardiography and 24-h Holter
monitoring were performed before the procedure, within 1
week after the procedure, then 1, 3, 6, and 12 months, and
every year thereafter.
Results Thirty-three patients (14.5%) who received trans-
catheter closure of pmVSD developed PPHBs. PPHBs
included right bundle branch block (57.6%), left bundle
branch block (24.2%), and atrioventricular block (18.2%).
High-degree atrioventricular blocks occurred in 4 patients
and recovered to normal conduction after intravenous
administration of hydrocortisone. PPHBs recovered to
normal conduction in 21 patients by the time of hospital
discharge. Compared with the patients without PPHBs,
the patients suffering PPHBs were characterized by
a signiﬁcantly longer distance between the aortic valve and
the defect (DAVD), a shorter distance from the lower rim
of the defect to the septal leaﬂet of the tricuspid valve
(DLRD-SLTV), and a larger diameter difference between
the occluder and ventricular septal defect (DDOV). The
earlier the PPHBs developed after the procedure, the more
difﬁcult the recovery to normal conduction.
Conclusions The outcome of PPHBs after transcatheter
closure of pmVSD was satisfactory, as most patients recov-
ered to normal conduction. Measurements of DLRD-
SLTV, DAVD, and DDOV may be useful in predicting
the incidence of PPHBs (68).
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Warfarin for Periprocedural Anticoagulation in
Patients Undergoing Radiofrequency Ablation for
Atrial Fibrillation: Results From a Multicenter
Prospective Registry
Objectives The purpose of this study was to evaluate the
feasibility and safety of periprocedural dabigatran during
atrial ﬁbrillation (AF) ablation.
Background AF ablation requires optimal periprocedural
anticoagulation for minimizing bleeding and thromboem-
bolic complications. The safety and efﬁcacy of dabigatran
as a periprocedural anticoagulant for AF ablation are
unknown.
Methods We performed a multicenter, observational study
from a prospective registry including all consecutive patients
undergoing AF ablation in 8 high-volume centers in the
United States. All patients receiving dabigatran therapy who
underwent AF ablation on periprocedural dabigatran, with
the dose held on the morning of the procedure, were
matched by age, sex, and type of AF with an equal number
of patients undergoing AF ablation with uninterrupted
warfarin therapy over the same period.
Results A total of 290 patients, including 145 taking
periprocedural dabigatran and an equal number of matched
patients taking uninterrupted periprocedural warfarin, were
included in the study. The mean age was 60 years with
79% being male and 57% having paroxysmal AF. Both
groups had a similar CHADS2 score, left atrial size, and
left ventricular ejection fraction. Three thromboembolic
complications (2.1%) occurred in the dabigatran group
compared with none in the warfarin group (p ¼ 0.25).
The dabigatran group had a signiﬁcantly higher major
bleeding rate (6% vs. 1%; p ¼ 0.019), total bleeding rate
(14% vs. 6%; p ¼ 0.031), and composite of bleeding and
thromboembolic complications (16% vs. 6%; p ¼ 0.009)
compared with the warfarin group. Dabigatran use was
conﬁrmed as an independent predictor of bleeding or
thromboembolic complications (odds ratio: 2.76, 95%
conﬁdence interval: 1.22 to 6.25; p ¼ 0.01) on multivar-
iate regression analysis.
Conclusions In patients undergoing AF ablation, peri-
procedural dabigatran use signiﬁcantly increases the risk of
bleeding or thromboembolic complications compared with
uninterrupted warfarin therapy (69).Impact of QRS Duration and Morphology on the
Risk of Sudden Cardiac Death in Asymptomatic
Patients With Aortic Stenosis: The SEAS
(Simvastatin and Ezetimibe in Aortic Stenosis)
Study
Objectives The aim of the study was to examine the
predictive value of QRS duration and morphology during
watchful waiting in asymptomatic patients with aortic
stenosis (AS).Background QRS duration and morphology are associated
with poor prognosis in many different populations, but the
predictive value, particularly of the risk of sudden cardiac
death (SCD), in asymptomatic patients with AS has not
been well studied.
Methods Data were obtained in asymptomatic AS patients
randomized to simvastatin/ezetimibe combination versus
placebo in the SEAS (Simvastatin and Ezetimibe in Aortic
Stenosis) study. The impact of QRS duration, evaluated as
a categorical variable of <85 ms versus 85 to 99 ms
and 100 ms (excluding bundle branch block [BBB]) and
QRS morphology in those with BBB, on cardiovascular
morbidity and mortality was assessed by adjusting for clinical
and echocardiographic covariates.
Results QRS data were available in 1,542 patients who
were followed for a mean of 4.3  0.8 years (6,631
patient-years of follow-up). There were 68 cardiovascular
deaths (4.6%), including 27 SCDs (1.8%). QRS duration
was <85 ms in 900 patients (58.4%), 85 to 99 ms in 396
(25.7%), 100 ms in those without BBB in 144 (9.3%),
and 102 (6.6%) in those with BBB. In multivariable
analyses, those with QRS duration 100 ms had,
compared with those with QRS duration <85 ms, a 5-
fold higher risk of SCD (95% conﬁdence interval: 1.8
to 13.7, p ¼ 0.002) and a 2.5-fold higher risk of
cardiovascular death (95% conﬁdence interval: 1.2 to 5.1,
p ¼ 0.01).
Conclusions QRS duration and morphology in asymp-
tomatic patients with AS are independently associated with
a poor prognosis, particularly the risk of SCD. (Simvastatin
Ezetimibe in Aortic Stenosis [SEAS]; NCT00092677) (70).Epistatic Effects of Potassium Channel Variation
on Cardiac Repolarization and Atrial Fibrillation
Risk
Objectives The aim of this study was to evaluate the role of
cardiac Kþ channel gene variants in families with atrial
ﬁbrillation (AF).
Background The Kþ channels play a major role in atrial
repolarization but single mutations in cardiac Kþ channel
genes are infrequently present in AF families. The collective
effect of background Kþ channel variants of varying preva-
lence and effect size on the atrial substrate for AF is largely
unexplored.
Methods Genes encoding the major cardiac Kþ channels
were resequenced in 80 AF probands. Nonsynonymous
coding sequence variants identiﬁed in AF probands were
evaluated in 240 control subjects. Novel variants were
characterized using patch-clamp techniques and in silico
modeling was performed using the Courtemanche atrial cell
model.
Results Nineteen nonsynonymous variants in 9 genes were
found, including 11 rare variants. Rare variants were more
frequent in AF probands (18.8% vs. 4.2%, p < 0.001), and
the mean number of variants was greater (0.21 vs. 0.04, p <
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modest functional effects. Modeling simulations to evaluate
combinations of Kþ channel variants of varying population
frequency indicated that simultaneous small perturbations of
multiple current densities had nonlinear interactions and
could result in substantial (>30 ms) shortening or length-
ening of action potential duration as well as increased
dispersion of repolarization.
Conclusions Families with AF show an excess of rare
functional Kþ channel gene variants of varying phenotypic
effect size that may contribute to an atrial arrhythmogenic
substrate. Atrial cell modeling is a useful tool to assess
epistatic interactions between multiple variants (71).
Histopathologic Characterization of Chronic
Radiofrequency Ablation Lesions for Pulmonary
Vein Isolation
Objectives This study describes the histopathologic and
electrophysiological ﬁndings in patients with recurrence
of atrial ﬁbrillation (AF) after pulmonary vein (PV)
isolation who underwent a subsequent surgical maze
procedure.
Background The recovery of PV conduction is commonly
responsible for recurrence of AF after catheter-based PV
isolation.
Methods Twelve patients with recurrent AF after acutely
successful catheter-based antral PV isolation underwent
a surgical maze procedure. Full-thickness surgical biopsy
specimens were obtained from the PV antrum in areas of
visible endocardial scar. Before biopsy, intraoperative
epicardial electrophysiological recordings were taken from
each PV using a circular mapping catheter.
Results Twenty-two PVs were biopsied from the 12
patients 8  11 months after ablation. Eleven of the 22
specimens (50%) revealed transmural scar, and 11 (50%)
showed viable myocardium with or without scar. Each
biopsy specimen demonstrated evidence of injury, most
commonly endocardial thickening (n ¼ 21 [95%]) and
ﬁbrous scar (n ¼ 18 [82%]). Seven of the 22 specimens
(32%) showed conduction block at surgery. Transmural scar
was more likely to be seen in the biopsy specimens from the
PVs with conduction block than in specimens from the PVs
showing reconnection. However, viable myocardium alone
or mixed with scar was seen in 2 specimens from PVs with
conduction block.
Conclusions PVs showing electrical reconnection after
catheter-based antral ablation frequently reveal anatomic
gaps or nontransmural lesions at the sites of catheter abla-
tion. Nontransmural lesions are noted in some PVs with
persistent conduction block, suggesting that lesion geometry
may inﬂuence PV conduction. The histological ﬁndings
show that nontransmural ablation can produce a dynamic
cellular substrate with features of reversible injury. Delayed
recovery from injury may explain late recurrences of AF after
PV isolation (72).The Clinical Impact of Incomplete Left Atrial
Appendage Closure With the Watchman Device in
Patients With Atrial Fibrillation: A PROTECT AF
(Percutaneous Closure of the Left Atrial
Appendage Versus Warfarin Therapy for
Prevention of Stroke in Patients With Atrial
Fibrillation) Substudy
Objectives The purpose of this study was to investigate the
frequency and clinical impact of incomplete left atrial
appendage (LAA) sealing and consequent peri-device
residual blood ﬂow in patients undergoing percutaneous
LAA closure with the Watchman device (Atritech, Inc.,
Plymouth, Minnesota).
Background During percutaneous LAA closure for
stroke prophylaxis, the geometric variability of the LAA
ostium may result in an incomplete seal of the LAA.
On the one hand, this could enhance thrombus forma-
tion and embolization of thrombi around the device
into the circulation; on the other hand, the relatively
small size of these leaks may preclude clinically relevant
embolizations.
Methods Patients randomly assigned to device implanta-
tion in the PROTECT AF (Percutaneous Closure of the
Left Atrial Appendage Versus Warfarin Therapy for
Prevention of Stroke in Patients With Atrial Fibrillation)
trial were analyzed. Transesophageal echocardiography was
performed at 45 days, 6 months, and 12 months. Per the
study protocol, patients discontinued warfarin therapy if
the 45-day Transesophageal echocardiogram revealed
either minimal or no peri-device ﬂow (jet 5 mm width).
The impact of peri-device ﬂow severity, deﬁned as minor,
moderate, or major (<1 mm, 1 mm to 3 mm, >3 mm,
respectively) on the composite primary efﬁcacy endpoint
(stroke, systemic embolism, and cardiovascular death) is
expressed as hazard ratio (HR) with 95% conﬁdence
interval (CI).
Results Transesophageal echocardiography follow-up
revealed that 32.0% of implanted patients had at least
some degree of peri-device ﬂow at 12 months. The HR of
the primary efﬁcacy endpoint per 1 mm larger per-device
ﬂow was 0.84 (95% CI: 0.62 to 1.14; p ¼ 0.256).
Compared to patients with no peri-device ﬂow, the HRs
were 0.85 (95% CI: 0.11 to 6.40), 0.83 (95% CI: 0.33 to
2.09), and 0.48 (95% CI: 0.11 to 2.09) for minor, moderate,
and major peri-device ﬂow, respectively (p ¼ 0.798).
Compared to patients with no peri-device ﬂow who dis-
continued warfarin, the HR for patients with any peri-device
ﬂow and continuing warfarin was 0.63 (95% CI: 0.14 to
2.71; p ¼ 0.530).
Conclusions These data indicate that residual peri-device
ﬂow into the LAA after percutaneous closure with the
Watchman device was common, and is not associated with
an increased risk of thromboembolism. This ﬁnding should
be interpreted with caution as the low event rate decreases
the conﬁdence of this conclusion (73).
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Time Full-Volume 3D Transthoracic
Echocardiography to Measure LV Volumes and
Systolic Function: A Fully Automated Endocardial
Contouring Algorithm in Sinus Rhythm and Atrial
Fibrillation
Objectives To assess the feasibility, accuracy, and repro-
ducibility of real-time full-volume 3-dimensional trans-
thoracic echocardiography (3D RT-VTTE) to measure left
ventricular (LV) volumes and ejection fraction (EF) using
a fully automated endocardial contouring algorithm and to
identify and automatically correct the contours to obtain
accurate LV volumes in sinus rhythm and atrial ﬁbrillation
(AF).
Background 3D transthoracic echocardiography is not used
routinely to quantify LV volumes and EF. A fully automated
workﬂow using RT-VTTE may improve clinical adoption.
Methods RT-VTTE was performed and 3D EF and
volumes obtained using an automated trabecular endocardial
contouring algorithm; an automated correction was applied
to track the compacted myocardium. Cardiac magnetic
resonance (CMR) and 2-dimensional biplane Simpson
method were the reference standard.
Results Ninety-one patients (67 in normal sinus rhythm
[NSR], 24 in AF) were included. Among all NSR patients,
there was excellent correlation between RT-VTTE and
CMR for end-diastolic volume (EDV), end-systolic volume
(ESV), and EF (r ¼ 0.90, 0.96, and 0.98, respectively; p <
0.001). In patients with EF 50% (n ¼ 36), EDV and ESV
were underestimated by 10.7  17.5 ml (p ¼ 0.001) and by
4.1  6.1 ml (p < 0.001), respectively. In those with
EF <50% (n ¼ 31), EDV and ESV were underestimated by
25.7  32.7 ml (p < 0.001) and by 16.2  24.0 ml (p ¼
0.001). Automated contour correction to track the com-
pacted myocardium eliminated mean volume differences
between RT-VTTE and CMR. In patients with AF, LV
volumes and EF were accurate by RT-VTTE (r ¼ 0.94,
0.94, and 0.91 for EDV, ESV, and EF, respectively; p <
0.001). Automated 3D LV volumes and EF were highly
reproducible.
Conclusions Rapid, accurate, and reproducible EF can be
obtained by RT-VTTE in NSR and AF patients by using
an automated trabecular edge contouring algorithm.
Furthermore, automated contour correction to detect the
compacted myocardium yields accurate and reproducible 3D
LV volumes (74).
Bioprosthetic Tricuspid Valve Regurgitation
Associated With Pacemaker or Deﬁbrillator Lead
Implantation
Objectives The goal of this study was to determine the
impact of transvenous pacemaker and deﬁbrillator leads on
the incidence of bioprosthetic tricuspid valve (BTV) regur-
gitation compared with BTV patients without a trans-
valvular lead.Background Although concern has been raised regarding
the potential deleterious effect of permanent transvenous
device leads on BTV function, little is known about the
incidence of prosthetic tricuspid regurgitation (TR) after
lead placement.
Methods A retrospective review of 58 patients who
underwent BTV implantation and subsequently required
endocardial pacemaker (n ¼ 52) or deﬁbrillator (n ¼ 6) lead
implantation across the BTV was conducted. Patient and
prosthesis characteristics, lead type, and clinical events were
collected. The incidence and severity of prosthetic TR,
determined by Doppler echocardiography, was compared
with 265 consecutive patients who underwent BTV
implantation without undergoing subsequent transvalvular
device lead implantation.
Results Over a mean follow-up of 25 months, in 5 patients
(9%) with a transvalvular lead signiﬁcant (moderate or
greater) prosthetic TR developed compared with 12 patients
(5%) in the control group (p ¼ 0.20). Kaplan-Meier analysis
revealed no signiﬁcant difference in the incidence of TR in
BTV patients with and without transvalvular leads (p ¼
0.45). Signiﬁcant prosthetic TR in patients with and
without a transvalvular lead more commonly occurred 2
years or later after lead or BTV implantation (4 of 5, 80%
and 10 of 12, 83%, respectively).
Conclusions Transvalvular device lead implantation in
BTV patients was not associated with an increased incidence
of signiﬁcant prosthetic TR (p ¼ 0.45). Based on these data,
transvalvular lead implantation appears to be an acceptable
approach for patients with a BTV who require permanent
pacemaker or deﬁbrillator placement (75).Misleading Long Post-Pacing Interval After
Entrainment of Typical Atrial Flutter From the
Cavotricuspid Isthmus
Objectives The purpose of this study was to evaluate the
prevalence and mechanism of a misleading long post-pacing
interval (PPI) upon entrainment of typical atrial ﬂutter
(AFL) from the cavotricuspid isthmus (CTI).
Background In typical AFL, the PPI from entrainment at
the CTI is expected to closely match the tachycardia cycle-
length (TCL).
Methods Sixty patients with conﬁrmed CTI-dependent
AFL were retrospectively analyzed and grouped into short
(30 ms) or long (>30 ms) PPI-TCL. Thereafter, we
prospectively studied 16 patients to acquire the PPI-TCL at
4 CTI sites with entrainment at pacing cycle-lengths
(PCLs) 10 to 40 ms shorter than the TCL. Conduction
times during AFL and entrainment were compared in 5
segments of the AFL circuit.
Results Eleven patients (18%) in the retrospective analysis
had a longPPI-TCLafter entrainment from theCTI. Subjects
with long PPI-TCL had similar baseline characteristics but
greater beat-to-beat TCL variability. In the prospective cohort,
PPI-TCL was inﬂuenced by the difference between PCL and
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with a long PPI-TCL were located predominantly in the
segment activated ﬁrst by the paced orthodromic wave front,
and were mainly due to local pacing latency, as conﬁrmed by
the use of monophasic action potential catheters.
Conclusions A long PPI upon entrainment of typical AFL
from the CTI is common and due to delayed conduction with
entrainment. Whether these ﬁndings apply to other macro–
re-entrant tachycardias warrants further investigation (76).
Role of AV Nodal Ablation in Cardiac
Resynchronization in Patients With Coexistent
Atrial Fibrillation and Heart Failure: A Systematic
Review
Objectives The aim of this study was to systematically
review the medical literature to evaluate the impact of AV
nodal ablation in patients with heart failure and coexistent
atrial ﬁbrillation (AF) receiving cardiac resynchronization
therapy (CRT).
Background CRT has a substantial evidence base in
patients in sinus rhythm with signiﬁcant systolic dysfunc-
tion, symptomatic heart failure, and prolonged QRS dura-
tion. The role of CRT is less well established in AF patients
with coexistent heart failure. AV nodal ablation has recently
been suggested to improve outcomes in this group.
Methods Electronic databases and reference lists through
September 15, 2010, were searched. Two reviewers indepen-
dently evaluated citation titles, abstracts, and articles. Studies
reporting the outcomes afterAVnodal ablation in patientswith
AF undergoing CRT for symptomatic heart failure and left
ventricular dyssynchrony were selected. Data were extracted
from 6 studies, including 768 CRT-AF patients, composed of
339 patients who underwent AV nodal ablation and 429
treated with medical therapy aimed at rate control alone.
Results AV nodal ablation in CRT-AF patients was
associated with signiﬁcant reductions in all-cause mortality
(risk ratio: 0.42 [95% conﬁdence interval: 0.26 to 0.68]),
cardiovascular mortality (risk ratio: 0.44 [95% conﬁdence
interval: 0.24 to 0.81]), and improvement in mean New
York Heart Association functional class (risk ratio: –0.52
[95% conﬁdence interval: –0.87 to –0.17]).
Conclusions AV nodal ablation was associated with
a substantial reduction in all-cause mortality and cardio-
vascular mortality and with improvements in New York
Heart Association functional class compared with medical
therapy in CRT-AF patients. Randomized controlled trials
are warranted to conﬁrm the efﬁcacy and safety of AV nodal
ablation in this patient population (77).
Transient Impairment of Vasomotion Function
After Successful Chronic Total Occlusion
Recanalization
Objectives The aim of our study was to assess coronary
vasomotion after successful revascularization of chronic total
occlusion (CTO).Background It is largely unknown whether the recovery of
anterograde ﬂow after CTO recanalization with drug-
eluting stent implantation affects vascular function in distal
coronary segments.
Methods One hundred consecutive CTOs successfully
treated with drug-eluting stents underwent coronary diam-
eter measurement after intracoronary nitroglycerin injection
5, 20, and 35 mm distal to the stented coronary segment
using 3-dimensional quantitative coronary angiography. In
a subgroup of 14 patients, coronary vasomotion was tested in
distal segments: incremental atrial pacing for endothelium-
dependent cases; and intracoronary nitroglycerin injection
for endothelium-independent cases. In another subgroup of
13 patients, distal vessels were assessed by intracoronary
ultrasounds.
Results Vessel diameters signiﬁcantly increased at follow-
up as compared to baseline values (2.0  0.52 mm vs.
2.25  0.50 mm, 1.76  0.49 mm vs. 2.05  0.58 mm, 1.54
 0.53 mm vs. 2.04  0.58 mm, at each segment analyzed;
p < 0.001). At baseline, distal segments failed to respond to
both endothelium-dependent and -independent stimuli. At
follow-up, atrial pacing induced vasoconstriction, whereas
nitroglycerine administration resulted in signiﬁcant vasodi-
lation (p < 0.05). Intracoronary ultrasounds failed to show
changes of the cross-sectional area of distal segments at
follow-up angiography.
Conclusions Recanalization of CTO is followed by
a hibernation of vascular wall at distal coronary seg-
ments that fail to respond to endothelium-dependent and
-independent stimuli. Distal vessel diameter increases over
time in the absence of positive remodeling and in spite of
persistent endothelial dysfunction. This severe impairment
of vasomotor tone after CTO reopening suggests that
intracoronary ultrasound assessment is of paramount
importance for the selection of stent size (78).Timing of the Most Recent Device Procedure
Inﬂuences the Clinical Outcome of Lead-
Associated Endocarditis: Results of the MEDIC
(Multicenter Electrophysiologic Device Infection
Cohort)
Objectives The purpose of this study was to determine
whether the timing of the most recent cardiac implantable
electronic device (CIED) procedure, either a permanent
pacemaker or implantable cardioverter-deﬁbrillator, inﬂu-
ences the clinical presentation and outcome of lead-
associated endocarditis (LAE).
Background The CIED infection rate has increased at
a time of increased device use. LAE is associated with
signiﬁcant morbidity and mortality.
Methods The clinical presentation and course of LAE were
evaluated by the MEDIC (Multicenter Electrophysiologic
Device Cohort) registry, an international registry enrolling
patients with CIED infection. Consecutive LAE patients
enrolled in the Multicenter Electrophysiologic Device
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analyzed. The clinical features and outcomes of 2 groups
were compared based on the time from the most recent
CIED procedure (early, <6 months; late, >6 months).
Results The Multicenter Electrophysiologic Device Cohort
registry entered 145 patients with LAE (early ¼ 43, late ¼
102). Early LAE patients presented with signs and symp-
toms of local pocket infection, whereas a remote source of
bacteremia was present in 38% of patients with late LAE but
only 8% of early LAE (p < 0.01). Staphylococcal species
were the most frequent pathogens in both early and late
LAE. Treatment consisted of removal of all hardware and
intravenous administration of antibiotics. In-hospital
mortality was low (early ¼ 7%, late ¼ 6%).
Conclusions The clinical presentation of LAE is inﬂu-
enced by the time from the most recent CIED procedure.
Although clinical manifestations of pocket infection are
present in the majority of patients with early LAE, late LAE
should be considered in any CIED patient who presents
with fever, bloodstream infection, or signs of sepsis, even if
the device pocket appears uninfected. Prompt recognition
and management may improve outcomes (79).Incidence of and Risk Factors for Sudden Cardiac
Death in Children With Dilated Cardiomyopathy: A
Report From the Pediatric Cardiomyopathy
Registry
Objectives The purpose of this study was to establish the
incidence of and risk factors for sudden cardiac death (SCD)
in pediatric dilated cardiomyopathy (DCM).
Background The incidence of SCD in children with DCM
is unknown. The ability to predict patients at high risk of
SCD will help to deﬁne who may beneﬁt most from
implantable cardioverter-deﬁbrillators.
Methods The cohort was 1,803 children in the PCMR
(Pediatric Cardiomyopathy Registry) with a diagnosis of
DCM from 1990 to 2009. Cumulative incidence competing-
risks event rates were estimated. We achieved risk stratiﬁca-
tion using Classiﬁcation and Regression Tree methodology.
Results The 5-year incidence rates were 29% for heart
transplantation, 12.1% non-SCD, 4.0% death from
unknown cause, and 2.4% for SCD. Of 280 deaths, 35 were
SCD, and the cause was unknown for 56. The 5-year
incidence rate for SCD incorporating a subset of the
unknown deaths is 3%. Patients receiving antiarrhythmic
medication were at higher risk of SCD (hazard ratio: 3.0,
95% conﬁdence interval: 1.1 to 8.3, p ¼ 0.025). A risk
stratiﬁcation model based on most recent echocardiographic
values had 86% sensitivity and 57% speciﬁcity. Thirty of 35
SCDs occurred in patients who met all these criteria: left
ventricular (LV) end-systolic dimension z-score >2.6, age at
diagnosis younger than 14.3 years, and the LV posterior wall
thickness to end-diastolic dimension ratio <0.14. Sex,
ethnicity, cause of DCM, and family history were not
associated with SCD.Conclusions The 5-year incidence rate of SCD in children
with DCM is 3%. A risk stratiﬁcation rule (86% sensitivity)
included age at diagnosis younger than 14.3 years, LV
dilation, and LV posterior wall thinning. Patients who
consistently meet these criteria should be considered for
implantable cardioverter-deﬁbrillator placement. (Pediatric
Cardiomyopathy Registry; NCT00005391) (80).Atrial Conduction Slows Immediately Before the
Onset of Human Atrial Fibrillation: A Bi-Atrial
Contact Mapping Study of Transitions to Atrial
Fibrillation
Objectives The aim of this study was to determine whether
onset sites of human atrial ﬁbrillation (AF) exhibit
conduction slowing, reduced amplitude, and/or prolonged
duration of signals (i.e., fractionation) immediately before
AF onset.
Background Few studies have identiﬁed functional deter-
minants of AF initiation. Because conduction slowing is
required for reentry, we hypothesized that AF from
pulmonary vein triggers might initiate at sites exhibiting
rate-dependent slowing in conduction velocity (CV restitu-
tion) or local slowing evidenced by signal fractionation.
Methods In 28 patients with AF (left atrial size 43 
5 mm; n ¼ 13 persistent) and 3 control subjects (no AF) at
electrophysiological study, we measured bi-atrial conduction
time (CT) electrogram fractionation at 64 or 128 electrodes
with baskets in left (n ¼ 17) or both (n ¼ 14) atria during
superior pulmonary vein pacing at cycle lengths (CL)
accelerating from 500 ms (120 beats/min) to AF onset.
Results Atrial ﬁbrillation initiated in 19 of 28 AF patients
and no control subjects. During rate acceleration, conduc-
tion slowed in 23 of 28 AF patients (vs. no control subjects,
p ¼ 0.01) at the site of AF initiation (15 of 19) or latest
activated site (20 of 28). The CT lengthened from 79  23
ms to 107  39 ms (p < 0.001) on acceleration, in a spec-
trum from persistent AF (greatest slowing) to control
subjects (least slowing; p < 0.05). Three patterns of CV
restitution were observed: 1) broad (gradual CT prolonga-
tion, 37% patients); 2) steep (abrupt prolongation, at CL
266  62 ms, 42%); and 3) ﬂat (no prolongation, 21% AF
patients, all control subjects). The AF initiation was more
prevalent in patients with CV restitution (17 of 23 vs. 2 of 8;
p ¼ 0.03) and immediately followed abrupt re-orientation of
the activation vector in patients with broad but not steep CV
restitution (p < 0.01). Patients with broad CV restitution
had larger atria (p ¼ 0.03) and were more likely to have
persistent AF (p ¼ 0.04). Notably, neither amplitude nor
duration (fractionation) of the atrial signal at the AF initi-
ation site were rate-dependent (both p ¼ NS).
Conclusions Acceleration-dependent slowing of atrial
conduction (CV restitution) precedes AF initiation, whereas
absence of CV restitution identiﬁes inability to induce AF.
Conduction restitution, but not fractionated electrograms,
may thus track the functional milieu enabling AF initiation
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cological therapy (81).Risk Factors for Malignant Ventricular Arrhythmias
in Lamin A/C Mutation Carriers: A European Cohort
Study
Objectives The purpose of this study was to determine risk
factors that predict malignant ventricular arrhythmias
(MVA) in Lamin A/C (LMNA) mutation carriers.
Background LMNA mutations cause a variety of clinical
phenotypes, including dilated cardiomyopathy and conduc-
tion disease. Many LMNA mutation carriers have a poor
prognosis, because of a high frequency of MVA and
progression to end-stage heart failure. However, it is unclear
how to identify mutation carriers that are at risk for MVA.
Methods In this multicenter cohort of 269 LMNA muta-
tion carriers, we evaluated risk factors for MVA, deﬁned as
sudden cardiac death, resuscitation, and appropriate im-
plantable cardioverter-deﬁbrillator (ICD) treatment.
Results In a median follow-up period of 43 months
(interquartile range: 17 to 101 months), 48 (18%) persons
experienced a ﬁrst episode of MVA: 11 persons received
successful cardiopulmonary resuscitation, 25 received ap-
propriate ICD treatment, and 12 persons died suddenly.
Independent risk factors for MVA were nonsustained ven-
tricular tachycardia, left ventricular ejection fraction <45%
at the ﬁrst clinical contact, male sex, and non-missense
mutations (ins-del/truncating or mutations affecting splic-
ing). MVA occurred only in persons with at least 2 of these
risk factors. There was a cumulative risk for MVA per
additional risk factor.
Conclusions Carriers of LMNA mutations with a high risk
of MVA can be identiﬁed using these risk factors. This
facilitates selection of LMNA mutation carriers who are
most likely to beneﬁt from an ICD (82).Hypothermia Therapy: Neurological and Cardiac
Beneﬁts
Due to its protective effect on the brain and the myocar-
dium, hypothermia therapy (HT) has been extensively
studied in cardiac arrest patients with coma as well as in
patients presenting with acute myocardial infarction (MI).
In the setting of cardiac arrest, randomized studies have
shown that HT decreases mortality and improves neuro-
logical outcomes. Subsequent guidelines have therefore
recommended cooling (32C to 34C) for 12 to 24 h in
unconscious adult patients with spontaneous circulation after
out-of-hospital cardiac arrest due to ventricular ﬁbrillation.
Observational studies have also conﬁrmed the feasibility of
this therapy in clinical practice and support its early appli-
cation in patients with nonventricular ﬁbrillation cardiac
arrest and in post-resuscitation circulatory shock. In patients
with acute MI, available clinical evidence does not yet
support HT as the standard of care, because no study to datehas shown a clear net beneﬁt in such a cohort. After a brief
review of the mechanisms of action for HT, we provide
a review of the clinical evidence, cooling techniques, and
potential adverse effects associated with HT in the setting of
post-cardiac arrest patient and acute MI (83).Procedural Complications, Rehospitalizations, and
Repeat Procedures After Catheter Ablation for
Atrial Fibrillation
Objectives The purpose of this study was to estimate rates
and identify predictors of inpatient complications and
30-day readmissions, as well as repeat hospitalization rates
for arrhythmia recurrence following atrial ﬁbrillation (AF)
ablation.
Background AF is the most common clinically signiﬁcant
arrhythmia and is associated with increased morbidity and
mortality. Radiofrequency or cryotherapy ablation of AF is
a relatively new treatment option, and data on post-
procedural outcomes in large general populations are limited.
Methods Using data from the California State Inpatient
Database, we identiﬁed all adult patients who underwent
their ﬁrst AF ablation from 2005 to 2008. We used
multivariable logistic regression to identify predictors of
complications and/or 30-day readmissions and Kaplan-
Meier analyses to estimate rates of all-cause and arrhythmia
readmissions.
Results Among 4,156 patients who underwent an initial
AF ablation, 5% had periprocedural complications, most
commonly vascular, and 9% were readmitted within 30 days.
Older age, female, prior AF hospitalizations, and less
hospital experience with AF ablation were associated with
higher adjusted risk of complications and/or 30-day read-
missions. The rate of all-cause hospitalization was 38.5% by
1 year. The rate of readmission for recurrent AF, atrial
ﬂutter, and/or repeat ablation was 21.7% by 1 year and
29.6% by 2 years.
Conclusions Periprocedural complications occurred in 1 of
20 patients undergoing AF ablation, and all-cause and
arrhythmia-related rehospitalizations were common. Older
age, female sex, prior AF hospitalizations, and recent
hospital procedure experience were associated with a higher
risk of complications and/or 30-day readmission after AF
ablation (84).Home Monitoring for Heart Failure Management
With a prevalence of 5.8 million in the United States alone,
heart failure (HF) is a common syndrome associated with
substantial morbidity, mortality, and healthcare expendi-
tures. Close to 1 million HF hospitalizations occur annually
in the United States, with the majority of these resulting
from worsening congestion in patients previously diagnosed
with HF. An estimated $37.2 billion is spent each year on
HF in the United States. These statistics emphasize the
need to develop and implement more effective strategies to
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ingly apparent that interventions geared toward identifying
and monitoring subclinical congestion would be of value in
the home management of chronic HF. Earlier identiﬁcation
and treatment of congestion together with improved care
coordination, management of comorbid conditions, and
enhanced patient self-management may help to prevent
hospitalizations in patients with chronic HF. Such home
monitoring extends from the promotion of self-care and
home visitations to telemedicine and remote monitoring
of external or implantable devices. This paper discusses
the challenges in monitoring patients with HF, reviews
clinical trials testing different monitoring strategies in HF,
and highlights ongoing investigations into the optimal
approaches to home monitoring for HF (85).Incidence, Predictive Factors, and Prognostic
Value of New-Onset Atrial Fibrillation Following
Transcatheter Aortic Valve Implantation
Objectives This study sought to evaluate the incidence,
predictive factors, and prognostic value of new-onset atrial
ﬁbrillation (NOAF) following transcatheter aortic valve
implantation (TAVI).
Background Very few data exist on the occurrence of
NOAF following TAVI.
Methods A total of 138 consecutive patients with no prior
history of atrial ﬁbrillation (AF) underwent TAVI with
a balloon-expandable valve. Patients were on continuous
electrocardiogram monitoring until hospital discharge, and
NOAF was deﬁned as any episode of AF lasting >30 s. All
clinical, echocardiographic, procedural, and follow-up data
were prospectively collected.
Results NOAF occurred in 44 patients (31.9%) at
a median time of 48 h (interquartile range: 0 to 72 h)
following TAVI. The predictive factors of NOAF were left
atrial (LA) size (odds ratio [OR]: 1.21 for each increase in
1 mm/m2, 95% conﬁdence interval [CI]: 1.09 to 1.34, p <
0.0001) and transapical approach (OR: 4.08, 95% CI: 1.35
to 12.31, p ¼ 0.019). At 30-day follow-up, NOAF was
associated with a higher rate of stroke/systemic embolism
(13.6% vs. 3.2%, p ¼ 0.021, p ¼ 0.047 after adjustment for
baseline differences between groups), with no differences in
mortality rate between groups (NOAF: 9.1%, no-NOAF:
6.4%, p ¼ 0.57). At a median follow-up of 12 months
(interquartile range: 5 to 20 months), a total of 27 patients
(19.6%) had died, with no differences between the NOAF
(15.9%) and no-NOAF (21.3%) groups, p ¼ 0.58. The
cumulative rate of stroke and stroke/systemic embolism at
follow-up were 13.6% and 15.9%, respectively, in the
NOAF group versus 3.2% in the no-NOAF group (p ¼
0.039, adjusted p ¼ 0.037 for stroke; p ¼ 0.020, adjusted
p ¼ 0.023 for stroke/systemic embolism).
Conclusions NOAF occurred in about one-third of the
patients with no prior history of AF undergoing TAVI and
its incidence was increased in patients with larger LA sizeand those undergoing transapical TAVI. NOAF was asso-
ciated with a higher rate of stroke/systemic embolism, but
not a higher mortality, at 30 days and at 1-year follow-up
(86).A Common b1-Adrenergic Receptor Polymorphism
Predicts Favorable Response to Rate-Control
Therapy in Atrial Fibrillation
Objectives In this study, we evaluated the impact of 2
common b1-adrenergic receptor (b1-AR) polymorphisms
(G389R and S49G) in response to ventricular rate control
therapy in patients with atrial ﬁbrillation (AF).
Background Randomized studies have shown that ven-
tricular rate control is an acceptable treatment strategy in
patients with AF. However, identiﬁcation of patients who
will adequately respond to rate-control therapy remains
a challenge.
Methods We studied 543 subjects (63%men; age 61.8 14
years) prospectively enrolled in the Vanderbilt AF registry
and managed with rate-control strategy. A “responder” dis-
played adequate ventricular rate control based on the
AFFIRM (Atrial Fibrillation Follow-Up Investigation of
Rhythm Management) criteria: average heart rate (HR)
at rest 80 beats/min; and maximum HR during a 6-min
walk test 110 beats/min or average HR during 24-h
Holter 100 beats/min.
Results A total of 295 (54.3%) patients met the AFFIRM
criteria. Baseline clinical characteristics were similar in
responders and nonresponders except for mean resting HR
(76  20 beats/min vs. 70  15 beats/min; p < 0.01) and
smoking (6% vs. 1%; p < 0.01). Multiple clinical variables
(age, gender, hypertension) failed to predict response to
rate-control therapy. By contrast, carriers of Gly variant at
389 were more likely to respond favorably to rate-control
therapy; 60% versus 51% in the Arg389Arg genotype,
p ¼ 0.04. This association persisted after correction for
multiple clinical factors (odds ratio: 1.42, 95% conﬁdence
interval: 1.00 to 2.03, p < 0.05). Among responders,
subjects carrying the Gly389 variant required the lowest
doses of rate-control medications; atenolol: 92 mg versus
68 mg; carvedilol: 44 mg versus 20 mg; metoprolol: 80 mg
versus 72 mg; diltiazem: 212 mg versus 180 mg, and
verapamil: 276 mg versus 200 mg, respectively (p < 0.01 for
all comparisons).
Conclusions We have identiﬁed a common b1-AR poly-
morphism, G389R, that is associated with adequate response
to rate-control therapy in AF patients. Gly389 is a loss-of-
function variant; consequently, for the same adrenergic
stimulation, it produces reduced levels of adenyl cyclase, and
hence, attenuates the b-adrenergic cascade. Mechanistically,
the effect of rate-control drugs will be synergistic with that
of the Gly389 variant, which could possibly explain our
ﬁndings. These ﬁndings represent a step forward in the
development of a long-term strategy of selecting treatment
options in AF based on genotype (87).
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of the PRELUDE (PRogrammed ELectrical
stimUlation preDictive valuE) Registry
Objectives The PRELUDE (PRogrammed ELectrical
stimUlation preDictive valuE) prospective registry was
designed to assess the predictive accuracy of sustained
ventricular tachycardia/ventricular ﬁbrillation (VTs/VF)
inducibility and to identify additional predictors of
arrhythmic events in Brugada syndrome patients without
history of VT/VF.
Background Brugada syndrome is a genetic disease asso-
ciated with increased risk of sudden cardiac death. Even
though its value has been questioned, inducibility of VTs/
VF is widely used to select candidates to receive a prophy-
lactic implantable deﬁbrillator, and its accuracy has never
been addressed in prospective studies with homogeneous
enrolling criteria.
Methods Patients with a spontaneous or drug-induced type
I electrocardiogram (ECG) and without history of cardiac
arrest were enrolled. The registry included 308 consecutive
individuals (247 men, 80%; median age 44 years, range 18
to 72 years). Programmed electrical stimulation was per-
formed at enrollment, and patients were followed-up every
6 months.
Results During a median follow-up of 34 months, 14
arrhythmic events (4.5%) occurred (13 appropriate shocks of
the implantable deﬁbrillator, and 1 cardiac arrest). Pro-
grammed electrical stimulation performed with a uniform
and pre-speciﬁed protocol induced ventricular tachyar-
rhythmias in 40% of patients: arrhythmia inducibility was
not a predictor of events at follow-up (9 of 14 events
occurred in noninducible patients). History of syncope and
spontaneous type I ECG (hazard ratio [HR]: 4.20),
ventricular refractory period <200 ms (HR: 3.91), and QRS
fragmentation (HR: 4.94) were signiﬁcant predictors of
arrhythmias.
Conclusions Our data show that VT/VF inducibility is
unable to identify high-risk patients, whereas the presence of
a spontaneous type I ECG, history of syncope, ventricular
effective refractory period <200 ms, and QRS fragmenta-
tion seem useful to identify candidates for prophylactic
implantable cardioverter deﬁbrillator (88).
Changes in Renal Function After Implantation of
Continuous-Flow Left Ventricular Assist Devices
Objectives The aim of this study was to determine renal
outcomes after left ventricular assist device (LVAD)
implantation.
Background Renal dysfunction before LVAD placement is
frequent, and it is unclear whether it is due to primary renal
disease or to poor perfusion.
Methods A retrospective single-center analysis was con-
ducted in 83 consecutive patients implanted with HeartMate
II continuous-ﬂow LVADs (Thoratec Corp., Pleasanton,
California). Calculated glomerular ﬁltration rate (GFR) wasassessed on admission and 1, 3, and 6 months after implan-
tation. To deﬁne predictors for improvement in GFR, clinical
variables were examined in patients with decreased renal
function (GFR <60 ml/min/1.73 m2) before LVAD,
surviving and dialysis-free at 1 month (n ¼ 44).
Results GFR signiﬁcantly increased from admission (53.2
21.4 ml/min/1.73 m2) to 1 month after LVAD implantation
(87.4 27.9ml/min/1.73m2) (p< 0.0001). Subsequently, at
3 and 6 months, GFR remained signiﬁcantly (p < 0.0001)
above pre-LVAD values. Of the 51 patients with
GFRs <60 ml/min/1.73 m2 before LVAD surviving at
1 month, 34 (67%) improved to GFRs >60 ml/min/
1.73 m2. Univariate pre-operative predictors for improve-
ment in renal function at 1 month included younger age
(p ¼ 0.049), GFR improvement with optimal medical
therapy (p < 0.001), intra-aortic balloon pump use (p ¼
0.004), kidney length above 10 cm (p ¼ 0.023), no treat-
ment with angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers (p ¼ 0.029), higher bilirubin
(p ¼ 0.002), higher Lietz-Miller score (p ¼ 0.019), and
atrial ﬁbrillation (p ¼ 0.007). Multivariate analysis indicated
pre-operative improved GFR (slope ¼ 0.5 U per unit
improved; 95% conﬁdence interval: 0.2 to 0.8; p ¼ 0.003),
atrial ﬁbrillation (slope ¼ 27; 95% conﬁdence interval: 8 to
46; p ¼ 0.006), and intra-aortic balloon pump use (slope ¼
14; 95% conﬁdence interval: 2 to 26; p ¼ 0.02) as inde-
pendent predictors.
Conclusions In most patients with end-stage heart failure
considered for LVAD implantation, renal dysfunction is
reversible and likely related to poor renal perfusion (89).Septal Involvement in Patients With Post-
Infarction Ventricular Tachycardia: Implications for
Mapping and Radiofrequency Ablation
Objectives The purpose of this study was to assess the
prevalence of the re-entry circuit within the interventricular
septum in post-infarction patients referred for ventricular
tachycardia (VT) ablation.
Background Post-infarction ventricular tachycardia can
involve the endocardial myocardium, the intramural myo-
cardium, the epicardium, or the His Purkinje system.
Methods Among 74 consecutive patients with recurrent
post-infarction VT, 33 patients (45%) were identiﬁed in
whom the critical part of the VT involved the interventric-
ular septum. A total of 206 VTs were induced in these 33
patients. In 46 of the 206 VTs, a critical component
was identiﬁed in the interventricular septum. The critical
isthmus of the re-entry circuit was identiﬁed by entrainment
mapping, activation mapping, or pace-mapping.
Results In 32 of 46 VTs (70%), the critical component of
the re-entry circuit was conﬁned to the endocardium. In 9 of
46 VTs (20%), the critical component involved the Purkinje
system, and in 5 of 46 VTs (11%), an intramural area was
critical. Entrainment and/or pace-mapping helped to iden-
tify critical areas of endocardial VTs as well as VTs involving
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localized intramural VTs. Electrocardiographic characteris-
tics were speciﬁc for each of the septal locations. All VTs
mapped to the interventricular septum were acutely success-
fully ablated. VTs recurred in 9 of 33 patients with septal
VTs during a mean follow-up period of 40  20 months.
Conclusions Post-infarction VT involving the interven-
tricular septum can involve the endocardial muscle, Purkinje
ﬁbers, or intramural muscle ﬁbers. Electrocardiographic
characteristics differ depending on the type of tissue
involved (90).
CHADS2 and CHA2DS2-VASc Scores in the
Prediction of Clinical Outcomes in Patients With
Atrial Fibrillation After Catheter Ablation
Objectives This study aimed to evaluate whether CHADS2
and CHA2DS2-VASc scores are useful for risk stratiﬁcation
in patients after catheter ablation of atrial ﬁbrillation (AF).
Background AF is associated with increased risk of
cardiovascular events. However, limited data are available on
the predictors of adverse events in patients with AF after
catheter ablation.
Methods A total of 565 patients with AF who underwent
catheter ablation were enrolled in the study. The clinical
endpoint was occurrence of thromboembolic events (ischemic
stroke, transient ischemic attack, peripheral embolism, or
pulmonary embolisms) or death during follow-up after cath-
eter ablation.
Results During a follow-up of 39.2  22.6 months, 27
patients (4.8%) experienced adverse events. Both the
CHADS2 andCHA2DS2-VASc scoreswere useful predictors
of events in separate multivariate models. The areas under the
receiver-operator characteristic curves based on the CHADS2
and CHA2DS2-VASc scores in predicting events were 0.785
and 0.830, respectively. Although the difference did not reach
statistical signiﬁcance (p ¼ 0.116), the CHA2DS2-VASc
score could be used to further stratify the patients with
CHADS2 scores of 0 or 1 into 2 groups with different event
rates (7.1% vs. 1.1%, p ¼ 0.003) at a cutoff value of 2.
Conclusions The CHADS2 and CHA2DS2-VASc scores
are useful predictors of adverse events after catheter ablation
of AF (91).
Inhibition of c-Src Tyrosine Kinase Prevents
Angiotensin II–Mediated Connexin-43 Remodeling
and Sudden Cardiac Death
Objectives The aim of this study was to test whether c-Src
tyrosine kinase mediates connexin-43 (Cx43) reduction and
sudden cardiac death in a transgenic mouse model of
cardiac-restricted overexpression of angiotensin-converting
enzyme (ACE8/8 mice).
Background Renin-angiotensin system activation is asso-
ciated with an increased risk for arrhythmia and sudden
cardiac death, but the mechanism is not well understood.
The up-regulation of c-Src by angiotensin II may result inthe reduction of Cx43, which impairs gap junction function
and provides a substrate for arrhythmia.
Methods Wild-type and ACE8/8 mice with and without
treatment with the c-Src inhibitor 1-(1,1-dimethylethyl)-
1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(PP1) were studied. Telemetry monitoring, in vivo elec-
trophysiologic studies, Western blot analyses for total and
phosphorylated c-Src and Cx43, immunohistochemistry
staining for Cx43, and functional assessment of Cx43 with
ﬂuorescent dye diffusion were performed.
Results The majority of the arrhythmic deaths resulted
from ventricular tachycardia degenerating to ventricular
ﬁbrillation (83%). Levels of total and phosphorylated c-Src
were increased and Cx43 reduced in ACE8/8 mice. PP1
reduced total and phosphorylated c-Src levels, increased
Cx43 level by 2.1-fold (p < 0.005), increased Cx43 at the
gap junctions (immunostaining), improved gap junctional
communication (dye spread), and reduced ventricular
tachycardia inducibility and sudden cardiac death. The
survival rate increased from 11% to 86% with 4 weeks of
PP1 treatment (p < 0.005). Treatment with an inactive
analog did not change survival or Cx43 levels.
Conclusions Renin-angiotensin system activation is asso-
ciated with c-Src up-regulation, Cx43 loss, reduced myocyte
coupling, and arrhythmic sudden death, which can be pre-
vented by c-Src inhibition. This suggests that an increase in
c-Src activity may help mediate renin-angiotensin system–
induced arrhythmias and that c-Src inhibitors might exert
antiarrhythmic activity (92).Implantable Cardioverter-Deﬁbrillator Patients
Who Are Upgraded and Respond to Cardiac
Resynchronization Therapy Have Less Ventricular
Arrhythmias Compared With Nonresponders
Objectives The purpose of this study was to evaluate the
impact of upgrading implantable cardioverter-deﬁbrillator
(ICD) therapy to cardiac resynchronization therapy (CRT)
combined with deﬁbrillator (CRT-D) on the occurrence of
ventricular arrhythmia (VA) and appropriate ICD therapies.
Background CRT has been shown to improve left
ventricular (LV) systolic function and induce reverse LV
remodeling. In addition, it has been hypothesized that CRT
may reduce the incidence of VA.
Methods Heart failure patients receiving an upgrade from
ICD to CRT-D were evaluated. Patients were considered
responders to CRT if LV end-systolic volume reduced15%
at 6 months of follow-up. Episodes of VA, triggering device
therapy (anti-tachycardia pacing and shocks) were recorded
before and after upgrade for the overall population. In
addition, these outcomes were compared between CRT
responders and nonresponders during the follow-up period
after CRT response was assessed.
Results One hundred ﬁfteen patients (93 males [81%], age
65  12 years) were evaluated during a mean follow-up of
54 34months before CRT-D upgrade and 37 27months
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VA requiring appropriate device therapy demonstrated
a trend toward a decrease from 0.51  0.79 to 0.30  0.59
per patient per year after CRT-D upgrade (p ¼ 0.052). In
CRT nonresponders (n¼ 45), the frequency of VA requiring
appropriate device therapy signiﬁcantly increased from
0.40 0.69 to 1.21 2.53 per patient per year after CRT-D
upgrade (p ¼ 0.014).
Conclusions After upgrade from ICD to CRT-D, nonre-
sponders to CRT showed a signiﬁcant increase in VA
burden requiring appropriate device therapy (93).
New Electrocardiographic Criteria for
Discriminating Between Brugada Types 2 and 3
Patterns and Incomplete Right Bundle Branch
Block
Objectives The aim of this study was to evaluate new
electrocardiographic (ECG) criteria for discriminating
between incomplete right bundle branch block (RBBB) and
the Brugada types 2 and 3 ECG patterns.
Background Brugada syndrome can manifest as either type
2 or type 3 pattern. The latter should be distinguished from
incomplete RBBB, present in 3% of the population.
Methods Thirty-eight patients with either type 2 or type 3
Brugada pattern that were referred for an antiarrhythmic drug
challenge (AAD) were included. Before AAD, 2 angles were
measured from ECG leads V1 and/or V2 showing incomplete
RBBB: 1) a, the angle between a vertical line and the
downslope of the r0-wave, and 2) b, the angle between the
upslope of the S-wave and the downslope of the r0-wave.
Baseline angle values, alone or combined with QRS duration,
were compared between patients with negative and positive
results onAAD.Receiver-operating characteristic curveswere
constructed to identify optimal discriminative cutoff values.
Results The mean b angle was signiﬁcantly smaller in the
14 patients with negative results on AAD compared to the
24 patients with positive results on AAD (36  20 vs. 62 
20, p < 0.01). Its optimal cutoff value was 58, which
yielded a positive predictive value of 73% and a negative
predictive value of 87% for conversion to type 1 pattern on
AAD; a was slightly less sensitive and speciﬁc compared
with b. When the angles were combined with QRS dura-
tion, it tended to improve discrimination.
Conclusions In patients with suspected Brugada syndrome,
simple ECG criteria can enable discrimination between
incomplete RBBB and types 2 and 3 Brugada patterns (94).
Structural Abnormalities in Atrial Walls Are
Associated With Presence and Persistency of
Atrial Fibrillation But Not With Age
Objectives The purpose of this study was to assess the
association between structural changes in human atria, age,
and history of atrial ﬁbrillation (AF).
Background Development of ﬁbrosis in atrial walls is
associated with deterioration of atrial conduction andpredisposes to AF in experiment. Human data, however, are
scarce, and whether ﬁbrosis is a cause or consequence of AF
is not known.
Methods Medical records for consecutive autopsies were
checked for AF history and duration. Atrial specimens from
30 patients (ages 64  12 years) were collected in 3 equal
age-matched groups as patients without AF history, with
paroxysmal AF, or with permanent AF. Tissue samples were
obtained at the level of superior pulmonary veins, inferior
pulmonary veins, center of posterior left atrial wall, terminal
crest, and Bachmann’s bundle. Histology sections were
assessed for extent of ﬁbrosis, fatty tissues, and inﬂammatory
inﬁltration at each location.
Results No correlation was observed between age and
ﬁbrosis at any location. Fibrosis extent and fatty inﬁltration
were twofold to threefold higher at all locations in patients
with history of AF and correlated with lymphomononuclear
inﬁltration. Patients with permanent AF had greater ﬁbrosis
extent than did patients with paroxysmal AF.
Conclusions In post-mortem material, structural changes
in the atria were not associated with age, but were signiﬁ-
cantly correlated with presence of AF and its severity. Our
ﬁndings suggest that age-related changes per se are unlikely
to be the sole cause of advanced ﬁbrosis underlying AF (95).Transcatheter Patch Occlusion of the Left Atrial
Appendage Using Surgical Adhesives in High-Risk
Patients With Atrial Fibrillation
Objectives The efﬁcacy of left atrial appendage (LAA)
occlusion using the Transcatheter Patch (TP) (Custom
Medical Devices, Athens, Greece) in conjunction with
surgical adhesives was assessed.
Background The TP is a bioabsorbable device that can be
adjusted for the shape and size of the LAA without the risk
of perforation. It is attached by a surgical adhesive and is
released in 45 min.
Methods Occlusion of the LAA was performed in 20 high-
risk patients, 59 to 89 years of age, with atrial ﬁbrillation. A
2-stage polyethylene glycol surgical adhesive was applied to
the distal half of the device. Activation of the adhesive was
achieved by direct injection of alkaline solution. Fluoroscopy
and transesophageal echocardiography only were used for
device placement in 17 patients. In 3 patients, angiography
was used as well. Follow-up transesophageal echocardiog-
raphy was performed upon discharge.
Results The procedure was successful in 17 cases. In the 3
patients in whom angiography was performed, the patch did
not attach and was retrieved. In 1 case, the patch was placed
beyond the mouth of the appendage, resulting in a residual
opening. There was further improvement of the occlusion
rate on the follow-up transesophageal echocardiography.
There was 1 complication related to the procedure, namely,
thrombus was released from the long sheath in the left
atrium upon withdrawal and required treatment to be dis-
solved. No recurrent strokes were reported.
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and effective in most patients with atrial ﬁbrillation at high
risk for embolic stroke. Angiography before placement
probably affects patch adhesion and is contraindicated (96).Omega-3 Fatty Acids and Cardiovascular Disease:
Effects on Risk Factors, Molecular Pathways, and
Clinical Events
We reviewed available evidence for cardiovascular effects of
n-3 polyunsaturated fatty acid (PUFA) consumption,
focusing on long chain (seafood) n-3 PUFA, including their
principal dietary sources, effects on physiological risk factors,
potential molecular pathways and bioactive metabolites,
effects on speciﬁc clinical endpoints, and existing dietary
guidelines. Major dietary sources include fatty ﬁsh and other
seafood. n-3 PUFA consumption lowers plasma triglycer-
ides, resting heart rate, and blood pressure and might also
improve myocardial ﬁlling and efﬁciency, lower inﬂamma-
tion, and improve vascular function. Experimental studies
demonstrate direct anti-arrhythmic effects, which have been
challenging to document in humans. n-3 PUFA affect
a myriad of molecular pathways, including alteration of
physical and chemical properties of cellular membranes,
direct interaction with and modulation of membrane chan-
nels and proteins, regulation of gene expression via nuclear
receptors and transcription factors, changes in eicosanoid
proﬁles, and conversion of n-3 PUFA to bioactive metab-
olites. In prospective observational studies and adequately
powered randomized clinical trials, beneﬁts of n-3 PUFA
seem most consistent for coronary heart disease mortality and
sudden cardiac death. Potential effects on other cardiovas-
cular outcomes are less-well-established, including conﬂict-
ing evidence from observational studies and/or randomized
trials for effects on nonfatal myocardial infarction, ischemic
stroke, atrial ﬁbrillation, recurrent ventricular arrhythmias,
and heart failure. Research gaps include the relative impor-
tance of different physiological and molecular mechanisms,
precise dose-responses of physiological and clinical effects,
whether ﬁsh oil provides all the beneﬁts of ﬁsh consumption,
and clinical effects of plant-derived n-3 PUFA. Overall,
current data provide strong concordant evidence that n-3
PUFA are bioactive compounds that reduce risk of cardiac
death. National and international guidelines have converged
on consistent recommendations for the general population to
consume at least 250 mg/day of long-chain n-3 PUFA or at
least 2 servings/week of oily ﬁsh (97).Mechanical Stretch of Atrial Myocyte Monolayer
Decreases Sarcoplasmic Reticulum Calcium
Adenosine Triphosphatase Expression and
Increases Susceptibility to Repolarization
Alternans
Objectives The purpose of this study was to investigate the
effect of stretch (the major risk factor for atrial ﬁbrillation[AF]) on spatial and temporal alternations of action
potential duration (APD-ALT) and calcium transient in
cultured atrial myocyte monolayer.
Background How rapid ﬁrings or premature beats trigger
AF is not completely understood. Discordant repolarization
alternans, characterized by simultaneous prolongation and
shortening of APD in different myocardial regions, is central
to the genesis of ventricular ﬁbrillation. We hypothesized
that repolarization alternans also is central to the initiation of
multiple re-entry circuits and AF.
Methods Conﬂuent HL-1 atrial myocyte monolayer with
spontaneous depolarization was cultured in silicone
membrane and subjected to mechanical stretch. Rapid ﬁeld
pacing was used to induce alternans. A high-resolution dual
optical mapping system was used to record action potentials
and calcium transients.
Results High-rate pacing induced APD-ALT and calcium
transient in atrial myocyte monolayer. Mechanical stretch
signiﬁcantly decreased the thresholds for APD-ALT and
calcium transient. Mechanical stretch decreased the expres-
sion of sarcoplasmic reticulum adenosine triphosphatase 2,
and thus slower calcium reuptake kinetics, which was
responsible for the susceptibility to alternans. Mechanical
stretch did not alter the APD restitution kinetics.Mechanical
stretch also enhanced spatially discordant alternans. Over-
expression of sarcoplasmic reticulum adenosine triphospha-
tase 2 reversed all the effects of stretch on susceptibility to
alternans. In intact atrium, mechanical stretch also enhanced
discordant alternans.
Conclusions Mechanical stretch increased the suscepti-
bility to alternans in atrial myocytes, which may explain
the susceptibility to AF in conditions of atrial stretch,
such as mitral valvular heart disease, heart failure, and
hypertension (98).Cardiovascular Outcomes in the AFFIRM Trial
(Atrial Fibrillation Follow-Up Investigation of
Rhythm Management): An Assessment of
Individual Antiarrhythmic Drug Therapies
Compared With Rate Control With Propensity
Score-Matched Analyses
Objectives The impact of individual antiarrhythmic drugs
(AADs) on mortality and hospital stay in atrial ﬁbrillation
(AF) was evaluated.
Background Cardiovascular (CV) outcomes in AF patients
receiving pharmacologic rhythm control therapy have not
been compared with rate control therapy on the basis of
AAD selection.
Methods We compared CV outcomes in the AFFIRM
(Atrial Fibrillation Follow-Up Investigation of Rhythm
Management) trial in subgroups deﬁned by the initial AAD
selected with propensity score matched subgroups from the
rate arm (Rate).
Results Seven hundred twenty-nine amiodarone patients,
606 sotalol patients, and 268 Class 1C patients were
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vascular hospital stays (CVH) showed better outcomes with
Rate compared with amiodarone (hazard ratio [HR]: 1.18,
95% conﬁdence interval [CI]: 1.03 to 1.36, p ¼ 0.02),
sotalol (HR: 1.32, 95% CI: 1.13 to 1.54, p < 0.001), and
Class 1C (HR: 1.22, 95% CI: 0.97 to 1.56, p ¼ 0.10). There
was a nonsigniﬁcant increase in mortality with amiodarone
(HR: 1.20, 95% CI: 0.94 to 1.53, p ¼ 0.15) with the risk of
non-CV death being signiﬁcantly higher with amiodarone
versus Rate (HR: 1.11, 95% CI: 1.01 to 1.24, p ¼ 0.04).
First CVH event rates at 3 years were 47% for amiodarone,
50% for sotalol, and 44% for Class 1C versus 40%, 40%, and
36%, respectively, for Rate (amiodarone HR: 1.20, 95% CI:
1.03 to 1.40, p ¼ 0.02, sotalol HR: 1.364, 95% CI: 1.16 to
1.611, p < 0.001, Class 1C HR: 1.24, 95% CI: 0.96 to 1.60,
p ¼ 0.09). Time to CVH with intensive care unit stay or
death was shorter with amiodarone (HR: 1.22, 95% CI: 1.02
to 1.46, p ¼ 0.03).
Conclusions In AFFIRM, composite mortality and CVH
outcomes differed for Rate and AADs due to differences in
CVH; CVH event rates during follow-up were high for all
cohorts, but they were higher for all groups on AADs.
Death, intensive care unit hospital stay, and non-CV death
were more frequent with amiodarone. (Atrial Fibrillation
Follow-Up Investigation of Rhythm Management;
NCT00000556) (99).Cardiac Tumors and Associated Arrhythmias in
Pediatric Patients, With Observations on Surgical
Therapy for Ventricular Tachycardia
Objectives The aim of this study was to describe a large
experience with primary cardiac tumors in pediatric patients,
characterize associated arrhythmias, and expand knowledge
of natural history and treatment options.
Background Primary cardiac tumors in children are rare.
The incidence of arrhythmias is not well-deﬁned, and
management plans vary widely.
Methods We employed a retrospective single-center review
of patients 21 years of age diagnosed with a primary
cardiac tumor between 1968 and 2010. Clinically signiﬁcant
arrhythmias were deﬁned as: 1) sudden cardiac arrest;
2) nonsustained and sustained ventricular tachycardia (VT);
3) pre-excitation; and 4) sustained supraventricular tachy-
cardia of any mechanism.
Results A total of 173 patients were identiﬁed: 106 rhab-
domyoma, 25 ﬁbroma, 14 myxoma, 6 vascular, 4 teratoma, 3
lipoma, and 15 other. Median age at diagnosis was 7 months
(prenatal to 21 years). Of these, 42 (24%) had clinically
signiﬁcant arrhythmias. Patients with large ﬁbromas were
the highest-risk group, with VT occurring in 64%. Among
rhabdomyoma patients, 10% had pre-excitation, and 6% had
VT. Over a mean follow-up of 6 years (1 day to 34 years,
median 4 years), surgical excision was performed in 62 cases,
with rhythm treatment being 1 of the indications in 20.
Post-operatively, clinically signiﬁcant arrhythmias wereeliminated in 18 of these 20, including all 13 ﬁbroma
patients.
Conclusions Clinically signiﬁcant arrhythmias occurred in
24% of pediatric patients with cardiac tumors, VT being the
most common type. Surgical excision for VT associated with
rhabdomyomas and ﬁbromas in selected patients is an
important and effective management strategy in these
patients (100).The Effect of Rate Control on Quality of Life in
Patients With Permanent Atrial Fibrillation: Data
From the RACE II (Rate Control Efﬁcacy in
Permanent Atrial Fibrillation II) Study
Objectives The aim of this study was to investigate the
inﬂuence of rate control on quality of life (QOL).
Background The RACE II (Rate Control Efﬁcacy in
Permanent Atrial Fibrillation II) trial showed that lenient
rate control is not inferior to strict rate control in terms of
cardiovascular morbidity and mortality. The inﬂuence of
stringency of rate control on QOL is unknown.
Methods In RACE II, a total of 614 patients with
permanent atrial ﬁbrillation (AF) were randomized to
lenient (resting heart rate [HR] <110 beats/min) or strict
(resting HR <80 beats/min, HR during moderate
exercise <110 beats/min) rate control. QOL was assessed in
437 patients using the Medical Outcomes Study 36-item
Short-Form Health Survey (SF-36) questionnaire, AF
severity scale, and Multidimensional Fatigue Inventory-20
(MFI-20) at baseline, 1 year, and end of study. QOL
changes were related to patient characteristics.
Results Median follow-up was 3 years. Mean age was 68 
8 years, and 66% were males. At the end of follow-up, all
SF-36 subscales were comparable between both groups. The
AF severity scale was similar at baseline and end of study. At
baseline and at end of study there were no differences in the
MFI-20 subscales between the 2 groups. Symptoms at
baseline, younger age, and less severe underlying disease,
rather than assigned therapy or heart rate, were associated
with QOL improvements. Female sex and cardiovascular
endpoints during the study were associated with worsening
of QOL.
Conclusions Stringency of heart rate control does not in-
ﬂuence QOL. Instead, symptoms, sex, age, and severity of
the underlying disease inﬂuence QOL. (Rate Control Efﬁ-
cacy in Permanent Atrial Fibrillation; NCT00392613) (101).Ambulatory External Electrocardiographic
Monitoring: Focus on Atrial Fibrillation
There has been progressive development in ambulatory
external electrocardiogram (AECG) monitoring technology.
AECG monitors initially consisted of 24- to 48-h Holter
monitors and patient-activated event and loop recorders.
More recently, several ambulatory cardiovascular telemetry
monitors and a patch-type 7- to 14-day Holter monitor have
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along with their utility and limitations, with particular
emphasis on their role in the diagnosis and evaluation of
patients with atrial ﬁbrillation (AF). AECG monitoring is
necessary when asymptomatic AF is suspected (as in patients
presenting with cryptogenic stroke) or when an ECG
diagnosis of unexplained arrhythmic symptoms is warranted.
In addition, AECG plays an important role in patients
with known AF to guide ventricular rate control and anti-
coagulation therapy, and assess the efﬁcacy of antiarrhythmic
drug therapy and/or ablation procedures. Finally, we outline
areas of uncertainty and provide recommendations for use of
available AECG monitors in clinical practice (102).Cardiac Resynchronization Therapy Reduces Left
Atrial Volume and the Risk of Atrial
Tachyarrhythmias in MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial with
Cardiac Resynchronization Therapy)
Objectives We hypothesized that reductions in left atrial
volume (LAV) with a cardiac resynchronization therapy–
deﬁbrillator (CRT-D) would translate into a subsequent
reduction in the risk of atrial tachyarrhythmias (AT).
Background There is limited information regarding the
effect of CRT-D on the risk of AT.
Methods Percent reduction inLAVat 1 year followingCRT-
D implantation (pre-speciﬁed as low [lowest quartile: <20%
reduction in LAV] and high [20% reduction in LAV]
response to CRT-D) were related to the risk of subsequent AT
(comprising atrial ﬁbrillation, atrial ﬂutter, atrial tachycardia,
and supraventricular tachyarrhythmias) among patients
enrolled in MADIT-CRT (Multicenter Automatic Deﬁbril-
lator Implantation Trial with Cardiac Resynchronization
Therapy).
Results The cumulative probability of AT 2.5 years after
assessment of echocardiographic response was lowest among
high LAV responders to CRT-D (3%) and signiﬁcantly
higher among both low LAV responders to CRT-D (9%)
and implantable cardioverter-deﬁbrillator–only patients (7%;
p ¼ 0.03 for the difference among the 3 groups). Consis-
tently, multivariate analysis showed that high LAV
responders to CRT-D experienced a signiﬁcant 53% (p ¼
0.01) reduction in the risk of subsequent AT as compared
with implantable cardioverter-deﬁbrillator–only patients,
whereas low LAV responders did not derive a signiﬁcant risk
reduction with CRT-D therapy (hazard ratio [HR]: 1.05
[95% conﬁdence interval (CI): 0.54 to 2.00]; p ¼ 0.89).
Patients who developed in-trial AT experienced signiﬁcant
increases in the risk for both the combined endpoint of
heart failure or death (HR: 2.28 [95% CI: 1.45 to 3.59];
p < 0.001) and the separate occurrence of all-cause mortality
(HR: 1.89 [95% CI: 1.08 to 3.62]; p ¼ 0.01).
Conclusions In the MADIT-CRT study, favorable reverse
remodeling of the left atrium with CRT-D therapy was
associated with a signiﬁcant reduction in risk of subsequentAT. (Multicenter Automatic Deﬁbrillator Implantation
Trial with Cardiac Resynchronization Therapy [MADIT-
CRT]; NCT00180271) (103).Left Atrial Contractile Function Following
a Successful Modiﬁed Maze Procedure at Surgery
and the Risk for Subsequent Thromboembolic
Stroke
Objectives The aim of this study was to evaluate whether
certain post-Maze left atrial (LA) contractile proﬁles may
pose a risk for ischemic stroke.
Background The mechanical contraction of the left atrium
may be modiﬁed after the Maze procedure. Whether this
imposes a risk for stroke, even in the presence of sinus
rhythm and after removal of the LA appendage, is not
known.
Methods Clinical, surgery-related, and echocardiographic
data from 150 patients who underwent radiofrequency and
cryoablation Maze procedures without the use of atrial
incisions between 2004 and 2009 and were in sustained
sinus rhythm were collected and analyzed. The occurrence of
stroke was evaluated by reviewing clinical records. All stroke
events were adjudicated by a neurologist.
Results At a mean follow-up time of 24.5 months, 15
patients (10%) had experienced ischemic strokes. Forty-
seven patients (31%) had no evidence of LA mechanical
contraction at 3 months after surgery (baseline assessment)
and on follow-up echocardiography. Multivariate analysis
showed that a lack of LA mechanical contraction at baseline
was associated with a 5-fold increase in the risk for stroke
(p ¼ 0.02) during follow-up. Larger atria imposed a signif-
icant risk as well; LA volume index 33 ml/m2 was asso-
ciated with a 3-fold risk increase (p ¼ 0.03). These effects
were maintained regardless of the lack of mechanical valve
implantation and anticoagulation treatment.
Conclusions Absence of LA contraction and LA volume
index 33 ml/m2 result in a signiﬁcant increase in the risk
for thromboembolic stroke after the Maze procedure for
patients in sinus rhythm (104).Effective Use of Radiation Shields to Minimize
Operator Dose During Invasive Cardiology
Procedures
Objectives This study sought to measure the protection
from scatter radiation offered to the primary physician by
a variety of available shields and to provide best practice
guidelines for shield use during invasive cardiology
procedures.
Background It is accepted that exposure to radiation
includes a predicted increase in cancer risk. In the cardiac
interventional laboratories, radiation shields are widely
available; however, proper use of the shields to optimize
protection during cardiac interventional procedures is not
well understood.
The Editors JACC Vol. 62, No. 21, 2013
JACC Topic Collection: Heart Rhythm Disorders November 19/26, 2013:e451–519
e488Methods The protection from scatter radiation offered by
a variety of shields used alone and in combination was
measured. Protection was assessed from air-kerma measure-
ments of scatter radiation from a phantom performed without
and with the shields. Protection was assessed for 3 patient-
access locations (right jugular vein, right femoral artery, and
left anterior chest) and for elevations ranging from 25 to 175
cm from the ﬂoor. The inﬂuence of precise placement of the
ceiling-mounted upper body shield was speciﬁcally assessed.
Results The utility and protection of shielding varied for
the 3 access points and with elevation. For femoral artery
access locations, the shields can provide at least 80%
protection from scatter at all elevations; however, protection
depends substantially on upper body shield position. A
disposable radiation-absorbing pad can provide 35% to 70%
upper body protection for procedures during which the
upper body shield cannot be used effectively.
Conclusions Radiation shields can provide substantial
protection from radiation during cardiac interventional proce-
dures. Shields must be thoughtfully and actively managed
to provide optimum protection. Best practice guidelines for
shield use are provided (105).Effects of Increasing Doses of Intracoronary
Adenosine on the Assessment of Fractional Flow
Reserve
Objectives The purpose of this study was to investigate the
effects of increasing dose of intracoronary adenosine on
fractional ﬂow reserve (FFR) measurement.
Backgrounds FFR is a validated method for the assessment
of the severity of coronary artery stenosis. It is based on the
change in the pressure gradient across the stenosis after the
achievement of maximal hyperemia of the coronary micro-
circulation that may be obtained by either intracoronary
bolus or intravenous infusion of adenosine. No study has
explored so far the effects of very high doses of intra-
coronary adenosine on FFR.
Methods FFR was assessed in 46 patients with 50 inter-
mediate lesions during cardiac catheterization by pressure-
recording guidewire (PrimeWire, Volcano, San Diego,
California). FFR was calculated as the ratio of the distal
coronary pressure to the aortic pressure at hyperemia.
Increasing doses of adenosine were administrated (60, 120,
180, 360, and 720 mg) as intracoronary boluses. Exclusion
criteria were: 1) allergy to adenosine; 2) baseline bradycardia
(heart rate <50 beats/min); 3) hypotension (blood
pressure <90 mm Hg); and 4) refusal to provide signed
informed consent.
Results High doses of intracoronary adenosine were well
tolerated, with no major side effects. Increasing doses up to
720 mg progressively decreased FFR values and increased the
percentage of patients showing an FFR <0.75. Among
angiographic parameters, both percent stenosis and lesion
length were independently associated with lower FFR
values.Conclusions This study shows that high doses of intra-
coronary adenosine (up to 720 mg) increased the sensitivity
of FFR in the detection of hemodynamically relevant
coronary stenoses. Furthermore, lesion length and stenosis
severity were independent angiographic determinants of
FFR (106).
Evidence of Atrial Functional Mitral Regurgitation
Due to Atrial Fibrillation: Reversal With Arrhythmia
Control
Objectives The purpose of this study was to determine
whether atrial ﬁbrillation (AF) might cause signiﬁcant mitral
regurgitation (MR), and to see whether this MR improves
with restoration of sinus rhythm.
Background MR can be classiﬁed by leaﬂet pathology
(organic/primary and functional/secondary) and by leaﬂet
motion (normal, excessive, restrictive). The existence of
secondary, normal leaﬂet motion MR remains controversial.
Methods We performed a retrospective cohort study.
Patients undergoing ﬁrst AF ablation at our institution (n ¼
828) were screened. Included patients had echocardiograms
at the time of ablation and at 1-year clinical follow-up. The
MR cohort (n ¼ 53) had at least moderate MR. A reference
cohort (n ¼ 53) was randomly selected from those patients
(n ¼ 660) with mild or less MR. Baseline echocardiographic
and clinical characteristics were compared, and the effect of
restoration of sinus rhythm was assessed by follow-up
echocardiograms.
Results MR patients were older than controls and more
often had persistent AF (62% vs. 23%, p < 0.0001). MR
patients had larger left atria (volume index: 32 cm3/m2 vs. 26
cm3/m2, p ¼ 0.008) and annular size (3.49 cm vs. 3.23 cm,
p ¼ 0.001), but similar left ventricular size and ejection
fraction. Annular size, age and persistent AF were inde-
pendently associated with MR. On follow-up echocardio-
gram, patients in continuous sinus rhythm had greater
reductions in left atrial size and annular dimension, and
lower rates of signiﬁcant MR (24% vs. 82%, p ¼ 0.005)
compared with those in whom sinus rhythm was not
restored.
Conclusions AF can result in “atrial functional MR” that
improves if sinus rhythm is restored (107).
Payment Source, Quality of Care, and Outcomes in
Patients Hospitalized With Heart Failure
Objectives The aim of this study was to analyze the rela-
tionship between payment source and quality of care and
outcomes in heart failure (HF).
Background HF is a major cause of morbidity and
mortality. There is a lack of studies assessing the association
of payment source with HF quality of care and outcomes.
Methods A total of 99,508 HF admissions from 244 sites
between January 2005 and September 2009 were analyzed.
Patients were grouped on the basis of payer status (private/
health maintenance organization, no insurance, Medicare, or
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the reference group.
Results The no-insurance group was less likely to receive
evidence-based beta-blockers (adjusted odds ratio [OR]:
0.73; 95% conﬁdence interval [CI]: 0.62 to 0.86),
implantable cardioverter-deﬁbrillator (OR: 0.59; 95% CI:
0.50 to 0.70), or anticoagulation for atrial ﬁbrillation (OR:
0.73; 95% CI: 0.61 to 0.87). Similarly, the Medicaid
group was less likely to receive evidence-based beta-
blockers (OR: 0.86; 95% CI: 0.78 to 0.95) or implantable
cardioverter-deﬁbrillators (OR: 0.86; 95% CI: 0.78
to 0.96). Angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers and beta-blockers were
prescribed less frequently in the Medicare group (OR:
0.89; 95% CI: 0.81 to 0.98). The Medicare, Medicaid,
and no-insurance groups had longer hospital stays. Higher
adjusted rates of in-hospital mortality were seen in
patients with Medicaid (OR: 1.22; 95% CI: 1.06 to 1.41)
and in patients with reduced systolic function with no
insurance.
Conclusions Decreased quality of care and outcomes for
patients with HF were observed in the no-insurance,
Medicaid, and Medicare groups compared with the
private/health maintenance organization group (108).Incidence and Predictors of Implantable
Cardioverter-Deﬁbrillator Therapy in Patients With
Arrhythmogenic Right Ventricular Dysplasia/
Cardiomyopathy Undergoing Implantable
Cardioverter-Deﬁbrillator Implantation for Primary
Prevention
Objectives The purpose of this study was to deﬁne the
incidence and predictors of implantable cardioverter-
deﬁbrillator (ICD) therapy in patients with arrhythmo-
genic right ventricular dysplasia/cardiomyopathy (ARVD/C)
after placement of an ICD for primary prevention.
Background Patients with a diagnosis of ARVD/C often
receive an ICD for prevention of sudden cardiac death.
Methods Patients (n ¼ 84) from the Johns Hopkins
registry with deﬁnite or probable ARVD/C who underwent
ICD implantation for primary prevention were studied.
Detailed phenotypic, genotype, and ICD event information
was obtained and appropriate ICD therapies were adjudi-
cated based on intracardiac electrograms.
Results Over a mean follow-up of 4.7  3.4 years,
appropriate ICD therapy was seen in 40 patients (48%), of
whom 16 (19%) received interventions for potentially fatal
ventricular ﬁbrillation/ﬂutter episodes. Proband status
(p < 0.001), inducibility at electrophysiologic study (p ¼
0.005), presence of nonsustained ventricular tachycardia
(p < 0 .001), and Holter premature ventricular complex
count >1,000/24 h (p ¼ 0.024) were identiﬁed as
signiﬁcant predictors of appropriate ICD therapy. The
5-year survival free of appropriate ICD therapy for patients
with 1, 2, 3, and 4 risk factors was 100%, 83%, 21%, and15%, respectively. Inducibility at electrophysiologic study
(hazard ratio: 4.5, 95% conﬁdence interval: 1.4 to 15,
p ¼ 0.013) and nonsustained ventricular tachycardia
(hazard ratio: 10.5, 95% conﬁdence interval: 2.4 to 46.2,
p ¼ 0.002) remained as signiﬁcant predictors on multi-
variable analysis.
Conclusions Nearly one-half of the ARVD/C patients
with primary prevention ICD implantation experience
appropriate ICD interventions. Inducibility at electrophysi-
ologic study and nonsustained ventricular tachycardia are
independent strong predictors of appropriate ICD therapy.
An increase in ventricular ectopy burden was associated with
progressively lower event-free (appropriate ICD interven-
tions) survival. Incremental risk of ventricular arrhythmias
and ICD therapy was observed with the presence of multiple
risk factors (109).Activation and Entrainment Mapping of
Hemodynamically Unstable Ventricular
Tachycardia Using a Percutaneous Left Ventricular
Assist Device
Objectives Our goal was to investigate the effects of
percutaneous left ventricular assist device (pLVAD) support
during catheter ablation of unstable ventricular tachycardia
(VT).
Background Mechanical cardiac support during ablation of
unstable VT is being increasingly used, but there is little
available information on the potential hemodynamic
beneﬁts.
Methods Twenty-three consecutive procedures in 22
patients (ischemic, n ¼ 11) with structural heart disease and
hemodynamically unstable VT were performed with either
pLVAD support (n ¼ 10) or no pLVAD support (intra-
aortic balloon pump counterpulsation, n ¼ 6; no support,
n ¼ 7). Procedural monitoring included vital signs, left atrial
pressure, arterial blood pressure, cerebral perfusion/oximetry,
VT characteristics, and ablation outcomes.
Results The pLVAD group was maintained in VT
signiﬁcantly longer than the non-pLVAD group (66.7 min
vs. 27.5 min; p ¼ 0.03) and required fewer early termina-
tions of sustained VT for hemodynamic instability (1.0 vs.
4.0; p ¼ 0.001). More patients in the pLVAD group had at
least 1 VT termination during ablation than non-pLVAD
patients (9 of 10 [90%] vs. 5 of 13 [38%]; p ¼ 0.03).
There were no differences between groups in duration of
cerebral deoxygenation, hypotension or perioperative
changes in left atrial pressure, brain natriuretic peptide levels,
lactic acid, or renal function.
Conclusions In patients with scar-related VT undergoing
catheter ablation, pLVAD support was able to safely
maintain end-organ perfusion despite extended periods of
hemodynamically unstable VT. Randomized studies are
necessary to determine whether this enhanced ability to
perform entrainment and activation mapping will translate
into a higher rate of clinical success (110).
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Methods of Measurement, and Clinical
UtilitydConsensus Guideline by International
Society for Holter and Noninvasive
Electrocardiology
This consensus guideline was prepared on behalf of the
International Society for Holter and Noninvasive Electro-
cardiology and is cosponsored by the Japanese Circulation
Society, the Computers in Cardiology Working Group on
e-Cardiology of the European Society of Cardiology, and
the European Cardiac Arrhythmia Society. It discusses the
electrocardiographic phenomenon of T-wave alternans
(TWA) (i.e., a beat-to-beat alternation in the morphology
and amplitude of the ST- segment or T-wave). This state-
ment focuses on its physiological basis and measurement
technologies and its clinical utility in stratifying risk for life-
threatening ventricular arrhythmias. Signal processing
techniques including the frequency-domain Spectral
Method and the time-domain Modiﬁed Moving Average
method have demonstrated the utility of TWA in arrhy-
thmia risk stratiﬁcation in prospective studies in >12,000
patients. The majority of exercise-based studies using both
methods have reported high relative risks for cardiovascular
mortality and for sudden cardiac death in patients with
preserved as well as depressed left ventricular ejection fraction.
Studies with ambulatory electrocardiogram-based TWA
analysis withModiﬁedMoving Average method have yielded
signiﬁcant predictive capacity. However, negative studies
with the Spectral Method have also appeared, including
2 interventional studies in patients with implantable deﬁ-
brillators. Meta-analyses have been performed to gain
insights into this issue. Frontiers of TWA research include
use in arrhythmia risk stratiﬁcation of individuals with
preserved ejection fraction, improvements in predictivity
with quantitative analysis, and utility in guiding medical as
well as device-based therapy. Overall, although TWA
appears to be a useful marker of risk for arrhythmic and
cardiovascular death, there is as yet no deﬁnitive evidence
that it can guide therapy (111).Sudden Death in Young Adults: An Autopsy-Based
Series of a Population Undergoing Active
Surveillance
Objectives The purpose of this study was to deﬁne the
incidence and characterization of cardiovascular cause of
sudden death in the young.
Background The epidemiology of sudden cardiac death
(SCD) in young adults is based on small studies and
uncontrolled observations. Identifying causes of sudden
death in this population is important for guiding approaches
to prevention.
Methods We performed a retrospective cohort study using
demographic and autopsy data from the Department of
Defense Cardiovascular Death Registry over a 10-yearperiod comprising 15.2 million person-years of active
surveillance.
Results We reviewed all nontraumatic sudden deaths in
persons 18 years of age and over. We identiﬁed 902 subjects
in whom the adjudicated cause of death was of potential
cardiac etiology, with a mean age of 38  11 years. The
mortality rate for SCD per 100,000 person-years for the
study period was 6.7 for males and 1.4 for females (p <
0.0001). Sudden death was attributed to a cardiac condition
in 715 (79.3%) and was unexplained in 187 (20.7%). The
incidence of sudden unexplained death (SUD) was 1.2 per
100,000 person-years for persons <35 years of age, and 2.0
per 100,000 person-years for those 35 years of age (p <
0.001). The incidence of fatal atherosclerotic coronary artery
disease was 0.7 per 100,000 person-years for those <35 years
of age, and 13.7 per 100,000 person-years for those 35
years of age (p < 0.001).
Conclusions Prevention of sudden death in the young
adult should focus on evaluation for causes known to be
associated with SUD (e.g., primary arrhythmia) among
persons <35 years of age, with an emphasis on atheroscle-
rotic coronary disease in those 35 years of age (112).16-Year Trends in the Infection Burden for
Pacemakers and Implantable Cardioverter-
Deﬁbrillators in the United States 1993 to 2008
Objectives We analyzed the infection burden associated
with the implantation of cardiac implantable electrophysio-
logical devices (CIEDs) in the United States for the years
1993 to 2008.
Background Recent data suggest that the rate of infection
following CIED implantation may be increasing.
Methods The Nationwide Inpatient Sample (NIS)
discharge records were queried between 1993 and 2008
using the 9th Revision of the International Classiﬁcation of
Diseases (ICD-9-CM). CIED infection was deﬁned as
either: 1) ICD-9 code for device-related infection (996.61)
and any CIED procedure or removal code; or 2) CIED
procedure code along with systemic infection. Patient health
proﬁle was evaluated by coding for renal failure, heart failure,
respiratory failure, and diabetes mellitus. The infection
burden and patient health proﬁle were calculated for each
year, and linear regression was used to test for changes over
time.
Results During the study period (1993 to 2008), the inci-
dence of CIED infection was 1.61%. The annual rate of
infections remained constant until 2004, when a marked
increase was observed, which coincided with an increase in
the incidence of major comorbidities. This was associated
with a marked increase in mortality and in-hospital ﬁnancial
charges.
Conclusions The infection burden associated with CIED
implantation is increasing over time and is associated with
prolonged hospital stays and high ﬁnancial costs (113).
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Deﬁbrillator Selection Is Associated With
Increased Complication Rates and Mortality
Among Patients Enrolled in the NCDR Implantable
Cardioverter-Deﬁbrillator Registry
Objectives The aim of this study was to compare single-
versus dual-chamber implantable cardioverter-deﬁbrillator
(ICD) implantation and complication rates in a large, real-
world population.
Background The majority of patients enrolled in ICD
efﬁcacy trials received single-chamber devices. Although
dual-chamber ICDs offer theoretical advantages over single-
chamber deﬁbrillators, the clinical superiority of dual-
chamber models has not been conclusively proven, and
they may increase complications.
Methods The National Cardiovascular Data Registry
ICD Registry was used to examine the association between
baseline characteristics and device selection in 104,049
patients receiving single- and dual-chamber ICDs between
January 1, 2006, and December 31, 2007. A longitudinal
cohort design was then used to determine in-hospital
complication rates.
Results Dual-chamber devices were implanted in 64,489
patients (62%). Adverse events were more frequent with dual-
chamber than with single-chamber device implantation
(3.17% vs. 2.11%, p < 0.001), as was the rate of in-hospital
mortality (0.40% vs. 0.23%, p < 0.001). After adjusting for
demographics, medical comorbidities, diagnostic test data,
and ICD indication, the odds of any complication (odds ratio:
1.40; 95% conﬁdence interval: 1.28 to 1.52; p< 0.001) and in-
hospital mortality (odds ratio: 1.45; 95% conﬁdence interval:
1.20 to 1.74; p < 0.001) were increased with dual-chamber
versus single-chamber ICD implantation.
Conclusions In this large, multicenter cohort of patients,
dual-chamber ICD use was common. Dual-chamber device
implantation was associated with increases in periprocedural
complications and in-hospital mortality compared with
single-chamber deﬁbrillator selection (114).Implantation-Related Complications of
Implantable Cardioverter-Deﬁbrillators and Cardiac
Resynchronization Therapy Devices: A Systematic
Review of Randomized Clinical Trials
The number of implantable cardioverter-deﬁbrillator (ICD)
and cardiac resynchronization therapy (CRT) implantations
is increasing drastically worldwide, and hence, the number of
implanting centers is also increasing. Despite abundant data
on the beneﬁcial effect of these devices, little is known
regarding safety and complication rates. Eleven ICD and 7
CRT trials were systematically reviewed to provide data on
the frequency of in-hospital mortality and complications
related to the implantation. Average in-hospital mortality
was 2.7% in trials using both thoracotomy and non-
thoracotomy ICDs, 0.2% in trials using nonthoracotomyICDs, and 0.3% in CRT trials. The pneumothorax rate was
similar between the nonthoracotomy ICD and CRT trials
(0.9%) Coronary sinus complications occurred in 2.0% of
patients undergoing CRT. Lead dislodgement rates were
higher in CRT trials (5.7%) than in nonthoracotomy ICD
trials (1.8%) (115).
Effect of Lenient Versus Strict Rate Control on
Cardiac Remodeling in Patients With Atrial
Fibrillation: Data of the RACE II (RAte Control
Efﬁcacy in permanent atrial ﬁbrillation II) Study
Objectives The aim of this study was to evaluate echocar-
diographic remodeling in permanent atrial ﬁbrillation (AF)
patients treated with either lenient or strict rate control.
Background It is unknown whether in permanent AF,
lenient rate control is associated with more adverse cardiac
remodeling than strict rate control.
Methods Echocardiography was conducted at baseline and
at follow-up in 517 patients included in the RACE II (RAte
Control Efﬁcacy in permanent atrial ﬁbrillation II) trial.
Echocardiographic parameters were compared between
patients randomized to lenient rate control (n ¼ 261) or
strict rate control (n ¼ 256).
Results Baseline echocardiographic parameters were
comparable between patients randomized to lenient and strict
rate control. Between baseline and follow-up, signiﬁcant
adverse atrial or ventricular remodeling was not observed in
either group. There were also no signiﬁcant differences in
atrial and ventricular remodeling between patients who
continuously had heart rates between 80 and 110 beats/min
and patients who continuously had heart rates<80 beats/min
during follow-up. Lenient rate control was not indepen-
dently associated with changes in echocardiographic
parameters: mean adjusted effect on left atrial size was
1.6 mm (p ¼ 0.09) and 1.1 mm on left ventricular end-
diastolic diameter (p ¼ 0.23). Instead, female sex was
independently associated with adverse remodeling: mean
adjusted effect on left atrial size was 2.4 mm (p ¼ 0.02)
and 6.5 mm on left ventricular end-diastolic diameter
(p < 0.0001).
Conclusions Female sex, not lenient rate control, seemed
to be associated with signiﬁcant adverse cardiac remodeling
in patients with permanent AF such as those enrolled in the
RACE II study. (RAte Control Efﬁcacy in Permanent
Atrial Fibrillation [RACE II]; NCT00392613) (116).Diastolic Dysfunction in Patients Undergoing
Cardiac Surgery: A Pathophysiological
Mechanism Underlying the Initiation of New-Onset
Post-Operative Atrial Fibrillation
Objectives Our goal was to investigate whether left
ventricular (LV) diastolic dysfunction was an important
pathophysiological mechanism underlying the initiation of
new-onset post-operative atrial ﬁbrillation (POAF).
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after cardiac surgery. However, the precise mechanism
underlying its development remains poorly understood.
Pre-existing alterations of myocardial diastolic function may
predispose patients to the development of POAF.
Methods Patients were residents of Olmsted County,
Minnesota, who underwent complete LV diastolic function
assessment before coronary artery bypass grafting and/or
valve surgery between January 1, 2000, and December 31,
2005. All were in sinus rhythm and had no history of atrial
ﬁbrillation, a pacemaker, mitral stenosis, or congenital heart
disease. POAF was deﬁned as any episode of atrial ﬁbrilla-
tion within 30 days after surgery.
Results POAF occurred in 135 of 351 patients (38.5%).
Patients with POAF were older (mean age 72.5  10.3 years
vs. 63.1  14.1 years; p < 0.001) and more likely to have
abnormal diastolic function. The rate of POAF increased
exponentially with diastolic function grade (DFG) severity
(p < 0.001). By multivariate analysis, after adjusting for
clinical and surgical risk factors, independent predictors of
POAF were older age (odds ratio [OR]: 1.05; p < 0.001),
higher body mass index (OR: 1.06; p ¼ 0.03), and abnormal
LV DFG (DFG 1, OR: 5.12 [p ¼ 0.006]; DFG 2, OR:
9.87 [p < 0.001]; and DFG 3, OR: 28.52 [p < 0.001]).
Conclusions LV diastolic dysfunction is a powerful, inde-
pendent predisposing substrate for the initiation of POAF.
Evaluation may be useful during risk stratiﬁcation of patients
undergoing cardiac surgery (117).Cardiac Resynchronization Therapy in Patients
With Minimal Heart Failure: A Systematic Review
and Meta-Analysis
Objectives The purpose of this study was to perform
a systematic review and meta-analysis of prospective
randomized clinical trials of cardiac resynchronization
therapy (CRT) versus implantable cardioverter-deﬁbrillator
(ICD) in patients with reduced ejection fraction (EF),
prolonged QRS interval, and New York Heart Association
(NYHA) functional class I to II heart failure (HF).
Background In patients with advanced HF, CRT improves
left ventricular (LV) function and reduces mortality and
hospitalizations. Recent data suggest that patients with
milder HF also beneﬁt from CRT.
Methods A meta-analysis of 5 clinical trials including
4,317 patients with NYHA functional class I/II HF was
performed.
Results Average age of patients was 65 years, and 80% were
male. Frequency of all-cause mortality for CRT versus ICD
was 8% versus 11.5% (risk ratio [RR]: 0.81; 95% conﬁdence
interval [CI]: 0.65 to 0.99, p ¼ 0.04); for HF hospitaliza-
tion, it was 11.6% versus 18.2% (RR: 0.68; 95% CI: 0.59 to
0.79, p < 0.001). Patients assigned to CRT had a signiﬁ-
cantly greater improvement in LVEF (þ5.9% vs. þ2.2%,
p < 0.001) and LV volume than ICD patients. Among
mildly symptomatic (NYHA functional class II) patients,CRT was associated with signiﬁcantly lower mortality
and HF hospitalization (RR: 0.73; 95% CI: 0.64 to 0.83),
p < 0.001). In asymptomatic (NYHA functional class I)
patients, HF hospitalization risk was lower (RR: 0.57; 95%
CI: 0.34 to 0.97, p ¼ 0.04) with CRT; however, there was
no difference in mortality. Twelve asymptomatic HF
patients needed to be treated with CRT to prevent 1
hospitalization.
Conclusions Cardiac resynchronization therapy decreases
all-cause mortality, reduces HF hospitalizations, and
improves LVEF in NYHA functional class I/II HF patients.
Although there was a reduction in HF hospitalization with
CRT for asymptomatic (NYHA functional class I) patients,
risks versus beneﬁts have to be carefully considered in this
subgroup (118).Device Therapy in Heart Failure Patients With
Chronic Kidney Disease
Heart failure (HF) and chronic kidney disease (CKD) both
carry signiﬁcant risk for sudden cardiac death, hospitaliza-
tion, and mortality; when combined, however, they mark-
edly increase the risk of morbidity and mortality. Device
therapies such as implantable cardioverter-deﬁbrillators
(ICDs) and cardiac resynchronization therapy (CRT) are
treatments proven to have signiﬁcant beneﬁt on clinical
outcomes in select patients with HF. However, the majority
of studies supporting the use of these devices have limited
data on patients with CKD or end-stage renal disease. In
this review, we discuss the intersection of HF and CKD as it
relates to progressive HF and the risk of sudden death.
Although these disorders are common and have a poor
prognosis, the evidence available for guiding treatment
decisions for the use of ICD and CRT devices in these
patients is lacking. Given this lack of clear evidence, prag-
matic clinical trials and comparative effectiveness studies are
needed to help identify the appropriate use of ICD and
CRT devices in this high-risk population of patients with
HF and CKD (119).Electrocardiographic Comparison of Ventricular
Arrhythmias in Patients With Arrhythmogenic Right
Ventricular Cardiomyopathy and Right Ventricular
Outﬂow Tract Tachycardia
Objectives The purpose of this study was to evaluate
whether electrocardiographic characteristics of ventricular
arrhythmias distinguish patients with arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C) from
those with right ventricular outﬂow tract tachycardia
(RVOT-VT).
Background Ventricular arrhythmias in RVOT-VT and
ARVD/C-VT patients can share a left bundle branch block/
inferior axis morphology.
Methods Wecompared the electrocardiographicmorphology
of ventricular tachycardia or premature ventricular contractions
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ARVD/C patients with that in 42 RVOT-VT patients.
Results ARVD/C patients had a signiﬁcantly longer mean
QRS duration in lead I (150  31 ms vs. 123  34 ms,
p ¼ 0.006), more often exhibited a precordial transition in
lead V6 (3 of 17 [18%] vs. 0 of 42 [0%] with RVOT-VT,
p ¼ 0.005), and more often had at least 1 lead with
notching (11 of 17 [65%] vs. 9 of 42 [21%], p¼ 0.001). The
most sensitive characteristics for the detection of ARVD/C
were a QRS duration in lead I of 120 ms (88% sensitivity,
91% negative predictive value). QRS transition at V6 was
most speciﬁc at 100% (100% positive predictive value, 77%
negative predictive value). The presence of notching on any
QRS complex had 79% sensitivity and 65% speciﬁcity of
(55% positive predictive value, 85% negative predictive
value). In multivariate analysis, QRS duration in lead I
of120ms (odds ratio [OR]: 20.4, p¼ 0.034), earliest onset
QRS in lead V1 (OR: 17.0, p ¼ 0.022), QRS notching
(OR: 7.7, p¼ 0.018), and a transition of V5 or later (OR: 7.0,
p ¼ 0.030) each predicted the presence of ARVD/C.
Conclusions Several electrocardiographic criteria can help
distinguish right ventricular outﬂow tract arrhythmias orig-
inating from ARVD/C compared with RVOT-VT patients
(120).Incidence of Asymptomatic Intracranial Embolic
Events After Pulmonary Vein Isolation:
Comparison of Different Atrial Fibrillation Ablation
Technologies in a Multicenter Study
Objectives We compared the safety of different devices by
screening for subclinical intracranial embolic events after
pulmonary vein isolation with either conventional irrigated
radiofrequency (RF) or cryoballoon or multielectrode phased
RF pulmonary vein ablation catheter (PVAC).
Background New devices speciﬁcally designed to facilitate
pulmonary vein isolation procedures have recently been
introduced.
Methods This prospective, observational, multicenter study
included patients with symptomatic atrial ﬁbrillation
referred for pulmonary vein isolation. Ablation was per-
formed using 1 of the 3 catheters. Strict periprocedural
anticoagulation, with intravenous heparin during ablation to
achieve an activated clotting time >300 s, was ensured in all
patients. Cerebral magnetic resonance imaging was per-
formed before and after ablation.
Results Seventy-four patients were included in the study:
27 in the irrigated RF group, 23 in the cryoballoon group,
and 24 in the PVAC group. Total procedure times were 198
 50 min, 174  35 min, and 124  32 min, respectively
(p < 0.001 for PVAC vs. irrigated RF and cryoballoon).
Findings on neurological examination were normal in all
patients before and after ablation. Post-procedure magnetic
resonance imaging detected a single new embolic lesion in 2
of 27 patients in the irrigated RF group (7.4%) and in 1 of
23 in the cryoballoon group (4.3%). However, in the PVACgroup 9 of 24 patients (37.5%) demonstrated 2.7  1.3 new
lesions each (p ¼ 0.003 for the presence of new embolic
events among the 3 groups).
Conclusions The PVAC is associated with a signiﬁcantly
higher incidence of subclinical intracranial embolic events.
Further study of the causes and signiﬁcance of these emboli
is required to determine the safety of the PVAC (121).
Prevalence and Characteristics of Early
Repolarization in the CASPER Registry: Cardiac
Arrest Survivors With Preserved Ejection Fraction
Registry
Objectives We evaluated the prevalence and characteris-
tics of early repolarization in patients in CASPER (Cardiac
Arrest Survivors With Preserved Ejection Fraction Registry).
Background Early repolarization has been implicated in
a syndrome of polymorphic ventricular tachycardia and
ﬁbrillation in patients without organic heart disease.
Methods One hundred patients with apparently unex-
plained cardiac arrest and preserved ejection fraction
underwent extensive clinical and genetic testing to unmask
subclinical electrical or structural disease. A blinded inde-
pendent analysis of the 12-lead electrocardiogram (ECG)
was performed. Early repolarization was deﬁned as 0.1 mV
QRS-ST junction (J-point) elevation with terminal QRS
slurring or notching in at least 2 contiguous inferior and/or
lateral leads.
Results One hundred cardiac arrest patients were enrolled
(40 females, age 43  14 years). Forty-four were diagnosed
with an established cause for cardiac arrest. Signiﬁcant early
repolarization was found in 19 patients, including 6 with
a primary diagnosis that explained their cardiac arrest (14%),
compared with 23% of the 56 patients with idiopathic
ventricular ﬁbrillation (IVF) (p ¼ 0.23). J-point elevation in
IVF patients had higher amplitude (0.25  0.11 mV vs. 0.13
 0.05 mV, p ¼ 0.02) and wider distribution (4.3  1.3
leads vs. 2.8  0.8 leads; p ¼ 0.01) than those with an
established cause of cardiac arrest. J-wave amplitude was
ﬂuctuant on serial ECGs; at least 1 ECG failed to
demonstrate early repolarization in 58% of patients.
Conclusions Early repolarization is present in a signiﬁcant
proportion of causally diagnosed and idiopathic VF. It is
often intermittent and more pronounced in IVF patients.
(Registry of Unexplained Cardiac Arrest; NCT00292032)
(122).
Reduction of the Risk of Recurring Heart Failure
Events With Cardiac Resynchronization Therapy:
MADIT-CRT (Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac Resynchronization
Therapy)
Objectives The evaluation of the risk of recurring heart
failure events (HFEs) was a pre-speciﬁed substudy of
MADIT-CRT (Multicenter Automatic Deﬁbrillator Im-
plantation Trial with Cardiac Resynchronization Therapy).
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cardiac resynchronization therapy with a deﬁbrillator (CRT-
D) on the occurrence of recurring heart failure episodes after
a ﬁrst post-implantation HFE.
Methods Data with regard to recurring HFEs were
prospectively collected for all 1,820 MADIT-CRT partici-
pants. The CRT-D versus deﬁbrillator-only risk for nonfatal
ﬁrst- and subsequent-HFEs was assessed by Cox propor-
tional hazards and Andersen-Gill proportional intensity
regression modeling, respectively, in efﬁcacy analyses
recognizing active device-type during follow-up.
Results Multivariate analysis showed that CRT-D was
associated with a signiﬁcant reduction in the risk of a ﬁrst
HFE (hazard ratio [HR]: 0.54, 95% conﬁdence interval
[CI]: 0.44 to 0.67, p < 0.001) and with a similar magnitude
of reduction in the risk of HFEs subsequent to a ﬁrst
post-enrollment event (HR: 0.62, 95% CI: 0.45 to 0.85,
p ¼ 0.003). The beneﬁt of CRT-D for the prevention of
ﬁrst and subsequent HFEs was pronounced among patients
with left bundle branch block (HR: 0.38, 95% CI: 0.29
to 0.49, p < 0.001; and HR: 0.50, 95% CI: 0.33 to 0.76,
p ¼ 0.001, respectively) and nonsigniﬁcant in non-left
bundle branch block patients (HR: 1.12, 95% CI: 0.77 to
1.64, p ¼ 0.55; and HR: 0.99, 95% CI: 0.58 to 1.69,
p ¼ 0.96, respectively; p values for interaction: p < 0.001
and p ¼ 0.06, respectively). The occurrences of ﬁrst and
second HFEs were associated with 7- and nearly 19-fold
respective increases in the risk of subsequent mortality.
Conclusions In the MADIT-CRT trial, the beneﬁt of
cardiac resynchronization therapy for the reduction in
recurring HFEs was maintained after the occurrence of
a ﬁrst post-enrollment event. The occurrence of HFEs
greatly increased the risk of death. (Multicenter Automatic
Deﬁbrillator Implantation With Cardiac Resynchronization
Therapy; NCT00180271) (123).Long-Term Follow-Up of Patients With Short QT
Syndrome
Objectives The aim of this study was to investigate the
clinical characteristics and the long-term course of a large
cohort of patients with short QT syndrome (SQTS).
Background SQTS is a rare channelopathy characterized
by an increased risk of sudden death. Data on the long-term
outcome of SQTS patients are not available.
Methods Fifty-three patients from the European Short QT
Registry (75% males; median age: 26 years) were followed up
for 64  27 months.
Results A familial or personal history of cardiac arrest was
present in 89%. Sudden death was the clinical presentation
in 32%. The average QTc was 314  23 ms. A mutation in
genes related to SQTS was found in 23% of the probands;
most of them had a gain of function mutation in HERG
(SQTS1). Twenty-four patients received an implantable
cardioverter deﬁbrillator, and 12 patients received long-term
prophylaxis with hydroquinidine (HQ), which was effectivein preventing the induction of ventricular arrhythmias.
Patients with a HERG mutation had shorter QTc at
baseline and a greater QTc prolongation after treatment
with HQ. During follow-up, 2 already symptomatic patients
received appropriate implantable cardioverter deﬁbrillator
shocks and 1 had syncope. Nonsustained polymorphic
ventricular tachycardia was recorded in 3 patients. The event
rate was 4.9% per year in the patients without antiar-
rhythmic therapy. No arrhythmic events occurred in patients
receiving HQ.
Conclusions SQTS carries a high risk of sudden death in
all age groups. Symptomatic patients have a high risk of
recurrent arrhythmic events. HQ is effective in preventing
ventricular tachyarrhythmia induction and arrhythmic events
during long-term follow-up (124).Radiofrequency Ablation of Atrial Fibrillation in
Patients With Mechanical Mitral Valve Prostheses:
Safety, Feasibility, Electrophysiologic Findings,
and Outcomes
Objectives The purpose of this study was to evaluate the
feasibility, safety, and outcomes of radiofrequency ablation of
atrial ﬁbrillation (AF) in patients with mechanical mitral
valve replacement (MVR).
Background The role of ablative therapy in patients with
MVR is not yet established, with safety concerns and very
few outcome data.
Methods Between January 2003 and December 2008, we
followed up 81 patients with MVR undergoing ﬁrst-time
AF ablation (compared with 162 age- and sex-matched
controls). Arrhythmia recurrences were identiﬁed by symp-
toms with documentation, event monitoring, Holter moni-
toring, and electrocardiograms.
Results All MVR and control patients underwent ablation
under therapeutic international normalized ratio. No
entrapment of catheters or stroke occurred. There were no
differences in terms of procedure-related complications
between the groups (p ¼ NS). Patients with MVR had
larger atria (p < 0.0001), lower left ventricular ejection
fractions (p ¼ 0.0001), and more concomitant atrial ﬂutter
at baseline (p < 0.0001). Over a 24-month follow-up, they
had higher recurrence rates compared with controls (49.4%
vs. 27.7% after a single ablation, p ¼ 0.0006). The creation
of ﬂutter lines signiﬁcantly reduced recurrences in patients
with any history of atrial ﬂutter (16.7% vs. 60.9%, p ¼
0.009). At last follow-up, 82.7% of MVR patients had their
arrhythmia controlled (69.1% not receiving antiarrhythmic
drugs).
Conclusions Radiofrequency ablation is feasible and safe
for patients with MVR. It allowed restoration of sinus
rhythm in a substantial proportion of patients undergoing
ablation. An abnormal atrial substrate underlies recurrences
in these patients. The ablation procedure needs to be further
reﬁned with a focus on extra pulmonary vein triggers and
concomitant ﬂutters to improve outcomes (125).
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Predicts Risk of Atrial Fibrillation Following
Cardiac Surgery
Objectives The purpose of this study was to examine
whether left atrial (LA) mechanical function, as measured by
LA total emptying fraction (TEF), is a predictor for the
development of post-operative atrial ﬁbrillation (POAF)
following cardiac surgery.
Background POAF is an important and frequent compli-
cation of cardiac surgery. LA enlargement has been reported
to be a risk factor for POAF, but the relationship between
LA mechanical function and POAF is not well understood.
We examined the relationship between pre-operative LA
function and POAF in patients without a history of atrial
ﬁbrillation.
Methods A total of 101 subjects (mean age 64  13 years)
underwent pre-operative transthoracic echocardiograms and
were followed for occurrence of POAF during the hospi-
talization for cardiac surgery. The left atrial maximum
volume (LAVmax) and left atrial minimum volume
(LAVmin) were measured and indexed to body surface area
(LAVmaxI and LAVminI, respectively). LA TEF was
calculated as: {[(LAVmax – LAVmin)/LAVmax]  100%}.
Univariate and multivariate analyses examined clinical and
echocardiographic predictors of POAF.
Results POAF occurred in 41% of subjects. Mean LA
TEF was 49  15%, mean LAVmaxI was 38  15 ml/m2,
and mean LAVminI was 20  13 ml/m2. Age, LA TEF,
and LAVminI were independent predictors of POAF. LA
TEF was lower in patients with POAF compared with those
without POAF (43  15% vs. 55  13%, p < 0.001), and
patients with a LA TEF <50% had a high risk of POAF
(odds ratio: 7.94, 95% conﬁdence interval: 3.23 to 19.54,
p < 0.001). Compared with LAVmaxI >32 ml/m2, LA
TEF <50% had higher discriminatory power for POAF,
which remained signiﬁcantly higher when adjusted for age
(p ¼ 0.04).
Conclusions LA TEF is an independent predictor of
POAF and is a stronger predictor of POAF than LAVmaxI
is. Impaired LA mechanical function may help to identify
patients who are most likely to beneﬁt from prophylaxis for
POAF (126).Prediction of Life-Threatening Arrhythmic Events in
Patients With Chronic Myocardial Infarction by
Contrast-Enhanced CMR
Objectives We hypothesized that infarct transmurality
assessed with late gadolinium enhancement cardiac magnetic
resonance (LGE-CMR) predicts arrhythmic events in
patients with chronic myocardial infarction.
Background Patients with decreased left ventricular func-
tion due to chronic myocardial infarction are at increased
risk for life-threatening arrhythmias related to infarcted
tissue. LGE-CMR accurately detects infarct morphology.Methods We prospectively enrolled 52 patients with
chronic myocardial infarction referred for primary preventive
implantable cardioverter-deﬁbrillator (ICD) implantation
following MADIT (Multicenter Automatic Deﬁbrillator
Implantation Trial) study criteria. Using LGE-CMR, left
ventricular volumes, function, and infarct morphology were
assessed including calculation of total and relative infarct
mass, infarct border, infarct border zone, and infarct
transmurality.
Results Patients were followed for 1,235  341 days. The
primary combined endpoint including appropriate device
therapy (ICD discharge or antitachycardia pacing) or death
from cardiac cause occurred in 16 individuals resulting in an
annual event rate of 4.7%. Six patients received an appro-
priate shock, 7 patients received recurrent appropriate anti-
tachycardia pacing for sustained ventricular tachycardia, and
3 patients died of cardiac cause. There was a signiﬁcant
association to relative infarct mass (38  8% vs. 28  14%,
p ¼ 0.02), infarct transmurality (24  8 g vs. 16  12 g, p ¼
0.02), and relative infarct transmurality (RIT) (63  12% vs.
48  23%, p ¼ 0.01). In separate logistic regression models,
no variable emerged as signiﬁcant when combined with
RIT. As a single effect, RIT emerged as a predictor of the
primary endpoint (p ¼ 0.02). A RIT cutoff at 43% resulted
in a sensitivity of 88%, a speciﬁcity of 50%, a positive
predictive value of 44%, and a negative predictive value of
90%.
Conclusions In patients with chronic myocardial infarction
scheduled for primary preventive ICD implantation, infarct
transmurality as deﬁned by LGE-CMR identiﬁes
a subgroup with increased risk for life-threatening arrhyth-
mias and cardiac death (127).Real-Life Observations of Clinical Outcomes With
Rhythm- and Rate-Control Therapies for Atrial
Fibrillation: RECORDAF (Registry on Cardiac
Rhythm Disorders Assessing the Control of Atrial
Fibrillation)
Objectives RECORDAF is the ﬁrst worldwide, prospec-
tive, observational survey of management of atrial ﬁbrillation
(AF) in unselected, community-based patients.
Background Primary outcomes were therapeutic success
and clinical outcomes associated with rhythm-control and
rate-control strategies.
Methods Patients with recent-onset AF were included
(n ¼ 5,604). Treatment strategy (rhythm control or rate
control) was noted at baseline. Follow-up was 12 months.
Therapeutic success required that strategy was unchanged
without clinical events. Further maintenance of sinus
rhythm was required in the rhythm-control group, and heart
rate 80 beats/min in the rate-control group.
Results Data from 5,171 patients were assessable. Thera-
peutic success was 54% overall (rhythm control 60% vs. rate
control 47%), a result driven by control of AF: rhythm
control, 81% vs. rate control, 74%. After adjustment for
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was signiﬁcantly related to superior therapeutic success
(odds ratio: 1.34, 95% conﬁdence interval: 1.15 to 1.55;
p ¼ 0.0002). Clinical events occurred in 18% of patients.
The arrhythmia management strategy was not predictive of
clinical events. The type (persistent), presence at baseline
visit, and duration (>3 months) of AF, together with age
older than 75 years and the presence of heart failure,
predicted progression to permanent AF. The choice of
rhythm control reduced the likelihood of AF progression
(odds ratio: 0.20, 95% conﬁdence interval: 0.17 to 0.25;
p < 0.0001).
Conclusions Clinical outcomes in AF patients were driven
mainly by hospitalizations for arrhythmia/proarrhythmia and
other cardiovascular causes, but not by the choice of rate or
rhythm strategy. Rhythm-control patients progressed less
rapidly to permanent AF (128).
Superiority of Simulator-Based Training Compared
With Conventional Training Methodologies in the
Performance of Transseptal Catheterization
Objectives This study aims to compare the performance of
electrophysiology fellows in transseptal catheterization
(TSP-C) after conventional (Conv-T) or simulator training
(Sim-T).
Background Current training for TSP-C, an increasingly
used procedure, relies on performance on patients with
supervision by an experienced operator. Virtual reality, a new
training option, could improve post-training performance.
Methods Fellows inexperienced in TSP-C were enrolled
and randomly assigned to Conv-T or Sim-T. The post-
training performance of each fellow was evaluated and
scored in 3 consecutive patient-based procedures by an
experienced operator blinded to the fellow’s training
assignment.
Results Fourteen fellows were randomized to Conv-T (n ¼
7) or to Sim-T (n ¼ 7) and, after training, performed 42
TSP-Cs independently. Training time was signiﬁcantly
longer for Conv-T than for Sim-T (median 30 days vs. 4
days; p ¼ 0.0175). The Conv-T fellows had signiﬁcantly
lower post-training performance scores (median 68 vs. 95;
p ¼ 0.0001) and a higher number of recurrent errors
(median 3 vs. 0; p ¼ 0.0006) when compared with Sim-T
fellows.
Conclusions The TSP-C training with virtual reality
results in shorter training times and superior post-training
performance (129).
Impact of Implanted Recalled Sprint Fidelis Lead
on Patient Mortality
Objectives This study sought to compare all-cause
mortality in patients with Fidelis leads (Medtronic, Min-
neapolis, Minnesota) to those with a nonadvisory lead.
Background Although Fidelis leads are prone to fracture,
and rare deaths due to lead failure have been reported, itis unclear whether the presence of a Fidelis lead is asso-
ciated with increased mortality. This study compares all-
cause mortality in a large cohort of patients with Fidelis
and Quattro implantable cardioverter-deﬁbrillator (ICD)
leads.
Methods All patients with Fidelis (Medtronic models
6931, 6948, and 6949) and Quattro (Medtronic model
6947) leads followed at 3 tertiary care centers were identiﬁed
from the medical records (implant dates: November 19,
2001, to December 23, 2008). Clinical and device-speciﬁc
data were collected into a common database. Deaths were
identiﬁed from medical records and the Social Security
Death Index. Survival was estimated using the Kaplan-
Meier method.
Results A total of 2,671 patients (1,030 Fidelis and 1,641
Quattro) were identiﬁed. There were 398 deaths: 147 in the
Fidelis group (mean follow-up: 34.4 months) and 251 in the
Quattro group (mean follow-up: 39.9 months). No deaths
were associated with 85 Fidelis and 23 Quattro failures. At
4 years, survival was diminished in patients with Fidelis
compared with Quattro leads (80.7% vs. 83.9%, p ¼ 0.025).
After adjustment for factors associated with mortality,
survival was similar between groups. One hundred percent
pacing was not associated with mortality. Elective removal of
nonfailed leads was performed in 5.1% of Fidelis and 0.9%
of Quattro patients.
Conclusions In a conservatively managed cohort, in whom
observation was predominantly utilized, adjusted survival is
similar between patients with Fidelis and Quattro ICD
leads (130).Epicardial Ablation of Rotors Suppresses
Inducibility of Acetylcholine-Induced Atrial
Fibrillation in Left Pulmonary Vein–Left Atrium
Preparations in a Beagle Heart Failure Model
Objectives The purpose of this study was to provide direct
evidences that rotor ablation suppresses atrial ﬁbrillation
(AF) inducibility.
Background Micro–re-entrant wavefronts have been sug-
gested to serve as sources of rapid activations during AF.
Whether AF inducibility is suppressed by elimination of
rotors remains unknown.
Methods We used optical mapping to study Langendorff-
perfused left pulmonary vein (PV)–left atrium (LA) prepa-
rations from 13 dogs with pacing-induced heart failure.
Atrial arrhythmias were induced by pacing and mapped
during acetylcholine infusion (1 mmol/l). Rotors were
identiﬁed from optical recordings. Epicardial ablation was
performed targeting the rotor anchoring sites in preparations
with sustained (>10 min) or incessant spontaneous AF.
Non-rotor ablation was performed in 4 preparations.
Repeated pacing was performed to test the AF inducibility
after ablation.
Results Sustained AF (n ¼ 12) and incessant spontaneous
AF (n ¼ 1) were induced after acetylcholine infusion.
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(9.2  4.2 beats/s), and rotor anchoring was found at the
left superior PV-LA junction in 13 preparations (9.1  4.6
beats/s) and at the ligament of Marshall-PV-LA junction
in 1 preparation. Epicardial rotor ablation successfully
inhibited the inducibility of sustained AF in 12 of 13
preparations (p < 0.01), including 4 with the maximal
dominant frequency sites located on the PV-LA junctional
rotor zones (direct elimination of mother rotors). The
longest AF duration was shortened signiﬁcantly by rotor
ablation (Wilcoxon Z ¼ 3.60, p ¼ 0.002, n ¼ 13), but
not by non-rotor ablation (Wilcoxon Z ¼ 1.00, p ¼ 0.317,
n ¼ 4).
Conclusions Epicardial ablation of the rotor anchoring
sites suppresses AF inducibility. The arrhythmogenicity at
the maximal dominant frequency sites is directly/indirectly
suppressed by the rotor ablation (131).Tachycardia-Induced Diastolic Dysfunction and
Resting Tone in Myocardium From Patients With
a Normal Ejection Fraction
Objectives The purpose of this study is to evaluate
tachycardia-induced relaxation abnormalities in myocardium
from patients with a normal ejection fraction.
Background Diastolic dysfunction and left ventricular
(LV) hypertrophy are closely linked. Tachycardia can
induce heart failure symptoms in otherwise asymp-
tomatic patients. To study the effects of tachycardia on
myocardial contractility and relaxation, we evaluated the
effects of increasing pacing rates in myocardial biopsy
samples obtained from patients with a normal ejection
fraction.
Methods LV biopsy samples were obtained during coro-
nary bypass surgery. Myocardial strip preparations were
electrically paced at rates from 60 to 180 beats/min. Dia-
stolic resting tone was assessed by cross-bridge deactivation.
Calcium transporting systems were functionally examined,
and myoﬁlament calcium sensitivity was studied.
Results Incomplete relaxation developed in 7 preparations,
with increased diastolic tension development at increasing
pacing rates. This was absent in the remaining 7 prepara-
tions. Incomplete relaxation was found to be associated with
increased LV mass and left atrial volume. Cross-bridge
deactivation showed that these preparations also had
a signiﬁcant resting tone. Additional functional analyses
suggest that incomplete relaxation is associated with
disproportionately elevated cellular calcium loads due to
a reduced sarcolemmal calcium extrusion reserve.
Conclusions Tachycardia-induced incomplete relaxation
was associated with increased LV mass and left atrial
volumes. We also found a disproportionately increased
calcium load at high rates and a substantial resting tone due
to diastolic cross-bridge cycling. These observations may
play a role in reduced exercise tolerance and tachycardia-
induced diastolic dysfunction (132).Syncope Due to Idiopathic Paroxysmal
Atrioventricular Block: Long-Term Follow-Up of
a Distinct Form of Atrioventricular Block
Objectives We present data on patients with syncope due
to paroxysmal atrioventricular (AV) block unexplainable in
terms of currently known mechanisms.
Background Paroxysmal AV block is known to be due to
intrinsic AV conduction disease or to heightened vagal tone.
Methods We evaluated 18 patients presenting with unex-
plained syncope who had: 1) normal baseline standard
electrocardiogram (ECG); 2) absence of structural heart
disease; and 3) documentation, by means of prolonged ECG
monitoring at the time of syncopal relapse, of paroxysmal
third-degree AV block with abrupt onset and absence of
other rhythm disturbances before or during the block.
Results The study group consisted of 9 men and 9 women,
mean age 55  19 years, who had recurrent unexplained
syncope for 8  7 years and were subsequently followed up
for as long as 14 years (4  4 years on average). The patients
had no structural heart disease, standard ECG was normal,
and electrophysiological study was negative. In all patients,
prolonged ECG monitoring documented paroxysmal
complete AV block with 1 or multiple consecutive pauses
(mean longest pause: 9  7 s at the time of syncope); AV
block occurred without P-P cycle lengthening or PR interval
prolongation. During the observation time, no patient had
permanent AV block; on permanent cardiac pacing, no
patient had further syncopal recurrences.
Conclusions Common clinical and electrophysiological
features deﬁne a distinct form of syncope due to idiopathic
paroxysmal AV block characterized by a long history of
recurrent syncope, absence of progression to persistent forms
of AV block, and efﬁcacy of cardiac pacing therapy (133).
Feasibility and Acute Efﬁcacy of Radiofrequency
Ablation of Cavotricuspid Isthmus–Dependent
Atrial Flutter Guided by Real-Time 3D TEE
Objectives The aim of this study was to evaluate the
feasibility and acute efﬁcacy of real-time 3-dimensional
transesophageal echocardiography (RT3DTEE)–guided
ablation of the cavotricuspid isthmus (CVTI).
Background The use of RT3DTEE to guide a trans-
catheter radiofrequency ablation procedure has never been
systematically investigated.
Methods Seventy consecutive patients with CVTI-
dependent atrial ﬂutter underwent CVTI ablation. Proce-
dural monitoring using RT3DTEE was assigned to patients
who requested general anesthesia for the procedure (n ¼ 21
[30%]). In the other 49 patients (the control group), the
procedures were monitored using the standard ﬂuoroscopic
approach. Procedural time was considered as skin-to-skin
electrophysiological procedure duration, not including
anesthesia preparation; adequate radiofrequency ablation
applications (with ﬁxed temperature and power settings)
were considered as lesions lasting  60 s.
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identiﬁed related structures in most patients (20 of 21);
anatomic features such as long CVTI (n ¼ 11), prominent
Eustachian ridge (n ¼ 9), prominent Eustachian valve (n ¼
6), septal recess (n ¼ 8), and pectinate muscles (n ¼ 10)
were frequent. Also, RT3DTEE allowed continuous visu-
alization of ablation catheter movement and contact.
Compared with the control group, RT3DTEE was equally
effective in achieving CVTI bidirectional block (100% in
both groups), and no complications occurred. RT3DTEE
shortened procedural time (median 73.0 min, interquartile
range [IQR] 60.0 to 90.0 min, vs. median 115.0 min, IQR
85.0 to 133.0 min, p < 0.001), reduced radiation exposure
(median ﬂuoroscopy time 4.2 min, IQR 3.1 to 8.4 min, vs.
median 19.3 min, IQR 12.9 to 36.4 min, p < 0.001; median
ﬂuoroscopy dose 575.4 cGy $ cm2, IQR 428.5 to 1,299.4
cGy $ cm2, vs. median 3,520.7 cGy $ cm2, IQR 1,700.0 to
6,709.0 cGy $ cm2, p < 0.001), and reduced the number
of radiofrequency applications to achieve bidirectional
block (median 7, IQR 6 to 10, vs. median 12, IQR 10 to 22,
p ¼ 0.007). A strong learning curve was detected by
comparing procedural data between the ﬁrst and last patients
treated using RT3DTEE.
Conclusions RT3DTEE-guided ablation of CVTI was
feasible, allowing real-time detailed morphological CVTI
characterization as well as continuous visualization of the
ablation catheter during radiofrequency ablation. This
approach entailed marked reductions in procedural time,
radiation exposure, and the number of radiofrequency
applications (134).Monomorphic Ventricular Tachycardia and
Mediastinal Adenopathy Due to Granulomatous
Inﬁltration in Patients With Preserved Ventricular
Function
Objectives This report characterizes a syndrome of gran-
ulomatous inﬁltration presenting as sustained monomorphic
ventricular tachycardia (SMVT) with mediastinal adenop-
athy in patients with preserved ventricular function.
Background Unlike truly idiopathic ventricular tachycardia,
SMVT due to granulomatous inﬁltration responds poorly to
radiofrequency ablation and has a poor prognosis.
Methods Patients without obstructive coronary artery disease
and with normal ventricular function presenting with SMVT
other than posterior fascicular morphology were evaluated.
Computed chest tomograms, cardiac magnetic resonance
imaging, and 18-ﬂuorodeoxyglucose positron emission tomo-
graphic scans (18FDG PET-CT) were performed. Signiﬁcant
lymph nodes were evaluated for tuberculosis and sarcoidosis.
Initial treatment included antiarrhythmic drugs  radio-
frequency ablation. Additionally, patients with evidence of
tuberculosis received anti-tuberculosis therapy; the rest were
treated as sarcoidosis.
Results Mediastinal adenopathy with mid-myocardial scar
and/or focal myocardial inﬂammation was observed in 14patients; lymph nodes revealed noncaseating granulomas in
all. Evidence of tuberculosis was present in 79%. During
follow-up (median duration 25 months), SMVT recurred
despite initial treatment in 92%. Addition of disease-speciﬁc
therapy abolished further recurrences in 64% of them.
Decrease in SMVT correlated with resolution of myocardial
inﬂammation on serial 18FDG PET-CTs. Appropriate
therapies occurred in 67% of patients receiving implantable
cardioverter-deﬁbrillators.
Conclusions A subset of patients with SMVT with
preserved ventricular function has a syndrome of arrhyth-
mogenic myocarditis with granulomatous mediastinal aden-
opathy due to myocardial tuberculosis or cardiac sarcoidosis.
This entity is optimally managed with a combination of
disease-speciﬁc therapy and antiarrhythmic measures (135).Plasma von Willebrand Factor Levels Are an
Independent Risk Factor for Adverse Events
Including Mortality and Major Bleeding in
Anticoagulated Atrial Fibrillation Patients
Objectives The purpose of this study was to evaluate the
prognostic value of plasma von Willebrand factor (vWF)
levels and ﬁbrin D-dimer in a large cohort of anticoagulated
permanent atrial ﬁbrillation (AF) patients.
Background In nonanticoagulated AF patients, plasma
vWF levels have been related to stroke and vascular events.
There are limited data on the prognostic role of biomarkers
in anticoagulated AF patients in relation to adverse
events (including thromboembolism), mortality, and major
bleeding.
Methods We studied 829 patients (50% male; median age
76 years) with permanent AF who were stabilized (for at
least 6 months) on oral anticoagulation therapy (interna-
tional normalized ratio: 2.0 to 3.0). Plasma D-dimer and
vWF levels were quantiﬁed by enzyme-linked immunosor-
bent assay. Patients were followed for 2 years, and adverse
events (thrombotic and vascular events, mortality, and major
bleeding) were recorded.
Results Patients were followed for a median of 828 days
(range 18 to 1,085 days). On multivariate analysis, age 75
years and older, previous stroke, heart failure, and high
plasma vWF levels (221 IU/dl) were associated with future
adverse cardiovascular events (all p values <0.05). High
plasma vWF levels, elderly patients, diabetes, hypercholes-
terolemia, and current smoking were associated with
mortality (all p values <0.05). High plasma vWF levels were
also an independent predictor of major bleeding (hazard
ratio: 4.47, 95% conﬁdence interval: 1.86 to 10.75;
p < 0.001). High plasma vWF levels were able to reﬁne
clinical risk stratiﬁcation schema for stroke (CHADS2
[Congestive heart failure, Hypertension, Age 75, Diabetes
mellitus, and prior Stroke or transient ischemic attack
(doubled)], CHA2DS2-VASc [Congestive heart failure,
Hypertension, Age 75 years, Diabetes mellitus, Stroke,
Vascular disease, Age 65 to 74 years, Sex category]) and
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liver function, Stroke, Bleeding history or predisposition,
Labile International Normalized Ratio, Elderly, Drugs/
alcohol concomitantly]). D-dimer did not show any signiﬁ-
cant impact on adverse events.
Conclusions High plasma vWF levels (221 IU/dl) are an
independent risk factor for adverse events in anticoagulated
permanent AF patients. This biomarker may potentially be
used to reﬁne stroke and bleeding clinical risk stratiﬁcation
in AF (136).Teamwork and Leadership in Cardiopulmonary
Resuscitation
Despite substantial efforts to make cardiopulmonary resus-
citation (CPR) algorithms known to healthcare workers, the
outcome of CPR has remained poor during the past decades.
Resuscitation teams often deviate from algorithms of CPR.
Emerging evidence suggests that in addition to technical
skills of individual rescuers, human factors such as teamwork
and leadership affect adherence to algorithms and hence the
outcome of CPR. This review describes the state of the
science linking team interactions to the performance of
CPR. Because logistical barriers make controlled measure-
ment of team interaction in the earliest moments of real-life
resuscitations challenging, our review focuses mainly on
high-ﬁdelity human simulator studies. This technique allows
in-depth investigation of complex human interactions using
precise and reproducible methods. It also removes variability
in the clinical parameters of resuscitation, thus letting
researchers study human factors and team interactions
without confounding by clinical variability from resuscitation
to resuscitation. Research has shown that a prolonged
process of team building and poor leadership behavior are
associated with signiﬁcant shortcomings in CPR. Teamwork
and leadership training have been shown to improve
subsequent team performance during resuscitation and have
recently been included in guidelines for advanced life
support courses. We propose that further studies on the
effects of team interactions on performance of complex
medical emergency interventions such as resuscitation are
needed. Future efforts to better understand the inﬂuence of
team factors (e.g., team member status, team hierarchy,
handling of human errors), individual factors (e.g., sex
differences, perceived stress), and external factors (e.g.,
equipment, algorithms, institutional characteristics) on team
performance in resuscitation situations are critical to improve
CPR performance and medical outcomes of patients (137).Reverse Remodeling and the Risk of Ventricular
Tachyarrhythmias in the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial–Cardiac
Resynchronization Therapy)
Objectives We aimed to evaluate the relationship between
echocardiographic response to cardiac resynchronizationtherapy (CRT) and the risk of subsequent ventricular
tachyarrhythmias (VTAs).
Background Current data regarding the effect of CRT on
the risk of VTA are limited and conﬂicting.
Methods The risk of a ﬁrst appropriate implantable
cardioverter-deﬁbrillator (ICD) therapy for VTA
(including ventricular tachycardia, ventricular ﬁbrillation,
and ventricular ﬂutter) was compared between high- and
low-echocardiographic responders to CRT deﬁbrillator
(CRT-D) therapy (deﬁned as 25% and <25% reductions,
respectively, in left ventricular end-systolic volume
[LVESV] at 1 year compared with baseline) and ICD-only
patients enrolled in the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial–Cardiac
Resynchronization Therapy).
Results The cumulative probability of a ﬁrst VTA at 2 years
after assessment of echocardiographic response was highest
among low responders toCRT-D (28%), intermediate among
ICD-only patients (21%), and lowest among high responders
to CRT-D (12%), with p < 0.001 for the overall difference
during follow-up. Multivariate analysis showed that high
responders to CRT-D experienced a signiﬁcant 55% reduc-
tion in the risk of VTA compared with ICD-only patients
(p < 0.001), whereas the risk of VTA was not signiﬁcantly
different between low responders and ICD-only patients
(hazard ratio [HR]: 1.26; p¼ 0.21). Consistently, assessment
of response to CRT-D as a continuous measure showed that
incremental 10% reductions in left ventricular end-systolic
volume were associated with corresponding reductions in
the risk of subsequent VTA (HR: 0.80; p < 0.001), VTA/
death (HR: 0.79; p < 0.001), ventricular tachycardia (HR:
0.80; p < 0.001), and ventricular ﬁbrillation/ventricular
ﬂutter (HR: 0.75; p ¼ 0.044).
Conclusions In patients with left ventricular dysfunction
enrolled in the MADIT-CRT trial, reverse remodeling was
associated with a signiﬁcant reduction in the risk of subse-
quent life-threatening VTAs. (Multicenter Automatic
Deﬁbrillator Implantation Trial–Cardiac Resynchronization
Therapy [MADIT-CRT]; NCT00180271) (138).Clinical Implications of Midventricular Obstruction
in Patients With Hypertrophic Cardiomyopathy
Objectives We investigated the prevalence, clinical char-
acteristics, and prognosis of hypertrophic cardiomyopathy
(HCM) patients with midventricular obstruction (MVO).
Background Previous descriptions of patients with MVO
have been conﬁned to case reports or small patient series,
and this subgroup of HCM patients has therefore remained
underrecognized.
Methods The study population included 490 HCM
patients. Left ventricular MVO was diagnosed when the
peak midcavitary gradient was estimated to be 30 mm Hg.
Results MVO was identiﬁed in 46 patients (9.4%).
Patients with MVO were more likely to be symptomatic
than those without. MVO was found to be an independent
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(hazard ratio [HR]: 2.23, p ¼ 0.016), and this trend was
especially pronounced for the combined endpoint of sudden
death and potentially lethal arrhythmic events (HR: 3.19,
p < 0.001). Apical aneurysm formation was identiﬁed in
28.3% of patients with MVO and strongly predicted HCM-
related death (HR: 3.47, p ¼ 0.008) and the combined
endpoint of sudden death and potentially lethal arrhythmic
events (HR: 5.08, p < 0.001). In addition, MVO without
apical aneurysm was also identiﬁed as an independent
determinant of the combined endpoint of sudden death and
potentially lethal arrhythmic events (HR: 2.43, p ¼ 0.045).
Conclusions This analysis identiﬁed MVO as an inde-
pendent predictor of adverse outcomes, especially the
combined endpoint of sudden death and potentially lethal
arrhythmic events. Our results suggest that longer periods of
exposure to MVO might lead to unfavorable consequences.
They also support the principle that the presence of MVO in
patients with HCM has important pathophysiological
implications (139).Low Prevalence of Risk Markers in Cases of
Sudden Death Due to Brugada Syndrome:
Relevance to Risk Stratiﬁcation in Brugada
Syndrome
Objectives The objective of this study was to determine the
prevalence of conventional risk factors in sudden arrhythmic
death syndrome (SADS) probands with Brugada syndrome
(BrS).
Background Patients with BrS and previous aborted
sudden cardiac death (SCD) are at high risk of recurrent
events. Other universally accepted clinical features associated
with higher risk include unheralded syncope and the pres-
ence of a spontaneous type 1 electrocardiogram (ECG).
Methods We analyzed reported symptoms and reviewed
ECGs from SADS probands with familial diagnoses of BrS,
established by cardiological evaluation, including ECG,
2-dimensional echocardiography, Holter monitoring, exer-
cise tolerance testing, and ajmaline provocation. These cases
underwent familial evaluation between 2003 and 2010.
Results A total of 49 consecutive families with a conﬁrmed
SADS death and a diagnosis of BrS were evaluated,
comprising assessment of 202 family members in total.
One family had 2 members with SADS, resulting in a total
of 50 probands included. Mean age of death of probands was
29.1  10.6 years, with 41 males (82%) (p < 0.05). Ante-
mortem ECGs were available for 5 SADS probands, 1 of
which demonstrated a spontaneous type 1 pattern. In 45
probands, symptoms before death were reported reliably by
family members. Of these, 9 (20%) had experienced at least
1 syncopal episode before the fatal event. Importantly, 68%
of probands would not have fulﬁlled any current criteria for
consideration of implantable cardioverter-deﬁbrillator.
Conclusions The “low-risk” asymptomatic BrS group
comprises the majority of SCD in this cohort. Current riskstratiﬁcation would appear to be inadequate, and new
markers of risk are vital (140).Preventing Overdiagnosis of Implantable
Cardioverter-Deﬁbrillator Lead Fractures Using
Device Diagnostics
Objectives This study sought to use implantable
cardioverter-deﬁbrillator (ICD) diagnostics to discriminate
ICD lead fractures from normally functioning leads with
high impedance and from connection problems between the
lead and header.
Background ICD diagnostics facilitate identiﬁcation of
fractures, but there are no accepted criteria for discrimi-
nating fractures from other causes of high impedance and/or
nonphysiological “noise” oversensing.
Methods We analyzed a development set of 91 leads to
construct a stepwise algorithm based on ICD diagnostics. It
included 40 fractures, 30 connection problems, and 21
functioning leads that triggered high-impedance alerts.
Then we applied this algorithm to an independent test set of
100 leads: 70 fractures and 30 intact leads with connection
problems that were misdiagnosed clinically as fractures. In
the algorithm, either extremely high maximum impedance
or noise oversensing with a normal impedance trend indi-
cated a fracture. A short interval from surgery to impedance
rise or prolonged stable impedance after an abrupt rise
indicated a connection problem. A gradual impedance
increase or stable, high impedance indicated a functioning
lead.
Results In the test set, the algorithm correctly classiﬁed
100% of fractures (95% conﬁdence interval [CI]: 95% to
100%) and 87% of connection problems that were mis-
diagnosed as fractures (95% CI: 70% to 95%).
Conclusions An algorithm using only ICD diagnostics
identiﬁes leads with oversensing or high impedance as
fractures or connection problems with a high degree of
accuracy (141).Flecainide Therapy Reduces Exercise-Induced
Ventricular Arrhythmias in Patients With
Catecholaminergic Polymorphic Ventricular
Tachycardia
Objectives This study evaluated the efﬁcacy and safety of
ﬂecainide in addition to conventional drug therapy in
patients with catecholaminergic polymorphic ventricular
tachycardia (CPVT).
Background CPVT is an inherited arrhythmia syndrome
caused by gene mutations that destabilize cardiac ryanodine
receptor Ca2þ release channels. Sudden cardiac death is
incompletely prevented by conventional drug therapy with
b-blockers with or without Ca2þ channel blockers. The
antiarrhythmic agent ﬂecainide directly targets the molecular
defect in CPVT by inhibiting premature Ca2þ release and
triggered beats in vitro.
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genotype-positive CPVT patient started on ﬂecainide at 8
international centers before December 2009. The primary
outcome measure was the reduction of ventricular arrhyth-
mias during exercise testing.
Results Thirty-three patients received ﬂecainide because of
exercise-induced ventricular arrhythmias despite conven-
tional (for different reasons, not always optimal) therapy
(median age 25 years; range 7 to 68 years; 73% female).
Exercise tests comparing ﬂecainide in addition to conven-
tional therapy with conventional therapy alone were available
for 29 patients. Twenty-two patients (76%) had either
partial (n ¼ 8) or complete (n ¼ 14) suppression of exercise-
induced ventricular arrhythmias with ﬂecainide (p < 0.001).
No patient experienced worsening of exercise-induced
ventricular arrhythmias. The median daily ﬂecainide dose
in responders was 150 mg (range 100 to 300 mg). During
a median follow-up of 20 months (range 12 to 40 months),
1 patient experienced implantable cardioverter-deﬁbrillator
shocks for polymorphic ventricular arrhythmias, which
were associated with a low serum ﬂecainide level. In 1
patient, ﬂecainide successfully suppressed exercise-induced
ventricular arrhythmias for 29 years.
Conclusions Flecainide reduced exercise-induced ventric-
ular arrhythmias in patients with CPVT not controlled by
conventional drug therapy (142).The V2 Transition Ratio: A New
Electrocardiographic Criterion for Distinguishing
Left From Right Ventricular Outﬂow Tract
Tachycardia Origin
Objectives We sought to develop electrocardiography
(ECG) criteria for distinguishing left ventricular outﬂow
tract (LVOT) from right ventricular outﬂow tract (RVOT)
origin in patients with idiopathic outﬂow tract ventricular
tachycardia (OTVT) and lead V3 R/S transition.
Background Several ECG criteria have been proposed for
differentiating left from right OTVT origin; ventricular
tachycardias (VTs) with left bundle branch block and V3
transition remain a challenge.
Methods We analyzed the surface ECG pattern of patients
with OTVT with a precordial transition in lead V3 who
underwent successful catheter ablation. Sinus and VT QRS
morphologies were measured in limb and precordial leads
with electronic calipers. The V2 and V3 transition ratios were
calculated by computing the percentage R-wave during VT
(R/RþS)VT divided by the percentage R-wave in sinus
rhythm (R/RþS)SR.
Results We retrospectively analyzed ECGs from 40
patients (mean age 44  14 years, 21 female) with outﬂow
tract premature ventricular contractions (PVCs)/VT.
Patients with structural heart disease, paced rhythms, and
bundle branch block during sinus rhythm were excluded.
The V2 transition ratio was signiﬁcantly greater for
LVOT PVCs compared with RVOT PVCs (1.27  0.60 vs.0.23  0.16; p < 0.001) and was the only independent
predictor of LVOT origin. In 21 prospective cases, a V2
transition ratio 0.60 predicted an LVOT origin with 91%
accuracy. A PVC precordial transition occurring later than
the sinus rhythm transition excluded an LVOT origin with
100% accuracy.
Conclusions The V2 transition ratio is a novel electrocar-
diographic measure that reliably distinguishes LVOT from
RVOT origin in patients with lead V3 precordial transition.
This measure might be useful for counseling patients and
planning an ablation strategy (143).The Early Repolarization Pattern in the General
Population: Clinical Correlates and Heritability
Objectives This study sought to describe the clinical
correlates and heritability of the early repolarization pattern
(ERP) in 2 large, population-based cohorts.
Background There is growing recognition that ERP is
associated with adverse outcomes.
Methods Participants of the Framingham Heart Study
(FHS) (N ¼ 3,995) and the Health 2000 Survey (H2K)
(N ¼ 5,489) were included. ERP was deﬁned as a J-point
elevation 0.1 mV in 2 leads in either the inferior (II, III,
aVF) or lateral (I, aVL, V4–6) territory or both. We tested
the association between clinical characteristics and ERP, and
estimated sibling recurrence risk.
Results ERP was present in 243 of 3,955 (6.1%) of FHS
and 180 of 5,489 (3.3%) of H2K subjects. Male sex, younger
age, lower systolic blood pressure, higher Sokolow-Lyon
index, and lower Cornell voltage were independently asso-
ciated with the presence of ERP. In the FHS sample,
siblings of individuals with ERP had an ERP prevalence of
11.6% (recurrence risk ratio of 1.89). Siblings of individuals
with ERP had an increased unadjusted odds of ERP
(odds ratio: 2.22, 95% conﬁdence interval: 1.01 to 4.85,
p ¼ 0.047).
Conclusions ERP has strong association with clinical
factors and has evidence for a heritable basis in the general
population. Further assessment of the genetic determinants
of ERP is warranted (144).Congenitally Corrected Transposition of the Great
Arteries: Ventricular Function at the Time of
Systemic Atrioventricular Valve Replacement
Predicts Long-Term Ventricular Function
Objectives The objective was to evaluate the systemic
ventricular ejection fraction (SVEF) at the time of systemic
atrioventricular valve (SAVV) replacement as a predictor of
SVEF 1 year after surgery in patients with congenitally
corrected transposition of the great arteries (CCTGA).
Background Progressive SAVV regurgitation causes
systemic ventricular failure in CCTGA patients, who are
commonly referred late for intervention. Survival after
surgery is poor when the pre-operative SVEF is <44%.
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operative SVEF 40% in 27 patients and <40% in 19
patients) with 2 good-sized ventricles, a morphologically
right systemic ventricle, and SAVV regurgitation requiring
surgery. Median follow-up was not different in patients with
a pre-operative SVEF 40% (8.8 years) or <40% (7.7 years,
p ¼ 0.36).
Results Pre-operative SVEF was the only independent
predictor of 1-year post-operative SVEF (p < 0.0001).
The late SVEF was preserved (deﬁned as 40%) in 63% of
patients who underwent surgery with an SVEF 40%
compared with 10.5% of patients who underwent surgery
with an SVEF <40%. Pre-operative variables associated
with late mortality were an SVEF 40%, a subpulmonary
ventricular systolic pressure 50 mm Hg, atrial ﬁbrillation,
and New York Heart Association functional class III to IV.
Conclusions Post-operative systemic ventricular function
after SAVV replacement can be predicted from the pre-
operative SVEF. For best results, operation should be
considered at an earlier stage, before the SVEF falls below
40% and the subpulmonary ventricular systolic pressure rises
above 50 mm Hg (145).The Incidence of Bradyarrhythmias and Clinical
Bradyarrhythmic Events in Patients With Acute
Coronary Syndromes Treated With Ticagrelor or
Clopidogrel in the PLATO (Platelet Inhibition and
Patient Outcomes) Trial: Results of the Continuous
Electrocardiographic Assessment Substudy
Objectives The aim of this study was to determine whether
ticagrelor increased the risk of ventricular pauses compared
with clopidogrel and whether these pauses were associated
with any clinical bradycardic events in patients presenting
with acute coronary syndromes.
Background Ticagrelor, an oral reversibly binding P2Y12
inhibitor, provides more potent and consistent inhibition of
platelet aggregation than clopidogrel but in a phase II study
was associated with increased risk for ventricular pauses. A
prospective continuous electrocardiographic (cECG) assess-
ment was therefore performed within the PLATO (Platelet
Inhibition and Patient Outcomes) study comparing ticagrelor
and clopidogrel in patients hospitalized with acute coronary
syndromes.
Methods Patients in the cECG assessment had planned
7-day cECG recording initiated at the time of randomiza-
tion (week 1), which was within 24 h of symptom onset, and
then repeated at 1 month after randomization during the
convalescent phase. The principal safety endpoint was the
incidence of ventricular pauses lasting at least 3 s. Investi-
gators also reported symptomatic bradycardic adverse events
during the entire study duration (median 277 days).
Results A total of 2,908 patients were included in the
cECG assessment, of whom 2,866 (98.5%) had week 1
recordings, 1,991 (68.4%) had 1-month recordings, and
1,949 (67.0%) had both. During the ﬁrst week afterrandomization, ventricular pauses 3 s occurred more
frequently in patients receiving ticagrelor than clopidogrel
(84 [5.8%] vs. 51 [3.6%]; relative risk: 1.61; p ¼ 0.006). At
1 month, pauses 3 s occurred overall less frequently and
were similar between treatments (2.1% vs. 1.7%). Most were
ventricular pauses, and the greatest excess associated with
ticagrelor were asymptomatic, sinoatrial nodal in origin
(66%), and nocturnal. There were no differences between
ticagrelor and clopidogrel in the incidence of clinically re-
ported bradycardic adverse events, including syncope,
pacemaker placement, and cardiac arrest.
Conclusions In the PLATO cECG assessment, more
patients treated with ticagrelor compared with clopidogrel
had ventricular pauses, which were predominantly asymp-
tomatic, sinoatrial nodal in origin, and nocturnal and
occurred most frequently in the acute phase of acute coro-
nary syndromes. There were no apparent clinical conse-
quences related to the excess in ventricular pauses in patients
assigned to ticagrelor. (A Comparison of AZD6140 and
Clopidogrel in Patients With Acute Coronary Syndrome
[PLATO]; NCT00391872) (146).Incidence, Causes, and Outcomes of
Out-of-Hospital Cardiac Arrest in Children: A
Comprehensive, Prospective, Population-Based
Study in the Netherlands
Objectives This study sought to determine comprehen-
sively the incidence of pediatric out-of-hospital cardiac arrest
(OHCA) and its contribution to total pediatric mortality,
the causes of pediatric OHCA, and the outcome of resus-
citation of pediatric OHCA patients.
Background There is a paucity of complete studies on
incidence, causes, and outcomes of pediatric OHCA.
Methods In this prospective, population-based study,
OHCA victims younger than age 21 years in 1 province of
the Netherlands were registered through both emergency
medical services and coroners over a period of 4.3 years.
Death certiﬁcate data on total pediatric mortality, survival
status, and neurological outcome at hospital discharge also
were obtained.
Results With a total mortality of 923 during the study
period and 233 victims of OHCA (including 221 who died
and 12 who survived), OHCA caused 24% (221 of 923) of
total pediatric mortality. Natural causes of OHCA amoun-
ted to 115 (49%) cases, with cardiac causes being most
prevalent (n ¼ 90, 39%). The incidence of pediatric OHCA
was 9.0 per 100,000 pediatric person-years (95% conﬁdence
interval: 7.8 to 10.3), whereas the incidence of pediatric
OHCA from cardiac causes was 3.2 (95% conﬁdence
interval: 2.5 to 3.9). Of 51 resuscitated patients, 12 (24%)
survived; among survivors, 10 (83%) had a neurologically
intact outcome.
Conclusions Out-of-hospital cardiac arrest accounts for
a signiﬁcant proportion of pediatric mortality, and cardiac
causes are the most prevalent causes of OHCA. The vast
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outcome (147).Pericardial Fat Is Associated With Atrial Fibrillation
Severity and Ablation Outcome
Objectives The aim of this study was to characterize the
relationship between pericardial fat and atrial ﬁbrillation
(AF).
Background Obesity is an important risk factor for AF.
Pericardial fat has been hypothesized to exert local patho-
genic effects on nearby cardiac structures above and beyond
that of systemic adiposity.
Methods One hundred ten patients undergoing ﬁrst-time
AF ablation and 20 reference patients without AF under-
went cardiac magnetic resonance imaging for the quantiﬁ-
cation of periatrial, periventricular, and total pericardial fat
volumes using a previously validated technique. Together
with body mass index and body surface area, these were
examined in relation to the presence of AF, the severity of
AF, left atrial volume, and long-term AF recurrence after
ablation.
Results Pericardial fat volumes were signiﬁcantly associated
with the presence of AF, AF chronicity, and AF symptom
burden (all p values <0.05). Pericardial fat depots were also
predictive of long-term AF recurrence after ablation (p ¼
0.035). Finally, pericardial fat depots were also associated
with left atrial volume (total pericardial fat: r ¼ 0.46, p <
0.001). Importantly, these associations persisted after
multivariate adjustment and additional adjustment for body
weight. In contrast, however, systemic measures of adiposity,
such as body mass index and body surface area, were not
associated with these outcomes in multivariate-adjusted
models.
Conclusions Pericardial fat is associated with the presence
of AF, the severity of AF, left atrial volumes, and poorer
outcomes after AF ablation. These associations are both
independent of and stronger than more systemic measures of
adiposity. These ﬁndings are consistent with the hypothesis
of a local pathogenic effect of pericardial fat on the
arrhythmogenic substrate supporting AF (148).Synchronicity of LV Contraction as a Determinant
of LV Twist Mechanics: Serial Speckle-Tracking
Analyses in WPW Syndrome Before and After
Radiofrequency Catheter Ablation
Objectives This study set out to investigate the isolated
impact of synchronous patterns of left ventricular (LV)
contraction (i.e., LV synchronicity) on LV twist behavior.
Background Although the relationships between LV load-
ing status/LV contractility and twist are well-established,
no data are available regarding the relation between LV
twist and LV synchronicity, without any interference
by changes in LV pre-load, afterload, and contractility.
Serial assessment of patients with Wolff-Parkinson-Whitesyndrome before and after radiofrequency catheter ablation
(RFCA) allows this to be explored.
Method Of the 40 Wolff-Parkinson-White patients
initially screened, 34 were enrolled. Two-dimensional and
Doppler echocardiography along with speckle tracking-
derived LV twist mechanics, apical-basal rotation delay,
and left ventricular dyssynchrony index (LVdys) were ob-
tained before and after RFCA. The LVdys was deﬁned as
the maximal delay in time-to-peak radial strain of different
LV segments at the papillary muscle level.
Results Overall, no signiﬁcant changes were demonstrated
in LV volumes, systolic and diastolic function, and end-
systolic wall stress before versus after RFCA. After RFCA,
median value of LVdys was attenuated from 33.5 (inter-
quartile range [IQR]: 14.0 to 84.3) to 14.0 (IQR: 11.5 to 21.8)
(p¼ 0.002), which was accompanied by a reduction in apical-
basal rotation delay from 9.7% (IQR: 3.5 to 23.7) to 3.3%
(IQR: 1.3 to 8.0) (p¼ 0.004). In contrast, LV twist increased
from14.2 (IQR: 9.1 to 18.4) before to 19.7 (IQR: 15.0 to
22.6) after RFCA (p ¼ 0.002). Delta LV twist pre- to
post-RFCA displayed a signiﬁcant inverse correlation with
changes in apical-basal rotation delay (r ¼ 0.42, p ¼ 0.01)
and Delta LVdys (r ¼ 0.39, p ¼ 0.02).
Conclusions The LV synchronous contraction is signiﬁ-
cantly related to LV twist (149).Prevalence and Prognostic Signiﬁcance of Left
Ventricular Reverse Remodeling in Dilated
Cardiomyopathy Receiving Tailored Medical
Treatment
Objectives The purpose of this study was to determine the
prevalence and prognostic role of left ventricular reverse
remodeling (LVRR) in idiopathic dilated cardiomyopathy
(IDCM).
Background Tailored medical therapy can lead to LVRR in
IDCM. The prevalence and prognostic impact of LVRR
remain unclear.
Methods We consecutively enrolled 361 IDCM patients.
LVRR was deﬁned as a left ventricular ejection fraction
increase of 10 U or a left ventricular ejection fraction
of 50% and a decrease in indexed left ventricular end-
diastolic diameter of 10% or indexed left ventricular
end-diastolic diameter of 33 mm/m2 at 24 months (range
9 to 36 months). Follow-up echocardiographic data were
available for 242 patients (67%), 34 (9%) died/underwent
heart transplantation (HTx) before re-evaluation, and 85
(24%) did not have a complete re-evaluation. After re-
evaluation, the surviving patients were followed for 110 
53 months; there were 55 deaths (23%) and 32 HTx (13%).
Results LVRR was found in 89 of 242 patients (37%).
Baseline predictors of LVRR were higher systolic blood
pressure (p ¼ 0.047) and the absence of left bundle branch
block (p ¼ 0.009). When added to a prognostic baseline
model including male sex, heart failure duration, New York
Heart Association functional classes III to IV, LVEF,
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New York Heart Association functional classes III to IV,
and signiﬁcant mitral regurgitation after 24 months emerged
as independent predictors of death/HTx and heart failure
death/HTx. The model including follow-up variables
showed additional prognostic power with respect to baseline
model (for death/HTx, area under the curve: 0.80 vs. 0.70,
respectively, p ¼ 0.004). Furthermore, only LVRR was
signiﬁcantly associated with sudden death/major ventricular
arrhythmia in the long-term.
Conclusions LVRR characterized approximately one-third
of IDCM patients surviving 2 years while receiving optimal
medical therapy and allowed a more accurate long-term
prognostic stratiﬁcation of the disease (150).Prolongation of the Atrioventricular Conduction in
Fetuses Exposed to Maternal Anti-Ro/SSA and
Anti-La/SSB Antibodies Did Not Predict
Progressive Heart Block: A Prospective
Observational Study on the Effects of Maternal
Antibodies on 165 Fetuses
Objectives We prospectively examined the prevalence and
outcome of untreated fetal atrioventricular (AV) prolonga-
tion in the presence of maternal anti-Ro antibodies.
Background It has been suggested that antibody-mediated
congenital complete atrioventricular block (CAVB) may be
preventable if detected and treated early when low-grade
block is present. With this rationale in mind, dexametha-
sone has been advocated by others to treat prolonged fetal
AV conduction >2 z-scores, consistent with ﬁrst-degree
heart block.
Methods Between July 2003 and June 2009, 165 fetuses
of 142 anti-Ro/La antibody–positive women were
referred to our center for serial echocardiography. Our
protocol included weekly evaluation of the fetal AV
conduction between 19 (range 17 to 23) and 24 (range
23 to 35) gestational weeks. AV times were compared
with institutional reference data and with post-natal
electrocardiograms.
Results Of 150 fetuses with persistently normal AV
conduction throughout the observation period, a diagnosis
of CAVB was subsequently made in 1 at 28 weeks, after the
serial evaluation had ended. Of 15 untreated fetuses either
with AV prolongation between 2 and 6 z-scores or with
type 1 second-degree block, progressive heart block devel-
oped in none of them. Three of these 15 fetuses (20%) had
a neonatal diagnosis of ﬁrst-degree block that spontane-
ously resolved (n ¼ 2) or has not progressed (n ¼ 1) on
follow-up examinations. No other cardiac complications
were detected.
Conclusions Fetal AV prolongation did not predict
progressive heart block to birth. Our ﬁndings question the
rationale of a management strategy that relies on the early
identiﬁcation and treatment of fetal AV prolongation to
prevent CAVB (151).Severe Renal Impairment and Stroke Prevention
in Atrial Fibrillation: Implications for
Thromboprophylaxis and Bleeding Risk
The prevalence of atrial ﬁbrillation (AF) in end-stage renal
failure is high, with an increased risk of stroke among these
patients with AF compared with the AF population without
severe renal impairment. Many trials have shown the net
clinical beneﬁt of oral anticoagulation therapy for primary
and secondary prevention of stroke in patient populations
with AF. However, current stroke risk stratiﬁcation schemes
are based on studies that have deliberately excluded patients
with severe renal impairment. Indeed, there are no large
randomized controlled trials that assess the real risk/beneﬁt
of full intensity anticoagulation in patients with severe renal
impairment. Also, rates of major bleeding episodes in anti-
coagulated hemodialysis patients with AF are high. These
data are inﬂuenced by the lack of appropriate monitoring,
the difﬁculties in maintaining the international normalized
ratio target (variable between the studies), and an inaccurate
bleeding classiﬁcation. Thus, the limited available data may
be difﬁcult to apply to such a heterogeneous patient pop-
ulation, characterized by both an increased risk of bleeding
and a hypercoagulability state, as seen in the patient pop-
ulation with severe renal impairment (152).
The CONNECT (Clinical Evaluation of Remote
Notiﬁcation to Reduce Time to Clinical Decision)
Trial: The Value of Wireless Remote Monitoring
With Automatic Clinician Alerts
Objectives The primary objective was to determine if
wireless remote monitoring with automatic clinician alerts
reduces the time from a clinical event to a clinical decision
in response to arrhythmias, cardiovascular (CV) disease
progression, and device issues compared to patients receiving
standard in-ofﬁce care. A secondary objective was to
compare the rates of CV health care utilization between
patients in the remote and in-ofﬁce arms.
Background In addition to providing life-saving therapy,
implantable cardioverter-deﬁbrillators collect advanced
diagnostics on the progression of the patient’s heart disease.
Device technology has progressed to allow wireless remote
monitoring with automatic clinician alerts to replace some
scheduled in-ofﬁce visits.
Methods The CONNECT (Clinical Evaluation of
Remote Notiﬁcation to Reduce Time to Clinical Decision)
study was a multicenter, prospective, randomized evaluation
involving 1,997 patients from 136 clinical sites who
underwent insertion of an implantable cardioverter-
deﬁbrillator (including cardiac resynchronization therapy
devices) and were followed up for 15 months. Health care
utilization data included all CV-related hospitalizations,
emergency department visits, and clinic ofﬁce visits.
Results The median time from clinical event to clinical
decision per patient was reduced from 22 days in the
in-ofﬁce arm to 4.6 days in the remote arm (p < 0.001). The
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length of stay per CV hospitalization visit from 4.0 days in
the in-ofﬁce arm to 3.3 days in the remote arm (p ¼ 0.002).
Conclusions Wireless remote monitoring with automatic
clinician alerts as compared with standard in-ofﬁce follow-
up signiﬁcantly reduced the time to a clinical decision in
response to clinical events and was associated with a signif-
icant reduction in mean length of CV hospital stay. (Clinical
Evaluation of Remote Notiﬁcation to Reduce Time to
Clinical Decision [CONNECT]; NCT00402246) (153).
Mechanisms of Fractionated Electrograms
Formation in the Posterior Left Atrium During
Paroxysmal Atrial Fibrillation in Humans
Objectives The aim of this paper was to study mechanisms
of formation of fractionated electrograms on the posterior
left atrial wall (PLAW) in human paroxysmal atrial ﬁbril-
lation (AF).
Background The mechanisms responsible for complex
fractionated atrial electrogram formation during AF are
poorly understood.
Methods In 24 patients, we induced sustained AF by
pacing from a pulmonary vein. We analyzed transitions
between organized patterns and changes in electrogram
morphology leading to fractionation in relation to interbeat
interval duration (systolic interval [SI]) and dominant
frequency. Computer simulations of rotors helped in the
interpretation of the results.
Results Organized patterns were recorded 31  18% of the
time. In 47% of organized patterns, the electrograms and
PLAW activation sequence were similar to those of incoming
waves during pulmonary vein stimulation that induced AF.
Transitions to fractionation were preceded by signiﬁcant
increases in electrogram duration, spike number, and SI short-
ening (R2 ¼ 0.94). Similarly, adenosine infusion during orga-
nized patterns caused signiﬁcant SI shortening leading to
fractionated electrograms formation. Activation maps during
organization showed incoming wave patterns, with earliest ac-
tivation located closest to the highest dominant frequency site.
Activation maps during transitions to fragmentation showed
areas of slowed conduction and unidirectional block. Simula-
tions predicted that SI abbreviation that heralds fractionated
electrograms formation might result from a Doppler effect on
wave fronts preceding an approaching rotor or by acceleration
of a stationary or meandering, remotely located source.
Conclusions During induced AF, SI shortening after
either drift or acceleration of a source results in intermittent
ﬁbrillatory conduction and formation of fractionated elec-
trograms at the PLAW (154).
Antiarrhythmic Effects of Simvastatin in Canine
Pulmonary Vein Sleeve Preparations
Objectives The purpose of this study was to determine the
electrophysiologic effects of simvastatin in canine pulmonary
vein (PV) sleeve preparations.Background Ectopic activity arising from the PV plays
a prominent role in the development of atrial ﬁbrillation.
Methods Transmembrane action potentials were recorded
from canine superfused left superior or inferior PV sleeves
using standard microelectrode techniques. Acetylcholine
(1 mM), isoproterenol (1 mM), high calcium ([Ca2þ]o ¼
5.4 mM), or a combination was used to induce early after-
depolarizations or delayed afterdepolarizations and triggered
activity. Voltage clamp experiments were performed in the
left atrium measuring fast and late sodium currents.
Results Under steady-state conditions, simvastatin (10
nM, n ¼ 9) induced a small increase in action potential
duration measured at 85% repolarization and a signiﬁcant
decrease in action potential amplitude, take-off potential,
and maximum rate of rise of action potential upstroke at the
fastest rates. The Vmax decreased from 175.1  34 V/s to
151.7  28 V/s and from 142  47 V/s to 97.4  39 V/s at
basic cycle lengths of 300 and 200 ms, respectively.
Simvastatin (10 to 20 nM) eliminated delayed after-
depolarizations and delayed afterdepolarization-induced
triggered activity in 7 of 7 PV sleeve preparations and
eliminated or reduced late-phase 3 early afterdepolarizations
in 6 of 6 PV sleeve preparations. Simvastatin (20 nM) did
not affect late or fast sodium currents measured using voltage
clamp techniques.
Conclusions Our data suggest that in addition to its
upstream actions to reduce atrial structural remodeling,
simvastatin exerts a direct antiarrhythmic effect by sup-
pressing triggers responsible for the genesis of atrial ﬁbril-
lation (155).Impact of Lesion Sets on Mid-Term Results of
Surgical Ablation Procedure for Atrial Fibrillation
Objectives The objective of this study was to evaluate the
effects of different lesion sets of ablation in patients
undergoing mitral surgery plus maze.
Background The role of lesion sets on outcome after maze
is poorly deﬁned.
Methods A total of 141 patients were prospectively fol-
lowed up. Two different lesion sets were prepared: 32
patients underwent a radiofrequency left atrial lesion set of
maze (“limited”), and 109 had combined left and right
atrial lesion sets of maze  ganglionic plexi isolation
(“extensive”). A longitudinal observational study assessed
the role of “extensive” versus “limited” ablation on atrial
ﬁbrillation (AF), New York Heart Association (NYHA)
functional class II/III, treatment with antiarrhythmic
drugs, follow-up recovery of the ratio of E- to A-wave
(E/A), and survival and time to hospitalization (overall and
for heart failure).
Results The prevalence of AF over time was lower in the
“extensive” arm (adjusted relative risk [RR]: 0.10; 95%
conﬁdence interval [CI]: 0.03 to 0.31; p < 0.001), with
signiﬁcantly lower prevalence at discharge, 3 months, and 18
months. The prevalence of patients in NYHA functional
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(adjusted RR: 0.11; 95% CI: 0.03 to 0.34; p < 0.001), with
signiﬁcant differences at any assessment (except the third
month). The differences in E/A recovery and use of anti-
arrhythmic drugs were less marked, with an RR of 1.55
(95% CI: 0.99 to 2.42; p ¼ 0.05) and RR of 0.76 (95% CI:
0.54 to 1.06; p ¼ 0.11), respectively, with a signiﬁcantly
lower prevalence of antiarrhythmic drugs in the “extensive”
ablation arm at 12, 18, and 24 months. Rates of hospitali-
zation for heart failure, overall hospitalization, and the
combined event death/hospitalization were lower in the
“extensive” arm (p ¼ 0.11, p ¼ 0.003, and p ¼ 0.002,
respectively).
Conclusions The addition of right-sided ablation improves
clinical and electrophysiologic results after maze procedure
(156).Risk Factors for Recurrent Syncope and
Subsequent Fatal or Near-Fatal Events in Children
and Adolescents With Long QT Syndrome
Objectives We aimed to identify risk factors for recurrent
syncope in children and adolescents with congenital long
QT syndrome (LQTS).
Background Data regarding risk assessment in LQTS after
the occurrence of the ﬁrst syncope episode are limited.
Methods The Prentice-Williams-Peterson conditional gap
time model was used to identify risk factors for recurrent
syncope from birth through age 20 years among 1,648
patients from the International Long QT Syndrome
Registry.
Results Multivariate analysis demonstrated that corrected
QT interval (QTc) duration (500 ms) was a signiﬁcant
predictor of a ﬁrst syncope episode (hazard ratio: 2.16),
whereas QTc effect was attenuated when the end points of
the second, third, and fourth syncope episodes were evalu-
ated (hazard ratios: 1.29, 0.99, 0.90, respectively; p < 0.001
for the null hypothesis that all 4 hazard ratios are identical).
A genotype-speciﬁc subanalysis showed that during child-
hood (0 to 12 years), males with LQTS type 1 had the
highest rate of a ﬁrst syncope episode (p ¼ 0.001) but
exhibited similar rates of subsequent events as other
genotype-sex subsets (p ¼ 0.63). In contrast, in the age
range of 13 to 20 years, long QT syndrome type 2 females
experienced the highest rate of both ﬁrst and subsequent
syncope events (p < 0.001 and p ¼ 0.01, respectively).
Patients who experienced 1 episodes of syncope had
a 6- to 12-fold (p < 0.001 for all) increase in the risk of
subsequent fatal/near-fatal events independently of QTc
duration. Beta-blocker therapy was associated with a signif-
icant reduction in the risk of recurrent syncope and subse-
quent fatal/near-fatal events.
Conclusions Children and adolescents who present after
an episode of syncope should be considered to be at a high
risk of the development of subsequent syncope episodes and
fatal/near-fatal events regardless of QTc duration (157).Cardiac Resynchronization Therapy Is More
Effective in Women Than in Men: The MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation
Trial With Cardiac Resynchronization Therapy) Trial
Objectives The purpose of this study was to investigate the
factors related to sex-speciﬁc outcomes for death and heart
failure events in the MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial With Cardiac Resynchro-
nization Therapy) trial.
Background In the MADIT-CRT trial, women seemed to
achieve a better result from resynchronization therapy than
men.
Methods All 1,820 patients (453 female and 1,367 male)
enrolled in the MADIT-CRT trial were included in this
sex-speciﬁc outcome analysis that compared the effect of
cardiac resynchronization therapy with deﬁbrillator (CRT-
D) relative to implanted cardioverter-deﬁbrillator (ICD) on
death or heart failure (whichever came ﬁrst), heart failure
only, and death at any time.
Results Female patients were more likely to have non-
ischemic cardiomyopathy and left bundle branch block and
less likely to have renal dysfunction than male patients.
Overall, female patients had a better result from CRT-D
therapy than male patients, with a signiﬁcant 69% reduc-
tion in death or heart failure (hazard ratio: 0.31, p < 0.001)
and 70% reduction in heart failure alone (hazard ratio: 0.30,
p < 0.001). Women had a signiﬁcant 72% reduction in all-
cause mortality in the total population (hazard ratio: 0.28,
p ¼ 0.02) and signiﬁcant 82% and 78% reductions in
mortality in those with QRS 150 ms and with left bundle
branch block conduction disturbance, respectively, with sex-
by-treatment interactions for mortality reduction signiﬁcant
at p < 0.05 in each of these 3 patient groups. These bene-
ﬁcial CRT-D effects among women were associated with
consistently greater echocardiographic evidence of reverse
cardiac remodeling in women than in men.
Conclusions Women in the MADIT-CRT trial obtained
signiﬁcantly greater reductions in death or heart failure
(whichever came ﬁrst), heart failure alone, and all-cause
mortality with CRT-D therapy than men, with consis-
tently greater echocardiographic evidence of reverse cardiac
remodeling in women than in men. (Multicenter Automatic
Deﬁbrillator Implantation Trial With Cardiac Resynchro-
nization Therapy [MADIT-CRT]; NCT00180271) (158).
Myocardial Fibrosis Predicts Appropriate Device
Therapy in Patients With Implantable
Cardioverter-Deﬁbrillators for Primary Prevention
of Sudden Cardiac Death
Objectives The purpose of this study was to evaluate the
association between regional myocardial ﬁbrosis and
ventricular arrhythmias in patients with cardiomyopathy.
Background Patients with heart failure are at risk of sudden
cardiac death (SCD). Current guidelines recommend
implantable cardioverter-deﬁbrillator (ICD) devices for
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signiﬁcant proportion of devices never discharge, hence
a more accurate method for targeting those at risk is
desirable.
Methods We prospectively enrolled 103 patients meeting
criteria for ICD implantation for primary prevention of
SCD. Cardiac magnetic resonance imaging was performed
before device implantation. Regional ﬁbrosis was identiﬁed
with late gadolinium enhancement (LGE).
Results Median follow-up was 573 days (interquartile
range: 379 to 863 days). The LGE identiﬁed regional
ﬁbrosis in 31 of 61 (51%) patients with nonischemic
cardiomyopathy (NICM) and in all 42 patients with
ischemic cardiomyopathy (ICM). There was a 29% (9 of
31) discharge rate in the NICM group with LGE
compared with a 14% (6 of 42) discharge rate in the ICM
group (p ¼ NS). There were no ICD discharges in the
NICM group without LGE, which was signiﬁcantly lower
than the rate observed in both the ICM patients (p ¼ 0.04)
and the NICM patients with LGE (p < 0.01). Left
ventricular ejection fraction was similar in patients with
and without device therapy (24  12% vs. 26  8%,
p ¼ NS) and those with or without LGE (25  9% vs.
26  9%, p ¼ NS).
Conclusions Patients with advanced cardiomyopathy and
myocardial ﬁbrosis demonstrated by LGE on cardiac
magnetic resonance imaging have a high likelihood of
appropriate ICD therapy. Correspondingly, absence of
LGE may indicate a lower risk for malignant ventricular
arrhythmias (159).The Short QT Syndrome: Proposed Diagnostic
Criteria
Objectives We aimed to develop diagnostic criteria for the
short QT syndrome (SQTS) to facilitate clinical evaluation
of suspected cases.
Background The SQTS is a cardiac channelopathy asso-
ciated with atrial ﬁbrillation and sudden cardiac death. Ten
years after its original description, a consensus regarding an
appropriate QT interval cutoff and speciﬁc diagnostic
criteria have yet to be established.
Methods The MEDLINE database was searched for all
reported cases of SQTS in the English language, and all
relevant data were extracted. The distribution of QT inter-
vals and electrocardiographic (ECG) features in affected
cases were analyzed and compared to data derived from
ECG analysis from general population studies.
Results A total of 61 reported cases of SQTS were iden-
tiﬁed. Index events, including sudden cardiac death, aborted
cardiac arrest, syncope, and/or atrial ﬁbrillation occurred in
35 of 61 (57.4%) cases. The cohort was predominantly male
(75.4%) and had a mean QTc value of 306.7 ms with values
ranging from 248 to 381 ms in symptomatic cases. In
reference to the ECG characteristics of the generalpopulation, and in consideration of clinical presentation,
family history, and genetic ﬁndings, a highly sensitive
diagnostic scoring system was developed.
Conclusions Based on a comprehensive review of 61 re-
ported cases of the SQTS, formal diagnostic criteria have
been proposed that will facilitate diagnostic evaluation in
suspected cases of SQTS. Diagnostic criteria may lead to
a greater recognition of this condition and provoke screening
of at-risk family members (160).Association of Left Atrial Fibrosis Detected by
Delayed-Enhancement Magnetic Resonance
Imaging and the Risk of Stroke in Patients With
Atrial Fibrillation
Objectives This study tried to determine the association
between left atrial (LA) ﬁbrosis, detected using delayed-
enhanced magnetic resonance imaging (DE-MRI), and
the CHADS2 score (point system based on individual
clinical risk factors including congestive heart failure,
hypertension, age, diabetes, and prior stroke) variables,
speciﬁcally stroke.
Background In patients with atrial ﬁbrillation (AF),
conventional markers for the risk of stroke base their higher
predictive effect on clinical features, particularly previous
stroke history, and not individual LA pathophysiological
properties. We aimed to determine the association between
LA ﬁbrosis, detected using DE-MRI, and the CHADS2
score variables, speciﬁcally stroke.
Methods Patients with AF who presented to the AF clinic
and received a DE-MRI of the LA were evaluated. Their
risk factor proﬁles, including a CHADS2 score, were cata-
logued. The degree of LA ﬁbrosis was determined as
a percentage of the LA area. Any history of previous strokes,
warfarin use, or cerebrovascular disease was recorded.
Results A total of 387 patients, having a mean age of 65 
12 years, 36.8% female, were included in this study. A
history of previous stroke was present in 36 (9.3%) patients.
Those patients with previous strokes had a signiﬁcantly
higher percentage of LA ﬁbrosis (24.4  12.4% vs. 16.2 
9.9%, p < 0.01). A larger amount of LA ﬁbrosis was also
seen in those patients with a higher CHADS2 score (2:
18.7  11.4 vs. <2: 14.7  9.2, p < 0.01). A logistic
regression analysis of all variables except strokes (CHAD
score) demonstrated that LA ﬁbrosis independently pre-
dicted cerebrovascular events (p ¼ 0.002) and signiﬁcantly
increased the predictive performance of the score (area under
the curve ¼ 0.77).
Conclusions Our preliminary, multicenter results suggest
DE-MRI–based detection of LA ﬁbrosis is independently
associated with prior history of strokes. We propose that the
amount of DE-MRI–determined LA ﬁbrosis could repre-
sent a marker for stroke and a possible therapeutic target
with potential applicability for clinical treatment for patients
with AF (161).
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Cardiac Death in the United States
The need for consistent and current data describing the true
incidence of sudden cardiac arrest (SCA) and/or sudden
cardiac death (SCD) was highlighted during the most
recent Sudden Cardiac Arrest Thought Leadership Alli-
ance’s (SCATLA) Think Tank meeting of national experts
with broad representation of key stakeholders, including
thought leaders and representatives from the American
College of Cardiology, American Heart Association, and
the Heart Rhythm Society. As such, to evaluate the true
magnitude of this public health problem, we performed
a systematic literature search in MEDLINE using the
MeSH headings, “death, sudden” OR the terms “sudden
cardiac death” OR “sudden cardiac arrest” OR “cardiac
arrest” OR “cardiac death” OR “sudden death” OR
“arrhythmic death.” Study selection criteria included peer-
reviewed publications of primary data used to estimate
SCD incidence in the U.S. We used Web of Science’s
Cited Reference Search to evaluate the impact of each
primary estimate on the medical literature by determining
the number of times each “primary source” has been cited.
The estimated U.S. annual incidence of SCD varied widely
from 180,000 to >450,000 among 6 included studies.
These different estimates were in part due to different data
sources (with data age ranging from 1980 to 2007), deﬁ-
nitions of SCD, case ascertainment criteria, methods of
estimation/extrapolation, and sources of case ascertainment.
The true incidence of SCA and/or SCD in the U.S. remains
unclear, with a wide range in the available estimates that
are badly dated. As reliable estimates of SCD incidence are
important for improving risk stratiﬁcation and prevention,
future efforts are clearly needed to establish uniform deﬁ-
nitions of SCA and SCD and then to prospectively and
precisely capture cases of SCA and SCD in the overall U.S.
population (162).Use of Intravenous Gamma Globulin and
Corticosteroids in the Treatment of Maternal
Autoantibody-Mediated Cardiomyopathy
Objectives This study sought to evaluate the outcome of
maternal autoantibody-mediated fetal cardiomyopathy/
endocardial ﬁbroelastosis following intravenous gamma
globulin (IVIG) and corticosteroid therapy.
Background We have previously shown that 85% of fetuses
and infants with maternal autoantibody-mediated fetal
cardiomyopathy/endocardial ﬁbroelastosis suffer demise or
need for transplant. In an attempt to improve this outcome,
in 1998, we began to empirically treat affected patients with
IVIG and corticosteroids.
Methods We reviewed the clinical records and echocar-
diograms of 20 affected patients encountered in our insti-
tutions and treated with IVIG and corticosteroids from 1998
to 2009.Results All 20 were initially referred at a median gesta-
tional age of 23 weeks (range 18 to 38 weeks). Nineteen
mothers were anti-Ro antibody positive, 8 anti-La antibody
positive, and 7 had clinical autoimmune disease. Endocar-
dial ﬁbroelastosis was seen in 16 and was not obvious in 4
others with reduced ventricular function, and 16 (80%) had
reduced or borderline ventricular shortening fraction
(30%) before or after birth. Eighteen had atrioventricular
block at referral (16 in 3). During pregnancy, maternal
IVIG was given in 9 and dexamethasone in 17. After birth,
17 infants received IVIG (n ¼ 14) and/or corticosteroids
(n ¼ 15). Twelve underwent pacemaker implantation. Four
with hydrops at presentation died perinatally, despite initial
improvement in function in 3. At a median follow-up of
2.9 years (1.1 to 9.8 years), 16 (80%) patients are currently
alive with normal systolic ventricular function and 6 are not
paced.
Conclusions Treatment of maternal autoantibody-mediated
fetal cardiomyopathy/endocardial ﬁbroelastosis with IVIG
and corticosteroids potentially improves the outcome of
affected fetuses. Further studies are needed to determine the
optimal dose and timing of IVIG administration (163).Inappropriate Implantable Cardioverter-
Deﬁbrillator Shocks: Incidence, Predictors, and
Impact on Mortality
Objectives The purpose of this study was to assess the
incidence, predictors, and outcome of inappropriate shocks
in implantable cardioverter-deﬁbrillator (ICD) patients.
Background Despite the beneﬁts of ICD therapy, inap-
propriate deﬁbrillator shocks continue to be a signiﬁcant
drawback. The prognostic importance of inappropriate
shocks outside the setting of a clinical trial remains unclear.
Methods From 1996 to 2006, all recipients of deﬁbrillator
devices equipped with intracardiac electrogram storage
were included in the current analysis and clinically assessed
at implantation. During follow-up, the occurrence of
inappropriate ICD shocks and all-cause mortality was
noted.
Results A total of 1,544 ICD patients (79% male, age 61 
13 years) were included in the analysis. During the follow-up
period of 41  18 months, 13% experienced 1 inappro-
priate shocks. The cumulative incidence steadily increased to
18% at 5-year follow-up. Independent predictors of the
occurrence of inappropriate shocks included a history of
atrial ﬁbrillation (hazard ratio [HR]: 2.0, p < 0.01) and age
younger than 70 years (HR: 1.8, p ¼ 0.01). Experiencing
a single inappropriate shock resulted in an increased risk of
all-cause mortality (HR: 1.6, p ¼ 0.01). Mortality risk
increased with every subsequent shock, up to an HR of 3.7
after 5 inappropriate shocks.
Conclusions In a large cohort of ICD patients, inappro-
priate shocks were common. The most important ﬁnding is
the association between inappropriate shocks and mortality,
independent of interim appropriate shocks (164).
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Inducibility and Autonomic Remodeling by Low-
Level Vagosympathetic Nerve Stimulation
Objectives We hypothesized that autonomic atrial
remodeling can be reversed by low-level (LL) vagosympa-
thetic nerve stimulation (VNS).
Background Previously, we showed that VNS can be
antiarrhythmogenic.
Methods Thirty-three dogs were subjected to electrical
stimulation (20 Hz) applied to both vagosympathetic trunks
at voltages 10% to 50% below the threshold that slowed
sinus rate or AV conduction. Group 1 (n ¼ 7): Programmed
stimulation (PS) was performed at baseline and during 6-h
rapid atrial pacing (RAP). PS allowed determination of
effective refractory period (ERP) and AF inducibility
measured by window of vulnerability (WOV). LL-VNS was
continuously applied from the 4th to 6th hours. Group 2
(n ¼ 4): After baseline ERP and WOV determinations, 6-h
concomitant RAPþLL-VNS was applied. Sustained AF
was induced by injecting acetylcholine (ACh) 10 mM into
the anterior right ganglionated plexus (Group 3, n ¼ 10) or
applying ACh 10 mM to right atrial appendage (Group 4,
n ¼ 9).
Results Group 1: The ERP progressively shortened and
the SWOV (sum of WOV from all tested sites) progres-
sively increased (p < 0.05) during 3-h RAP then returned
toward baseline during 3-h RAPþLL-VNS (p < 0.05).
Group 2: 6-h concomitant RAPþLL-VNS did not induce
any signiﬁcant change in ERP and SWOV. Group 3 and
Group 4: AF duration (AF-D) and cycle length (AF-CL)
were markedly altered by 3-h LL-VNS (Group 3: baseline:
AF-D ¼ 389  90 s, AF-CL ¼ 45.1  7.8 ms; LL-VNS:
AF-D ¼ 50  15 s, AF-CL ¼ 82.0  13.7 ms [both
p < 0.001]; Group 4: baseline: AF-D ¼ 505  162 s,
AF-CL ¼ 48.8  6.6 ms; LL-VNS: AF-D ¼ 71  21 s,
AF-CL ¼ 101.3  20.9 ms [both p < 0.001]).
Conclusions LL-VNS can prevent and reverse atrial
remodeling induced by RAP as well as suppress AF induced
by strong cholinergic stimulation. Inhibition of the intrinsic
cardiac autonomic nervous system by LL-VNS may be
responsible for these salutary results (165).Long-Term Cardiovascular Mortality After
Radiotherapy for Breast Cancer
Objectives This study sought to investigate long-term
cardiovascular mortality and its relationship to the use of
radiotherapy for breast cancer.
Background Cardiovascular diseases are among the main
long-term complications of radiotherapy, but knowledge is
limited regarding long-term risks because published studies
have, on average, <20 years of follow-up.
Methods A total of 4,456 women who survived at least
5 years after treatment of a breast cancer at the Institut
Gustave Roussy between 1954 and 1984 were followed upfor mortality until the end of 2003, for over 28 years on
average.
Results A total of 421 deaths due to cardiovascular diseases
were observed, of which 236 were due to cardiac disease.
Women who had received radiotherapy had a 1.76-fold
(95% conﬁdence interval [CI]: 1.34 to 2.31) higher risk of
dying of cardiac disease and a 1.33-fold (95% CI: 0.99 to
1.80) higher risk of dying of vascular disease than those who
had not received radiotherapy. Among women who had
received radiotherapy, those who had been treated for a left-
sided breast cancer had a 1.56-fold (95% CI: 1.27 to 1.90)
higher risk of dying of cardiac disease than those treated for
a right-sided breast cancer. This relative risk increased with
time since the breast cancer diagnosis (p ¼ 0.05).
Conclusions This study conﬁrmed that radiotherapy, as
delivered until the mid-1980s, increased the long-term risk
of dying of cardiovascular diseases. The long-term risk of
dying of cardiac disease is a particular concern for women
treated for a left-sided breast cancer with contemporary
tangential breast or chest wall radiotherapy. This risk may
increase with a longer follow-up, even after 20 years
following radiotherapy (166).
Overexpression of CaMKIIdc in RyR2R4496CD/L
Knock-In Mice Leads to Altered Intracellular Ca2D
Handling and Increased Mortality
Objectives We investigated whether increased Ca2þ/
calmodulin-dependent kinase II (CaMKII) activity aggra-
vates defective excitation-contraction coupling and proar-
rhythmic activity in mice expressing R4496C mutated
cardiac ryanodine receptors (RyR2).
Background RyR2 dysfunction is associated with
arrhythmic events in inherited and acquired cardiac disease.
Methods CaMKIIdc transgenic mice were crossbred with
RyR2R4496Cþ/ knock-in mice.
Results Heart weight-to-body weight ratio in CaMKIIdc/
RyR2R4496C and CaMKIIdc mice was similarly increased
approximately 3-fold versus wild-type mice (p < 0.05).
Echocardiographic data showed comparable cardiac dilation
and impaired contractility in CaMKIIdc/RyR2R4496C and
CaMKIIdc mice. Sarcoplasmic reticulum Ca2þ content in
isolated myocytes was decreased to a similar extent in
CaMKIIdc/RyR2R4496C and CaMKIIdc mice. However,
relaxation parameters and Ca2þ decay at 1 Hz were pro-
longed signiﬁcantly in CaMKIIdc mice versus CaMKIIdc/
RyR2R4496C mice. Sarcoplasmic reticulum Ca2þ spark
frequency and characteristics indicated increased sarco-
plasmic reticulum Ca2þ leak in CaMKIIdc/RyR2R4496C
versus CaMKIIdc myocytes (p < 0.05), most likely because
of increased RyR2 phosphorylation. Delayed after-
depolarizations were signiﬁcantly more frequent with
increased amplitudes in CaMKIIdc/RyR2R4496C versus
CaMKIIdc mice. Increased arrhythmias in vivo (67% vs.
25%; p < 0.05) may explain the increased mortality in
CaMKIIdc/RyR2R4496C mice, which died prematurely with
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weeks.
Conclusions CaMKIIdc overexpression in RyR2R4496Cþ/
knock-in mice increases the propensity toward triggered
arrhythmias, which may impair survival. CaMKII contrib-
utes to further destabilization of a mutated RyR2 receptor
(167).
Alcohol Consumption and Risk of Atrial Fibrillation:
A Meta-Analysis
Objectives The purpose of this meta-analysis is to
summarize the estimated risk of atrial ﬁbrillation (AF)
related to alcohol consumption.
Background Results from observational studies examining
the relationship between alcohol consumption and AF are
inconsistent.
Methods A systematic electronic search of Medline
(January 1966 to December 2009) and Embase (January
1974 to December 2009) databases was conducted for
studies using key words related to alcohol and AF. Studies
were included if data on effect measures for AF associated
with habitual alcohol intake were reported or could be
calculated. The effect measures for AF for the highest versus
lowest alcohol intake in individual studies were pooled with
a variance-based method. Linear and spline regression
analyses were conducted to quantify the relationship
between alcohol intake and AF risk.
Results Fourteen eligible studies were included in this
meta-analysis. The pooled estimate of AF for the highest
versus the lowest alcohol intake was 1.51 (95% conﬁdence
interval: 1.31 to 1.74). A linear regression model showed
that the pooled estimate for an increment of 10 g per day
alcohol intake was 1.08 (95% conﬁdence interval: 1.05 to
1.10; R2 ¼ 0.43, p < 0.001). A spline regression model also
indicated that the AF risk increased with increasing levels of
alcohol consumption.
Conclusions Results of this meta-analysis suggest that not
consuming alcohol is most favorable in terms of AF risk
reduction (168).
Left Atrial Strain Predicts Reverse Remodeling
After Catheter Ablation for Atrial Fibrillation
Objectives The purpose of this study was to assess left atrial
(LA) strain during long-term follow-up after catheter
ablation for atrial ﬁbrillation and to ﬁnd predictors for LA
reverse remodeling.
Background The association between LA reverse remod-
eling and improvement in LA strain after catheter ablation
has not been investigated thus far.
Methods In 148 patients undergoing catheter ablation for
atrial ﬁbrillation, LA volumes and LA strain were assessed
with echocardiography at baseline and after a mean of 13.2
 6.7 months of follow-up. The study population was
divided according to LA reverse remodeling at follow-up:
responders were deﬁned as patients who exhibited 15% ormore reduction in maximum LA volume at long-term
follow-up. Left atrial systolic (LAs) strain was assessed
with tissue Doppler imaging.
Results At follow-up, 93 patients (63%) were classiﬁed as
responders, whereas 55 patients (37%) were nonresponders.
At baseline, LAs strain was signiﬁcantly higher in the
responders as compared with the nonresponders (19  8%
vs. 14  6%; p ¼ 0.001). Among the responders, a signiﬁ-
cant increase in LAs strain was noted from baseline to
follow-up (from 19  8% to 22  9%; p < 0.05), whereas
no change was noted among the nonresponders. LAs strain
at baseline was an independent predictor of LA reverse
remodeling (odds ratio: 1.813; 95% conﬁdence interval:
1.102 to 2.982; p ¼ 0.019).
Conclusions In the present study, 63% of the patients
exhibited LA reverse remodeling after catheter ablation for
atrial ﬁbrillation, with a concomitant improvement in LA
strain. LA strain at baseline was an independent predictor of
LA reverse remodeling (169).Suppression of Re-Entrant and Multifocal
Ventricular Fibrillation by the Late Sodium Current
Blocker Ranolazine
Objectives The purpose of this study was to test the
hypothesis that the late Na current blocker ranolazine
suppresses re-entrant and multifocal ventricular ﬁbrillation
(VF).
Background VF can be caused by either re-entrant or focal
mechanism.
Methods Simultaneous voltage and intracellular Caþ2
optical mapping of the left ventricular epicardial surface
along with microelectrode recordings was performed in 24
isolated-perfused aged rat hearts. Re-entrant VF was
induced by rapid pacing and multifocal VF by exposure to
oxidative stress with 0.1 mM hydrogen peroxide (H2O2).
Results Rapid pacing induced sustained VF in 7 of 8 aged
rat hearts, characterized by 2 to 4 broad propagating wave-
fronts. Ranolazine signiﬁcantly (p < 0.05) reduced the
maximum slope of action potential duration restitution curve
and converted sustained to nonsustained VF lasting 24  8 s
in all 7 hearts. Exposure to H2O2 initiated early after-
depolarization (EAD)-mediated triggered activity that led to
sustained VF in 8 out of 8 aged hearts. VF was characterized
by multiple foci, appearing at an average of 6.8  3.2 every
100 ms, which remained conﬁned to a small area averaging
2.8  0.85 mm2 and became extinct after a mean of 43  16
ms. Ranolazine prevented (when given before H2O2) and
suppressed H2O2-mediated EADs by reducing the number
of foci, causing VF to terminate in 8 out of 8 hearts.
Simulations in 2-dimensional tissue with EAD-mediated
multifocal VF showed progressive reduction in the number
of foci and VF termination by blocking the late Na current.
Conclusions Late Na current blockade with ranolazine is
effective at suppressing both pacing-induced re-entrant VF
and EAD-mediated multifocal VF (170).
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the Efﬁcacy and Safety of Vernakalant to
Amiodarone in Recent-Onset Atrial Fibrillation
Objectives This randomized double-blind study compared
the efﬁcacy and safety of intravenous vernakalant and
amiodarone for the acute conversion of recent-onset atrial
ﬁbrillation (AF).
Background Intravenous vernakalant has effectively con-
verted recent-onset AF and was well tolerated in placebo-
controlled studies.
Methods A total of 254 adult patients with AF (3 to 48 h
duration) eligible for cardioversion were enrolled in the study.
Patients received either a 10-min infusion of vernakalant
(3 mg/kg) followed by a 15-min observation period and
a second 10-min infusion (2 mg/kg) if still in AF, plus a sham
amiodarone infusion, or a 60-min infusion of amiodarone
(5 mg/kg) followed by a maintenance infusion (50 mg) over
an additional 60 min, plus a sham vernakalant infusion.
Results Conversion from AF to sinus rhythm within the
ﬁrst 90 min (primary end point) was achieved in 60 of 116
(51.7%) vernakalant patients compared with 6 of 116 (5.2%)
amiodarone patients (p < 0.0001). Vernakalant resulted in
rapid conversion (median time of 11 min in responders) and
was associated with a higher rate of symptom relief
compared with amiodarone (53.4% of vernakalant patients
reported no AF symptoms at 90 min compared with 32.8%
of amiodarone patients; p ¼ 0.0012). Serious adverse events
or events leading to discontinuation of study drug were
uncommon. There were no cases of torsades de pointes,
ventricular ﬁbrillation, or polymorphic or sustained ventric-
ular tachycardia.
Conclusions Vernakalant demonstrated efﬁcacy superior to
amiodarone for acute conversion of recent-onset AF. Both
vernakalant and amiodarone were safe and well tolerated in
this study. (A Phase III Superiority Study of Vernakalant vs
Amiodarone in Subjects With Recent Onset Atrial Fibril-
lation [AVRO]; NCT00668759) (171).
Catheter Ablation for Atrial Fibrillation: Are
Results Maintained at 5 Years of Follow-Up?
Objectives This study describes 5-year follow-up results of
catheter ablation for atrial ﬁbrillation (AF).
Background Long-term efﬁcacy following catheter abla-
tion of AF remains unknown.
Methods A total of 100 patients (86 men, 14 women), age
55.7  9.6 years, referred to our center for a ﬁrst AF ablation
(63% paroxysmal; 3.5  1.4 prior ineffective antiarrhythmic
agents) were followed for 5 years. Complete success was
deﬁned as absence of any AF or atrial tachycardia recurrence
(clinical or by 24-h Holter monitoring) lasting 30 s.
Results Arrhythmia-free survival rates after a single cath-
eter ablation procedure were 40%, 37%, and 29% at 1, 2, and
5 years, respectively, with most recurrences over the ﬁrst 6
months. Patients with long-standing persistent AF experi-
enced a higher recurrence rate than those with paroxysmal orpersistent forms (hazard ratio [HR]: 1.9, 95% conﬁdence
interval [CI]: 1.0 to 3.5; p ¼ 0.0462). In all, 175 procedures
were performed, with a median of 2 per patient.
Arrhythmia-free survival following the last catheter ablation
procedure was 87%, 81%, and 63% at 1, 2, and 5 years,
respectively. Valvular heart disease (HR: 6.0, 95% CI: 2.0 to
17.6; p ¼ 0.0012) and nonischemic dilated cardiomyopathy
(HR: 34.0, 95% CI: 6.3 to 182.1; p < 0.0001) indepen-
dently predicted recurrences. Major complications (cardiac
tamponade requiring drainage) occurred in 3 patients (3%).
Conclusions In selected patients with AF, a catheter
ablation strategy with repeat intervention as necessary
provides acceptable long-term relief. Although most recur-
rences transpire over the ﬁrst 6 to 12 months, a slow but
steady decline in arrhythmia-free survival is noted thereafter
(172).Noninvasive Identiﬁcation of Ventricular
Tachycardia-Related Conducting Channels Using
Contrast-Enhanced Magnetic Resonance Imaging
in Patients With Chronic Myocardial Infarction:
Comparison of Signal Intensity Scar Mapping and
Endocardial Voltage Mapping
Objectives We performed noninvasive identiﬁcation of
post-infarction sustained monomorphic ventricular tachy-
cardia (SMVT)–related slow conduction channels (CC) by
contrast-enhanced magnetic resonance imaging (ceMRI).
Background Conduction channels identiﬁed by voltage
mapping are the critical isthmuses of most SMVT. We
hypothesized that CC are formed by heterogeneous tissue
(HT) within the scar that can be detected by ceMRI.
Methods We studied 18 consecutive VT patients (SMVT
group) and 18 patients matched for age, sex, infarct location,
and left ventricular ejection fraction (control group). We
used ceMRI to quantify the infarct size and differentiate it
into scar core and HT based on signal-intensity (SI)
thresholds (>3 SD and 2 to 3 SD greater than remote
normal myocardium, respectively). Consecutive left ventricle
slices were analyzed to determine the presence of continuous
corridors of HT (channels) in the scar. In the SMVT group,
color-coded shells displaying ceMRI subendocardial SI were
generated (3-dimensional SI mapping) and compared with
endocardial voltage maps.
Results No differences were observed between the 2 groups
in myocardial, necrotic, or heterogeneous mass. The HT
channels were more frequently observed in the SMVT group
(88%) than in the control group (33%, p < 0.001). In the
SMVT group, voltage mapping identiﬁed 26 CC in 17 of 18
patients. All CC corresponded, in location and orientation,
to a similar channel detected by 3-dimensional SI mapping;
15 CC were related to 15 VT critical isthmuses.
Conclusions SMVT substrate can be identiﬁed by ceMRI
scar heterogeneity analysis. This information could help
identify patients at risk of VT and facilitate VT ablation
(173).
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e512Device-Detected Atrial Tachyarrhythmias Predict
Adverse Outcome in Real-World Patients With
Implantable Biventricular Deﬁbrillators
Objectives The purpose of this analysis was to evaluate the
correlation between atrial tachycardia (AT) or atrial ﬁbril-
lation (AF) and clinical outcomes in heart failure (HF)
patients implanted with a cardiac resynchronization therapy
deﬁbrillator (CRT-D).
Background In HF patients, AT and AF have high prev-
alence and are associated with compromised hemodynamic
function.
Methods Forty-four Italian cardiological centers followed
up 1,193 patients who received a CRT-D according to
current guidelines for advanced HF, New York Heart
Association functional class II, left ventricular ejection
fraction 35%, and QRS complex 120 ms. All patients
were in sinus rhythm at implant.
Results During a median follow-up period of 13 months,
AT/AF >10 min occurred in 361 of 1,193 (30%) patients.
The composite end point (deaths or HF hospitalizations)
occurred in 174 of 1,193 (14.6%). Multivariate time-
dependent Cox regression analyses showed that composite
end point risk was higher among patients with device-
detected AT/AF (hazard ratio [HR]: 2.16, p ¼ 0.032),
New York Heart Association functional class III or IV
compared with II (HR: 2.09, p ¼ 0.002), and absence of
beta-blockers (HR: 1.36, p ¼ 0.036). Furthermore, the
composite end point risk was inversely associated with left
ventricular ejection fraction (HR: 1.04, p ¼ 0.045),
increasing by a factor of 4% for each 1% decrease in left
ventricular ejection fraction.
Conclusions In HF patients with CRT-D, device-detected
AT/AF is associated with a worse prognosis. Continuous
device diagnostics monitoring and Web-based alerts may
inform the physician of AT/AF occurrences and identify
patients at risk of cardiac deterioration or patients with
suboptimal rate or rhythm control. (Italian ClinicalService
Project; NCT01007474) (174).The Effect of Air Pollution on Spatial Dispersion of
Myocardial Repolarization in Healthy Human
Volunteers
Objectives We tested the hypothesis that exposure to
concentrated ambient particles (CAP) and/or ozone (O3)
would increase dispersion of ventricular repolarization.
Background Elevated levels of air pollution are associated
with cardiac arrhythmias through mechanisms yet to be
elucidated.
Methods Each of 25 volunteers (18 to 50 years of age) had
four 2-h exposures to 150 mg/m3 CAP; 120 parts per billion
O3; CAP þ O3; and ﬁltered air (FA). Exposure-induced
changes (D ¼ 5-min epochs at end-start) in spatial disper-
sion of repolarization were determined from continuous
12-lead electrocardiographic recording.Results Spatial dispersion of repolarization assessed by
corrected DT-wave peak to T-wave end interval increased
signiﬁcantly for CAP þ O3 (0.17  0.03, p < 0.0001)
exposure only, remaining signiﬁcant when factoring FA
(CAP þO3  FA) as control (0.11  0.04, p¼ 0.013). The
inﬂuence on repolarization was further veriﬁed by a signiﬁ-
cant increase in DQT dispersion (for CAP þ O3 compared
with FA (5.7  1.4, p ¼ 0.0002). When the low-frequency
to high-frequency ratio of heart rate variability (a conven-
tional representation of sympathetic-parasympathetic
balances) was included as a covariate, the effect estimate
was positive for both corrected DT-wave peak to T-wave
end interval (p ¼ 0.002) and DQT dispersion (p ¼ 0.038).
When the high-frequency component (parasympathetic
heart rate modulation) was included as a covariate with
corrected DT-wave peak to T-wave end interval, the effect
estimate for high frequency was inverse (p ¼ 0.02).
Conclusions CAP þ O3 exposure alters dispersion of
ventricular repolarization in part by increasing sympa-
thetic and decreasing parasympathetic heart rate modu-
lation. Detection of changes in repolarization parameters,
even in this small cohort of healthy individuals, suggests
an underappreciated role for air pollutants in urban
arrhythmogenesis (175).Comparative Validation of a Novel Risk Score for
Predicting Bleeding Risk in Anticoagulated
Patients With Atrial Fibrillation: The HAS-BLED
(Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile
INR, Elderly, Drugs/Alcohol Concomitantly) Score
Objectives The purpose of this study was to investigate
predictors of bleeding in a cohort of anticoagulated patients
and to evaluate the predictive value of several bleeding risk
stratiﬁcation schemas.
Background The risk of bleeding during antithrombotic
therapy in patients with atrial ﬁbrillation (AF) is not
homogeneous, and several clinical risk factors have been
incorporated into clinical bleeding risk stratiﬁcation
schemas. Current risk stratiﬁcation schemas for bleeding
during anticoagulation therapy have been based on complex
scoring systems that are difﬁcult to apply in clinical practice,
and few have been derived and validated in AF cohorts.
Methods We investigated predictors of bleeding in
a cohort of 7,329 patients with AF participating in the
SPORTIF (Stroke Prevention Using an ORal Thrombin
Inhibitor in Atrial Fibrillation) III and V clinical trials and
evaluated the predictive value of several risk stratiﬁcation
schemas by multivariate analysis. Patients were anti-
coagulated orally with either adjusted-dose warfarin (target
international normalized ratio 2 to 3) or ﬁxed-dose xime-
lagatran 36 mg twice daily. Major bleeding was centrally
adjudicated, and concurrent aspirin therapy was allowed in
patients with clinical atherosclerosis.
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bleeding were concurrent aspirin use (hazard ratio [HR]:
2.10; 95% conﬁdence interval [CI]: 1.59 to 2.77; p < 0.001);
renal impairment (HR: 1.98; 95% CI: 1.42 to 2.76; p <
0.001); age 75 years or older (HR: 1.63; 95% CI: 1.23 to
2.17; p ¼ 0.0008); diabetes (HR: 1.47; 95% CI: 1.10 to
1.97; p ¼ 0.009), and heart failure or left ventricular
dysfunction (HR: 1.32; 95% CI: 1.01 to 1.73; p ¼ 0.041).
Of the tested schemas, the new HAS-BLED (Hyperten-
sion, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/
Alcohol Concomitantly) score performed best, with a step-
wise increase in rates of major bleeding with increasing
HAS-BLED score (ptrend <0.0001). The c statistic for
bleeding varied between 0.50 and 0.67 in the overall entire
cohort and 0.68 among patients naive to warfarin at baseline
(n ¼ 769).
Conclusions This analysis identiﬁes diabetes and heart
failure or left ventricular dysfunction as potential risk factors
for bleeding in AF beyond those previously recognized. Of
the contemporary bleeding risk stratiﬁcation schemas, the
new HAS-BLED scheme offers useful predictive capacity
for bleeding over previously published schemas and may be
simpler to apply (176).Risk for Life-Threatening Cardiac Events in
Patients With Genotype-Conﬁrmed Long-QT
Syndrome and Normal-Range Corrected QT
Intervals
Objectives This study was designed to assess the clinical
course and to identify risk factors for life-threatening events
in patients with long-QT syndrome (LQTS) with normal
corrected QT (QTc) intervals.
Background Current data regarding the outcome of
patients with concealed LQTS are limited.
Methods Clinical and genetic risk factors for aborted
cardiac arrest (ACA) or sudden cardiac death (SCD) from
birth through age 40 years were examined in 3,386
genotyped subjects from 7 multinational LQTS registries,
categorized as LQTS with normal-range QTc (440 ms
[n ¼ 469]), LQTS with prolonged QTc interval (>440 ms
[n ¼ 1,392]), and unaffected family members (genotyped
negative with 440 ms [n ¼ 1,525]).
Results The cumulative probability of ACA or SCD in
patients with LQTS with normal-range QTc intervals (4%)
was signiﬁcantly lower than in those with prolonged QTc
intervals (15%) (p < 0.001) but higher than in unaffected
family members (0.4%) (p < 0.001). Risk factors ACA or
SCD in patients with normal-range QTc intervals included
mutation characteristics (transmembrane-missense vs. non-
transmembrane or nonmissense mutations: hazard ratio:
6.32; p ¼ 0.006) and the LQTS genotypes (LQTS type
1:LQTS type 2, hazard ratio: 9.88; p ¼ 0.03; LQTS type
3:LQTS type 2, hazard ratio: 8.04; p ¼ 0.07), whereas
clinical factors, including sex and QTc duration, wereassociated with a signiﬁcant increase in the risk for ACA or
SCD only in patients with prolonged QTc intervals (female
age >13 years, hazard ratio: 1.90; p ¼ 0.002; QTc duration,
8% risk increase per 10-ms increment; p ¼ 0.002).
Conclusions Genotype-conﬁrmed patients with concealed
LQTS make up about 25% of the at-risk LQTS population.
Genetic data, including information regarding mutation
characteristics and the LQTS genotype, identify increased
risk for ACA or SCD in this overall lower risk LQTS
subgroup (177).Screening for Copy Number Variation in Genes
Associated With the Long QT Syndrome: Clinical
Relevance
Objectives The aim of this study was to investigate, in a set
of 93 mutation-negative long QT syndrome (LQTS)
probands, the frequency of copy number variants (CNVs) in
LQTS genes.
Background LQTS is an inherited cardiac arrhythmia
characterized by a prolonged heart rate–corrected QT (QTc)
interval associated with sudden cardiac death. Recent studies
suggested the involvement of duplications or deletions in the
occurrence of LQTS. However, their frequency remains
unknown in LQTS patients.
Methods Pointmutations inKCNQ1,KCNH2, and SCN5A
genes were excluded by denaturing high-performance liquid
chromatography or direct sequencing. We applied Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA) to detect
CNVs in exons of these 3 genes. Abnormal exon copy
numbers were conﬁrmed by quantitative multiplex PCR of
short ﬂuorescent fragment (QMPSF). Array-based compar-
ative genomic hybridization (array CGH) analysis was per-
formed using Agilent Human Genome 244K Microarrays to
further map the genomic rearrangements.
Results We identiﬁed 3 different deletions in 3 unrelated
families: 1 in KCNQ1 and 2 involving KCNH2. We showed
in the largest family that the deletion involving KCNH2 is
fully penetrant and segregates with the long QT phenotype
in 7 affected members.
Conclusions Our study demonstrates that CNVs in
KCNQ1 and KCNH2 explain around 3% of LQTS in
patients with no point mutation in these genes. This
percentage is likely higher than the frequency of point
mutations in ANKB, KCNE1, KCNE2, KCNJ2, CACNA1C,
CAV3, SCN4B, AKAP9, and SNTA1 together. Thus, we
propose that CNV screening in KCNQ1 and KCNH2 may
be performed routinely in LQTS patients (178).Iodine-123 mIBG Imaging for Predicting the
Development of Atrial Fibrillation
Objectives We investigated whether cardiac sympathetic
nervous system (SNS) activity measured by iodine-123
meta-iodobenzylguanidine (123I-mIBG) imaging would be
associated with both the occurrence of heart failure (HF)
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patients with paroxysmal AF.
Background Atrial ﬁbrillation occurs suddenly and tran-
siently and can persist, and results in the occurrence of HF.
An important feature of AF and HF is their propensity to
coexist not only because they share antecedent risk factors,
but also because the one may directly predispose the heart to
the other. However, a useful modality for predicting the
occurrences of both those has not been established in
patients with paroxysmal AF.
Methods The 123I-mIBG scintigraphy was performed to
evaluate cardiac SNS activity presented as the heart/medi-
astinum ratio in 98 consecutive patients (age 66  13 years,
63.3% male) with idiopathic paroxysmal AF and preserved
left ventricular ejection fraction (50%).
Results During 4  3.6 years of follow-up, the transit to
permanent AF was associated with the occurrence of HF
(34.3% in 12 of 35 patients with permanent AF vs. 6.3% in
4 of 63 patients without, p < 0.0001). Lower heart/medi-
astinum ratio and lower left ventricular ejection fraction were
the independent predictors of the transit to permanent AF
with adjusted hazard ratios of 3.44 (95% conﬁdence interval
[CI]: 1.9 to 6.2, p < 0.0001) and 1.04 (95% CI: 1.01 to
1.08, p ¼ 0.014). Further, these factors and higher plasma
brain natriuretic peptide concentration were the indepen-
dent predictors of the occurrence of HF with permanent
AF, with adjusted hazard ratios of 5.08 (95% CI: 1.5 to
17.5, p ¼ 0.011), 1.11 (95% CI: 1.03 to 1.19, p ¼ 0.004),
and 1.004 (95% CI: 1.001 to 1.008, p ¼ 0.014).
Conclusions Cardiac SNS abnormality was associated
with the occurrence of both HF and permanent AF in
paroxysmal AF patients, and 123I-mIBG imaging may be a
useful modality for predicting the development of AF (179).
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